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The transplantation of glial cells, including olfactory ensheathing cells (OECs) and Schwann 
cells, for the treatment of various CNS lesions, such as demyelination and spinal cord 
injuries, has attracted a lot of recent focus. However, there has been much debate as to 
which is the superior cell for these transplantation therapies. OECs are generally 
considered to be superior to Schwann cells due to their greater capacity for migration and 
their ability to co-exist within astrocyte-rich environments. In addition, OECs induce less 
reactivity in host astrocytes following transplantation. However, the mechanisms which 
determine the differential interactions of Schwann cells and OECs with astrocytes are at 
present unknown. The aim of this thesis was to determine the nature o f these mechanisms, 
with intent to further characterise these very similar glial cell types, and to highlight 
possible molecular targets for improving the potential of OECs and Schwann cells for 
transplantation.
I have addressed these issues by using in vitro cultures which model the interactions of 
OECs and Schwann cells with astrocytes, reflecting those which occur following 
transplantation. Initial studies confirmed that Schwann cells have a limited ability to 
migrate in the presence of astrocytes in comparison to OECs. However, using migration 
assays it was demonstrated that Schwann cells are not inferior to OECs with regard to their 
inherent migrational capacity, but that this inhibition only results upon contact with 
astrocytes. In agreement with this, Schwann cells displayed greater adhesion than OECs to 
astrocytes, reflecting their reduced migration upon this substrate.
To identify factors which influence the different migrational capacities of OECs and 
Schwann cells following astrocyte contact, I have investigated the role o f the cell adhesion 
molecule, N-cadherin. Previous studies demonstrated that the inhibition of Schwann cell 
migration upon astrocyte monolayers is N-cadherin dependent, suggesting that this could 
be a difference between OECs and Schwann cells. I have shown here that N-cadherin is 
present on both OECs and Schwann cells, and is functional with regard to cell-cell 
interactions. However, using both N-cadherin peptide inhibitors, and siRNA to reduce N- 
cadherin expression, it was also demonstrated that OECs and Schwann cells have a 
different dependency upon N-cadherin for cell-cell interactions. Schwann cells, but not
XX IV
OECs, were dependent upon N-cadherin to form strong adhesions. In addition, removal of 
N-cadherin overcame astrocyte-induced inhibition of migration in Schwann cells, and 
allowed them to intermingle with astrocytes in a manner more akin to OEC-astrocyte 
interactions. Thus, this demonstrates that not only do Schwann cells and OECs differ in 
their dependency upon N-cadherin for adhesion and migration, but also that N-cadherin is a 
major factor in determining the ability of Schwann cells to intermingle with astrocytes.
Due to the observation that Schwann cells induce a greater degree of astrocytosis than 
OECs, I have assessed some of the factors determining this astrocytic response. In order to 
achieve this, the role of Schwann cell-secreted factors was investigated. It is shown here 
that media conditioned by Schwann cells or OECs stimulated astrocytes to produce the 
axon-growth inhibitory molecules, chondroitin sulphate proteoglycans (CS-PGs). 
However, in order for astrocytes to undergo other changes characteristic of the astrocytic 
reactive response, such as GFAP upregulation and an increase in astrocytic area, both 
Schwann cell-conditioned media and an OEC-contact signal are necessary. In this way, 
astrocytes which are co-cultured with OECs in the presence of Schwann cell-secreted 
factors become reactive, but not if either OEC-contact or Schwann cell-secreted factors are 
absent. In addition, OECs were unable to migrate within these reactive astrocytes, but 
formed boundaries with astrocytes in a manner similar to Schwann cells. Thus, Schwann 
cell-secreted factors may be responsible for the reactive astrocytes observed in Schwann 
cell-astrocyte co-cultures. Since the presence of these reactive astrocytes appears to 
determine the ability of OECs to migrate amongst them, they may be responsible for the 
limited migration seen by Schwann cells in the presence of astrocytes.
In conclusion, both the function of N-cadherin and the presence of reactive astrocytes, are 
involved in determining the ability of Schwann cells and OECs to migrate within astrocyte- 
rich areas. Schwann cells differ from OECs in that they are dependent upon N-cadherin 
function for both adhesion and migration following interactions with astrocytes. In 
addition, unlike OECs, Schwann cells secrete factors which induce astrocytosis. Therefore, 
N-cadherin, or its various signalling components, and the putative factors secreted by 
Schwann cells, may now offer themselves as potential targets for intervention in order to 
improve the migration and integration of the cellular transplant into the host.
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CHAPTER 1 
Introduction
21.1 Regenerative properties of the nervous system
The nervous system consists o f both a central and a peripheral component. The brain and 
spinal cord constitute the central nervous system (CNS), whereas the peripheral nervous 
system (PNS) connects the rest of the body to the brain and the spinal cord. They have 
different regenerative responses following injury, in that the regeneration of the PNS can be 
successful whereas CNS regeneration typically fails. It is hoped that understanding the 
processes which are successful in the PNS may shed some light on why regeneration fails 
in the CNS, and how we may overcome this.
1.1.1 Peripheral regeneration
For over a century, the ability of the peripheral nerve to regenerate and reinnervate 
denervated targets has been recognised. Many factors are involved in determining the 
outcome of such repair, such as whether the neuron survives the injury, how supportive 
the growth environment is, and the ability of the nerve to reinnervate the appropriate target 
(Fu and Gordon, 1997).
Following injury, peripheral nerves undergo a well characterised process known as 
Wallerian degeneration, where axonal and myelin-derived material is removed, and the 
environment for regeneration is prepared. After breakdown of the distal nerve and myelin, 
the debris is phagocytosed by macrophages and Schwann cells. The role of Schwann cells 
in this process was shown when macrophages were denied access to the distal nerve stump 
(Beuche and Friede, 1984). In fact, during the first two days after injury, when macrophage 
invasion is minimal, Schwann cells are the major phagocytotic cell (Stoll et al., 1989). After 
this time, macrophages continue to break myelin down until approximately two weeks 
after injury, when they either apoptose or migrate to the lymph nodes (Kuhlmann et al, 
2001).
Following axotomy, surviving neurons undergo a process known as chromatolysis. This 
involves morphological changes such as disintegration of the Nissl bodies, large granular 
condensations of rough endoplasmic reticulum, nucleolar enlargement, and cell swelling 
(Lieberman, 1971). The axon can then begin to regenerate, usually within a few hours of
3axotomy (Fawcett and Keynes, 1990). The environment through which the axon 
regenerates consists of Schwann cells and their basal lamina, fibroblasts and extracellular 
matrix (ECM). The role of Schwann cells in this process appears to be the critical factor 
(see Section 1.3.1.3), whereby they produce a range of cytokines, such as interleukin 1 (IL- 
1; Bergensdottir et al., 1991; Skundric et al., 1997; Rutkowski et al., 1999), IL - 6  (Murwani 
et al., 1996; Rutkowski et al., 1999) and tumour necrosis factor a  (TN Fa; Murwani et al., 
1996; Wagner and Myers, 1996). In addition, the axon synthesises many neurotrophic 
factors including nerve growth factor (NGF) (Ernfors et al., 1989), brain-derived 
neurotrophic factor (BNDF), neurotrophin 3 (NT-3) (Ernfors & Persson, 1991) and 
platelet-derived growth factor (PDGF) (Yeh et al., 1991), which may help give the 
regenerating neuron the trophic support it needs.
1.1.2 CNS regenerative failure
The situation within the CNS is different to the PNS, since it is non-permissive to axonal 
regeneration. This is principally due to the inhibitory nature of the glial environment, where 
both the presence of myelin, and the injury response which results in a glial scar, prevent 
repair taking place. As a result, an injury to the CNS can result in a permanent loss of 
function.
Following injury, degeneration occurs in a manner similar to the PNS. Firstly, the distal 
part o f the cut axon and associated myelin are removed, similar to Wallerian degeneration, 
involving both resident microglial and recruited macrophages (Kreutzberg, 1996). However, 
following this, cavitation around the injury site occurs due to secondary cell death of both 
neurons and glia (Dusart and Schwab, 1994, Fitch et al., 1999). This is induced, not by the 
initial injury, but rather the resulting inflammatory response. Around the injury site, a glial 
scar then develops, which eventually fills any vacant space (Fawcett and Asher, 1999). 
Before this scar appears, the surviving proximal segment of the axon may exhibit a 
regenerative response within 6  hours of injury (Schwab and Bartholdi, 1996) as growth 
cone ‘clubs’ develop at the severed end (Ramon y Cajal, 1928 -  cited in Fry, 2001) and are 
directed towards the injury site. However, these sprouts can only extend for about 1mm 
before growth is aborted and the new sprouts are gradually retracted (Clemente, 1964). The 
role o f the inhibitory environment in growth cone abortion was demonstrated using a PNS
tissue bridge between the adult rat medulla and spinal cord after a CNS injury. This allowed 
injured host axons to extend along the bridge, although they were unable to re-enter the host 
tissue (David and Aguayo, 1981). This was the first demonstration that CNS axons have 
the capacity to grow when given a permissive environment.
1.1.2.1 Myelin
Inhibitory myelin proteins, which are not normally present on the outer surface of intact 
myelin, become exposed following injury. This is due to both direct damage to the myelin 
sheath itself, and the presence of dying oligodendrocytes. These proteins are probably the 
main factor contributing to inhibition of axonal regeneration in the period before the glial 
scar has formed, and they are only removed slowly by microglia, a process which can take 
several weeks (Buss and Schwab, 2003). The role o f myelin in inhibiting neuronal 
regeneration has been known for a while (Berry, 1982), and its appearance during 
development correlates with the loss in the ability of neurons to regenerate (Macklin and 
Weill, 1985; Ferretti et al., 2003).
There are three principle molecules which have been shown to inhibit neuronal outgrowth, 
Nogo, myelin associated glycoprotein (MAG) and oligodendrocyte myelin glycoprotein 
(OMgp). Nogo exists in three isoforms, -A, -B and -C , formed by differences in promoter 
usage and splicing. However, they all share a common carboxy terminal domain containing 
two transmembrane domains separated by a 6 6  amino acid extracellular loop (Nogo6 6 ) 
(GrandPre et al., 2000). Both Nogo6 6 , and the amino terminal domain, can induce growth 
cone collapse in extending neurons (GrandPre et al., 2000; Prinjha et al., 2000). MAG is 
another inhibitory molecule (McKerracher et al., 1994), containing an extracellular domain 
which is inhibitory to axonal regeneration (Tang et al., 1997). Unlike Nogo, MAG is 
present in both the CNS and the PNS (Schachner & Bartsch, 2000), although within the 
PNS, its removal by phagocytosis is necessary before regeneration can occur (Fawcett and 
Keynes, 1990). A third, recently discovered inhibitory myelin protein is OMpg (Wang et 
al., 2002b). This is a glycosylphosphatidylinositol (GPI)-linked protein, expressed on the 
surface o f oligodendrocytes and adjacent myelin layers (Mikol et al., 1988; Mikol et al., 
1990), which potently inhibits neurite outgrowth in culture (Wang et al., 2002b).
t>
Interestingly, all three molecules have been shown to bind the same receptor (Foumeir et 
al., 2001; Woolf and Bloechlinger, 2002; Wang et al., 2002), which is termed the Nogo 
receptor (NgR) due to its original demonstration to bind Nogo (Foumeir et al., 2001). This 
observation probably explains the redundancy observed between inhibitory myelin 
molecules. However, NgR has no transmembrane or cytoplasmic domains and therefore 
must induce inhibition through a membrane-bound co-receptor, which transduces the 
extracellular signals. An interesting development has been the observation that p75NTR is 
probably this co-receptor, where it is involved in both MAG signalling (Wong et al., 2002) 
as well as Nogo and OMgp (Wang et al., 2002a). The guanosine triphosphatase (GTPase) 
Rho appears to be the downstream target of such receptor complexes, since blocking Rho- 
GTPase activity allows neurites to grow on MAG substrates in vitro (Lehmann et al.,
1999), as does inhibiting its downstream target, Rho-kinase. These observations lend 
themselves to more potent methods of blocking myelin-induced inhibition, where targeting 
either NgR or p75NTR, or even Rho, may be a better strategy than targeting each of the three 
inhibitory molecules individually.
In contrast, a recent study demonstrated that deletion of the NgR gene failed to relieve the 
effect o f myelin inhibition (Zheng et al., 2004). Here it was shown that neurons cultured in 
vitro were as susceptible to myelin inhibition as wild type neurons. In addition, there was 
little corticospinal tract (CST) regeneration following a dorsal hemisection o f the spinal 
cord. The apparent contradiction between this study and others demonstrating that 
inhibitors o f NgR reduced myelin inhibition (GrandPre et al., 2002; Fournier et al., 2002) 
may result from differences in myelin preparations. Alternatively, the possibility exists 
that NgR antagonists may also target other myelin receptors, for example other NgR 
homologues, which are not disrupted by NgR gene deletion. An additional study analysing 
an NgR knock out mouse confirmed that CST regeneration was minimal, but did report that 
regeneration was possible in alternative tracts, such as raphe spinal fibres (Kim et al., 
2004).
61.1.2.2 The glial scar
The major barrier to regeneration within the CNS, is the formation of a glial scar following 
injury. This occurs over a period of several days and involves several different types of 
cells, with astrocytes playing the major role (Fawcett and Asher, 1999).
The first cells to arrive, within hours of the injury, are macrophages, recruited from the 
blood, and microglia, which are activated from a quiescent state within the CNS 
(Kreutzberg, 1996). Another cell type recruited to areas o f injury are oligodendrocyte 
precursors, which are identified by their expression of the proteoglycan NG2, and the 
PDGF-alpha receptor. A proportion of these cells have been shown to respond to 
demyelination by differentiating into myelin-expressing mature oligodendrocytes (Gensert 
and Goldman, 1997), and therefore probably contribute to endogenous remyelination of 
axons. Although these cells, unlike mature oligodendrocytes, do not express inhibitory 
myelin proteins, certain proteoglycans such as NG2 are present on their surface, and are 
also inhibitory to axonal growth (Dou and Levine, 1994; Fiddler et al., 1999).
The major cellular component of the glial scar, however, is the astrocyte. These cells 
undergo several defined changes upon injury, known as astrocytosis, including 
morphological changes as well as changes in gene expression. This process allows the 
damaged area to be sealed off and will be discussed in more detail (Section 1.2.1.4). Where 
the surface of the brain has also been disrupted, meningeal cells can also invade, and along 
with the astrocytes, they participate in reforming the glia limitans (Kruger et al., 1986).
1.1.2.3 CSPGs
Another key component of the glial scar are inhibitory extracellular matrix (ECM) 
molecules, including the chondroitin sulphate proteoglycans (CS-PGs). These were 
originally believed to be only produced by astrocytes, although it is now understood that 
many other cell types, including oligodendrocyte precursor cells (OPCs), meningeal cells 
and macrophages also produce them (Jones et al., 2002; Fawcett and Asher, 1999) (see 
Table 1.1).
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Several lines of evidence point to the inhibitory nature of the CS-PGs. It has been 
demonstrated that there is a correlation between the presence of CS-PGs and areas 
inhibitory to axonal growth. Following injury, there is a considerable increase in CS-PG 
expression around the injury site, and in fact these CS-PG deposits have been precisely 
shown to correlate with the areas where axonal regrowth stops (Davies et a l, 1997). This 
same correlation is seen in development where axons are directed away from inhibitory glial 
boundaries which are rich in CS-PGs (Fitch and Silver, 1997a; Fawcett and Asher, 1999). 
For example, the optic axons in the retina are directed towards the centrally located optic 
nerve by the presence of inhibitory CS-PGs in the peripheral retina (Brittis et al., 1992). In 
addition, the inhibitory nature of CS-PGs has been demonstrated directly in vitro, where 
CS-PGs act to either inhibit axon growth directly (Yamada et al., 1997; Dou and Levine,
1994), or to inhibit molecular interactions that promote axon growth (Milev et al 1994; 
Fawcett and Asher, 1999). Furthermore, direct evidence of the role of CS-PGs in inhibiting 
regeneration has been demonstrated in models of injury, where digestion of CS-PGs was 
achieved through use o f the enzyme chondroitinase ABC. Here, the removal of inhibitory 
CS-PGs allowed subsequent axonal regeneration (Moon et al., 2001), and even functional 
recovery (Bradbury et al., 2002).
The CS-PG family consists of many different members, with great structural and functional 
diversity. They are all highly glycosylated glycoproteins, containing glycosaminoglycan 
(GAG) chains linked to their core proteins. These GAG chains consist of different 
repeating disaccharides which can be linked at various positions, as well as being differently 
modified. For example, the CS-PG family, as opposed to other proteoglycans, contain D- 
glucoronic acid (GlcA)-N-acetly-D-galactosamine (GalNAc)-repeating GAG units, 
modified by sulphate additions (Prydz and Dalen, 2001). The core protein can either be 
linked to the cell membrane via a GPI anchor, or present as a transmembrane or ECM 
component. It is both the GAGs and the core protein which are believed to mediate CS-PG 
functions (Fawcett et al., 2001). The inhibitory nature of the GAG chains themselves has 
been demonstrated through their digestion using chondroitinase (Moon et al., 2001; 
Bradbury et al., 2002), and inhibition of their sulphation using sodium chlorate (Smith- 
Thomas et al., 1995), both of which led to increased axonal outgrowth.
How CS-PGs affect axonal outgrowth is still not fully understood, but various theories 
have been put forth, such as, they may interact with the binding properties of adhesion 
molecules, or alternatively mask growth-promoting ECM molecules. Several types o f CS- 
PGs have been shown to interact directly with adhesion molecules, such as neurocan and 
phosphocan. Neurocan interacts with N-CAM (Friedlander et al., 1994), TAG-l/axonin-1 
(Milev et al., 1996), and tenascin (Milev et al., 1997), and inhibits axon growth mediated 
by Ng-CAM/Ll (Friedlander et al., 1994)). It has also been shown to regulate N-cadherin 
and pl-integrin-mediated adhesion and neurite outgrowth via a neurocan receptor, 
GalNAcPTase (Li et al., 2000). Phosphacan has also been shown to block several 
interactions that promote axon growth through interacting with contactin (Peles et al.,
1995), N-CAM, Ng-CAM/Ll (Milev et al., 1994), TAG-l/axonin-1 (Milev et al., 1996) 
and tenascin (Milev et al., 1997). It was demonstrated that some CS-PGs may mask other 
growth-promoting molecules, since digestion of CS-PGs allowed axon growth upon CNS 
cryostat sections, which was then inhibited by antibodies against laminin. Such a role has 
also been demonstrated for specific CS-PGs such as versican (Schnaelfedt et al., 2000) and 
brevican (Yamada et al., 1997). In contrast, the mouse form of phosphacan, DSD-1, as well 
as being inhibitory, can actually promote the growth of embryonic hippocampal axons 
(Clement et al., 1998, Faissner et al., 1997). This has also been demonstrated for the 
transmembrane form of phosphacan, receptor tyrosine phosphatase RPTP-p (Sakurai et 
al., 1997).
Very little is known about the mechanisms by which CS-PGs are regulated, although as 
previously mentioned, upon injury they are expressed by most of the cell types involved 
in the glial scar. Astrocytes upregulate expression of neurocan (McKeon et al., 1999; Asher 
et al., 2000), brevican (Yamada et al., 1997) and possibly phosphacan (McKeon et al.,
1999), whereas OPCs upregulate NG2 (Jones et al., 2002) and versican (Asher et al.,
2002). TGF(3 has been implicated in the regulation of CS-PGs since TGF(3 neutralising 
agents reduced the deposition of CS-PGs in the glial scar. In addition, TGF|3 was shown to 
directly upregulate neurocan expression in astrocytes in culture (Asher et al., 2000). In fact, 
several cytokines and growth factors involved in triggering and maintaining the activated 
astrocyte response, such as fibroblast growth factor 2 (FGF-2, also known as basic FGF or 
bFGF) and IL-6 , may be involved in CS-PG production due to a correlation between areas
of expression, and CS-PG deposition (Fitch and Silver, 1997b). Neurocan expression in 
cultured astrocytes is upregulated by epidermal growth factor (EGF), and downregulated 
by PDGF and IFNy (Asher et al., 2000).
As to which CS-PGs are contributing most to the inhibitory response, CS-56 
immunoreactive CS-PGs and neurocan appear to be the most abundant, and correlate 
closely with areas o f astrocytosis, suggesting a key role in inhibition (McKeon et al., 1999; 
Asher et al., 2000). However, despite NG2 making up less than 1% of the total ECM in 
the glial scar, it has been shown to be very potent, and thus may be making a greater 
contribution (Fidler et al., 1999; Jones et al., 2002).
1.1.2.4 Intrinsic neuronal state
Although the environment can modulate the ability o f axons to regenerate, the inherent 
properties of neurons can also be a factor with different classes o f axons demonstrating 
different growth response in the same environment. For example, following a dorsal root 
crush, the dorsal root ganglion (DRG) neurons can regenerate back towards the spinal cord, 
but are blocked at the CNS interface. In contrast, if motor axons are directed to the same 
place, by anastomosing the ventral horn and reattaching it to the dorsal root horn, they can 
penetrate much further into the spinal cord (Fawcett, 1992). These differences between 
neurons have been shown to be dependent upon the age as well as the type of neuron 
(Fawcett, 1992). This may reflect the ability of neurons to reexpress genes associated with 
growth and development. Certainly, following CNS injury, neurons fail to reexpress at least 
some of the growth-associated proteins that are expressed during development (Fu and 
Gordon, 1997), for example, Purkinje cells in the cerebellar cortex do not upregulate growth 
associated protein 43 kDA (GAP-43) in response to axotomy (Vuadano et al., 1995).
The response of a neuron to inhibitory factors is also modulated by its intrinsic state. For 
example, during development, rather than being inhibitory, MAG actually functions as a 
growth-promoting molecule. However, after development there is a switch to an inhibitory 
function for MAG, which has been shown to be caused by a decrease in intracellular cyclic 
adenosine monophosphate (cAMP) concentration within the neuron (Cai et al., 2001). In 
the same way, the response of an axon to a guidance cue, such as BDNF or acetylcholine, is
dependent upon intracellular levels of cAMP, such that an attractive response can be 
switched to a repulsive response through cAMP inhibition, using either a protein kinase A 
inhibitor or by applying a competitive analogue of cAMP (Song et al., 1997). This same 
mechanism is seen for axonal repulsion of Xenopus spinal axons induced by semaphorin III 
(Sema3) which is reversed in the presence of an analogue for cyclic guanosine 
monophosphate (cGMP) (Song et al., 1998).
In order to understand how cAMP functions to modulate axon growth, the Rho family of 
GTPases, Rho A, B, C and G; RaclA, IB and C; and Cdc42; are now being investigated. 
These are important regulators of the actin cytoskeleton (Luo et al., 1997) and have been 
shown to regulate growth cone collapse and neurite retraction (Dickson et al., 2001). Their 
involvement in these processes was demonstrated when inhibition o f Rho blocked myelin- 
induced growth cone collapse (Lehmann et al., 1999). In addition, Sema3A-induced growth 
cone collapse (see below) can be blocked by dominant negative Rac in both DRG neurons 
and spinal motor neurons (Jin & Strittmatter, 1997).
1.1.2.6 Inhibitory axon guidance molecules
Another set o f molecules involved in the inhibitory environment o f the CNS are guidance 
molecules, including the semaphorins, netrins, ephrins and slits. These act both as short 
range guidance molecules via cell to cell contact and also as long range diffusible factors 
(Astic et al., 2002). They have mainly repulsive effects, although can also be attractive, 
functioning by instructing growth cones to turn towards or away, to alter their speed and 
expand or collapse. This is achieved through alterations in the axonal actin cytoskeleton, 
probably mediated by the Rho family of GTPases (Yu & Bargmann, 2001).
The most widely studied family of guidance molecules are the glycoprotein semaphorins, 
o f which more than 20 have currently been characterised. Semaphorins exist in either a 
secreted or transmembrane form, and are classified by the presence o f a 500 amino acid 
conserved C-terminal “sema” domain (Goodman et al., 1999). They were originally called 
collapsins due to their induction of growth cone collapse, and function via two families of 
receptors, the neuropilins and the plexins (Fujisawa, 2004). The first semaphorin to be 
discovered and subsequently the best known, is Sema3A (formerly known as collapsin-1).
Another family of guidance molecules are a group of laminin-related proteins called netrins. 
So far six members have been described, netrinl-4 (Yin et al., 2000), [3-netrin (Koch et al.,
2000) and netrin-Gl (Nakashiba et al., 2000). These function through transmembrane 
receptors o f the Ig superfamily, deleted in colorectal cancer (DCC or UNC-40) and UNC-5. 
Like the semaphorins, netrins can act as both repulsive or attractive guidance cues, where 
UNC-5 receptors mediate repulsive netrin signalling, and DCC are mainly required for 
attraction, although the interaction of DCC and UNC-5 may determine this outcome (Hong 
et al., 1999). The netrins are secreted molecules that play an important role in the 
developing nervous system. They may also be involved in the adult nervous system, 
particularly netrin - 1 which is constitutively expressed by both neurons and 
oligodendrocytes in the adult spinal cord. It is particularly enriched in the periaxonal 
myelin at the interface between axon and myelin (Manitt et al., 2001), leading to the 
suggestion that netrin-1 may contribute to the inhibitory environment o f the adult CNS.
The Eph receptor tyrosine kinase family and their ephrin ligands also play important roles 
in controlling neuronal growth cone movement through repulsive cues. Ephrin proteins fall 
into two classes, ephrin-A class, defined by a GPI linkage to the cell membrane, and 
ephrin-B class, which have a transmembrane domain and a short cytoplasmic region. The 
Eph receptors are likewise subclassified, where EphA receptor bind ephrin-B class, and 
EphB receptors bind ephrin-A class (Gale et al., 1996). Eph receptors and ephrins provide 
important signals during development for migrating neural crest cells. Through mainly 
repulsive cues, they prevent cells or axons from entering inappropriate territory, and in 
turn establish patterns of tissue organisation. This is achieved through the expression of 
complementary Eph receptors and ephrins in appropriate domains (Wilkinson, 2001). This 
system may be involved in restricting axonal regeneration following injury, since not only 
are ephrins and their ligands expressed in the adult CNS but they are also upregulated 
following spinal cord injury, particularly by reactive astrocytes (Miranda et al., 1999; 
Willson et al., 2002; Bundesen et al., 2003).
A more recently described group of axonal guidance molecules are the slit family, encoded 
for by three genes, slit 1, 2 and 3 (Brose & Tessier-Lavigne, 2000). These are secreted 
proteins which bind to the roundabout (Robo) group of receptors, also encoded for by 
three genes, robol, robo2 and rig-1 (Camurri et al., 2004), although Rig-1 might not be Slit
binding. The Slit-Robo system is involved in repulsion o f migratory neurons (Brose et al., 
1999; Li et al., 1999), but may also promote axon branching (Brose & Tessier-Lavigne,
2000). Mediatation of repulsion appears to be via GTPase family members (Wong et al., 
2001; Ghose and Vactor, 2002). A clear role, however, has not yet been shown for slit-robo 
in CNS regeneration failure, although it may be likely since both slit and Robo mRNAs are 
expressed in the adult brain (Marillat et al., 2002).
1.1.2.7 Inflammatory response
It is still a matter for debate as to whether the inflammatory response is beneficial or 
inhibitory for axonal regeneration following CNS injury. Microglia are known to release a 
range o f inflammatory cytokines and other factors including IL-1 and IL - 6  (Woodroofe et 
al., 1991), tumour necrosis factor a  (TNFa) (Frei et al., 1987), TGFp (Keifer et al., 1993), 
glutamate (Piani et al., 1991) and nitric oxide (Minghetti & Levi, 1998). It has been 
suggested that these may exacerbate damage within the system. Indeed some of these 
factors, such as TGFp, have been implicated in the initiation o f reactive astrocytosis 
(Reilly et al., 1998; Krohn et al., 1999) and the formation of the glial scar (see section 
1.2.1.3). In addition, microglia, as well as probably inducing expression of CS-PGs through 
release of 11-6, and TGFcx and p, (see section 1.1.2.3), have also been identified as a source 
themselves o f inhibitory CS-PGs such as NG2 (Jones et al., 2002).
In contrast, evidence also exists to suggest that macrophages and microglia may actually be 
beneficial for regeneration. Unlike the PNS, where the macrophage response is rapid, the 
CNS response is a lot slower (Avellino et al., 1995). This leads to a slower removal of 
myelin and axonal debris. Since this debris is inhibitory to axonal growth, its persistence 
within the CNS is detrimental to regeneration. Support for this theory comes from studies 
on fish and amphibia, where microglia and macrophages respond as rapidly in the CNS as 
the PNS, and CNS regeneration is also observed (Avellino et al., 1995).
1.1.3 Strategies to promote CNS repair
1.1.3.1 Removal of inhibitory factors
Due to an understanding of the role inhibitory components play in preventing the 
regeneration of the CNS following injury, a range of procedures have been developed in 
order to promote regeneration by making the environment more permissive. A crude way 
to achieve this is to remove all inhibitory glia from the vicinity of the lesion, as has been 
demonstrated by ethidium bromide treatment. This resulted in a dramatic regrowth of axons 
for a limited time until endogenous glia surrounding the lesion were able to invade (Moon et 
al., 2000). This method was advantageous since it dealt with all inhibitory glia, instead of 
being cell-type specific. However, it is quite invasive and also abolished all beneficial 
properties of surrounding glia. An alternative method has been devised to remove only the 
reactive astrocytes by inserting the herpes thymidine kinase (HTK) gene under the glial 
fibrillary acidic protein (GFAP) promoter. When GFAP was upregulated by reactive 
astrocytes, so was HTK, which in the presence of systemic gancilovir killed the cell, 
leaving unreactive astrocytes in place (Delaney et al., 1996; Bush et al., 1998, Faulkner et 
al., 2004). This resulted in some increase of axonal growth, but also in disruption of the 
blood brain barrier, and a gross invasion of inflammatory cells (Bush et al., 1998).
A less invasive approach is to neutralise specific inhibitory molecules. The antibody IN-1 
specifically binds the myelin protein Nogo-A, and has been successfully used both to 
promote regeneration of the CST (Thallmair et al., 1998), and to restore forelimb function 
following ischaemia induced by middle cerebral artery occlusion (Papadopulos et al., 2002). 
Due to the discovery that three known inhibitory myelin proteins, Nogo, MAG and 
Ompg, all signal via the same receptor, NgR, a more direct approach would be to block this 
receptor. This has been demonstrated using an antagonist peptide of NgR which allowed 
CST fibre re-growth following a hemisection, and again resulted in functional recovery 
(GrandPre et al., 2002).
Since the CS-PGs are one of the major inhibitory components of the injured CNS (see 
section 1.1.2.3), approaches to overcome their effects have been investigated. The enzyme 
chondroitinase ABC, which degrades many different CS-PG family members through
cleavage of their inhibitory GAG chains, has been used in different injury models. 
Application of chondroitinase ABC into lesioned dorsal columns, resulted not only in the 
up-regulation of GAP-43, but also the regeneration of both ascending and descending CST 
axons, resulting in the restoration of synaptic activity (Bradbury et al., 2002). In addition, 
it stimulated the long distance regeneration of axons following lesioning o f the nigrostriatal 
tract (Moon et al., 2001).
A more general approach to reduce the inhibitory nature o f the glial environment has been 
to prevent its activation by inflammatory factors. Since both macrophages and microglia 
have been shown to promote gliosis following spinal cord injury, they were depleted by an 
injection o f liposome-encapsulated clodronate (Popovich et al., 1999). This resulted in 
increased axonal sprouting and an improvement in hindlimb movement. Alternatively, a 
blocking antibody against TGF(32, a gliosis promoting factor, was applied following 
lesioning of the cerebral cortx (Logan et al., 1999). This resulted in reduced glial scarring, as 
well as enhanced neurite extension
1.1.3.2 Promotion of intrinsic regenerative state of neurons
Another strategy to promote regeneration is to enable axons to overcome the inhibitory 
nature of the CNS environment. One method for achieving this is to modulate the levels of 
cAMP within the neuron. As was mentioned earlier, a decrease in cAMP is associated with 
an increased sensitivity to inhibitory components (see section 1.1.2.4). Therefore, by 
increasing cAMP levels, the neuron should be rendered less susceptible to inhibition. This 
has been achieved both by a conditioning lesion, or by treatment with cAMP analogues. A 
conditioning lesion was made in a peripheral nerve 1-2 weeks before a lesion to the CNS 
part o f a dorsal column, allowing axonal regrowth through the lesion site and beyond 
(Neumann and Woolf, 1999). Alternatively, addition o f a cAMP analogue at both 48 hours 
(Neumann et al., 2002) and 1 week (Qui et al., 2002) prior to lesioning of the dorsal root 
resulted in the same effect.
Since CNS axons fail to up-regulate certain growth-promoting genes in response to injury, 
one strategy was to over express these genes prior to injury. Co-expression of GAP-43 and
CAP-23, both major growth cone components, resulted in extension of axons in adult mice 
following spinal cord injury (Bomze et al., 2001).
However, the translation of this kind of approach to the clinic is at present unclear since 
there is a need for treatment before an accident happens. Despite this, it does demonstrate 
a clear principle for tackling spinal cord injuries.
1.1.3.3 Application of neurotrophic factors
Neurotrophic factors have been proposed to treat CNS injury due to their role in regulating 
many aspects of neuronal regeneration, from survival and differentiation, to growth and 
plasticity. Many different strategies for delivering them to injury sites have been 
investigated. NGF, NT-3 and glial-derived neurotrophic factor (GDNF) treatment, when 
applied directly to the spinal cord following a dorsal root crush injury, resulted in nerve 
growth across the dorsal root entry zone (DREZ) into the spinal cord (Ramer et al., 2000). 
Although only small diameter non-myelinated axons responded, functional and behavioural 
recovery were detected. In this experiment, BDNF treatment did not promote axon growth, 
although recovery of synaptic activity was supported.
Fibroblasts genetically modified to express neutrorophins have been used successfully for 
transplantation into several models of injury. BDNF-expressing fibroblasts supported the 
regeneration of rubrospinal tract axons, accompanied by recovery of forelimb movement 
(Liu et al., 1999). NT-3-expressing fibroblasts supported regeneration of corticospinal tract 
axons through the grey matter for substantial distances, although these were unable to 
penetrate the white matter (Grill et al., 1997). In addition, GDNF-expressing fibroblasts 
promoted the regeneration of motor axons following transection o f the hypoglossal nerve 
(Blesch et al., 1998)
An alternative delivery method into injury sites is the implantation of matrices infused 
with growth factors. Implantation of an NT-3-containing collagen matrix into a CNS lesion 
induced sprouting and regeneration o f corticospinal fibres (Houweling et al., 1998).
Furthermore, viral vectors have been used to deliver genes o f interest. Using this approach, 
BDNF was introduced into rubrospinal neurons, where it prevented their atrophy
following spinal cord injury (Ruitenberg et al., 2004). Additionally, NGF has been 
introduced in this way before a lesion, where it promoted axonal sprouting in the cortex 
(Ramirez et al., 2003). Gene transfer of GDNF also helped preserve neuronal fibres 
following a spinal cord contusion, as well as promoting hindlimb locomotor recovery (Tai 
et al., 2003).
1.1.3.4 Transplantation studies
Transplantation into lesion sites using a range of different cell types and tissue has been 
investigated, with the aim of producing a more permissive environment for axonal 
regeneration through either replacing lost cells, enriching the tissue with growth factors, or 
acting as suitable substrates for growth.
As has been mentioned in the previous section, the transplantation of fibroblasts 
expressing various neurotrophins has been performed with some success. In addition, 
transplantation of inflammatory cell types, such as microglia (Rabchevzky et al., 1997) and 
macrophages (Rapalino et al., 1998) has also resulted in axonal outgrowth. As discussed in 
Section 1.1.2.6, there is still some debate about whether inflammatory cells are beneficial or 
not for regeneration, nor is it clear whether resultant regeneration is due to the transplanted 
cells directly, or whether they recruit endogenous cells such as Schwann cells. The use of 
embryonic stem cells in transplant-mediated repair has also proved promising, where they 
have been shown to differentiate into appropriate CNS cells, such as oligodendrocytes and 
astrocytes (McDonald et al., 1999; Liu et al., 2000), although few neurons were generated. 
Studies have also been carried out with mouse embryonic stem cells restricted to a neural 
fate, seeded into a degradeable polymer scaffold, and transplanted into a hemi-section 
spinal cord injury (Teng et al., 2 0 0 2 ) which resulted in an improvement in functional 
recovery. Foetal tissue transplantation is another avenue of investigation since it is rich in 
both ECM and trophic factors (Vaudano et al., 1995), and has been shown to promote 
axonal regeneration (Courmans et al., 2001; Duchossoy et al., 2001). However, such axons 
do not enter the host CNS (Bregman et al., 1997), although this can be partially overcome 
by supplementing the graft with exogenous BDNF and NT-3 (Coumans et al., 2001; 
Bregmann et al., 1997). Another focus of transplantation therapies is the use of glial cells, 
particularly OECs and Schwann cells, due to their growth-promoting properties in situ.
Since this is a very exciting area, which relates directly to the contents to this thesis, it will 
be dealt with in detail in section 1.3.1.4 and 1.4.4.
Despite the benefits of using many of the above strategies to promote regeneration of the 
damaged CNS, it looks like a combinatorial approach would be a more realistic way to 
tackle CNS injury. In this way we can take advantage of a range o f different beneficial 
properties, where one strategy alone may favour sprouting, and another long distance 
growth. This has already been carried out with some success, for example, foetal grafts 
(Courmans et al., 2001) and Schwann cell bridges (Xu et al., 1995a) have both been 
supplemented with neutrotrophins, which allow the re-entry of axons into the host tissue. 
In addition, Schwann cell grafts have been supplemented with methods to raise the 
neuronal cAMP concentration, such as addition of rolipram (phosphodiesterase IV 
inhibitor) or dibutyryl (db)-cAMP. This resulted in an increased sparing of neurons 
following spinal cord contusion, and also increased myelination (Pearse et al., 2004). Best 
results were obtained when both rolipram and db-cAMP were used with Schwann cell 
grafts, resulting in significantly more nerve fibre growth beyond the grafts, and even 
recovery of locomotor function (Pearse et al., 2004).
1.2 Glial cells of the CNS
1.2.1 Astrocytes
The most abundant cell type within the CNS are the astrocytes, which comprise as much 
as 25% of the cells and 35% of the total mass of the CNS (Eng et al., 1992). They are 
generally stellate in shape with branching processes, which wrap around neuronal cell 
bodies and dendrites, and interact with the basal lamina of blood vessels and the pial 
surface (Goldstein, 1988; Suarez and Raff, 1989). However, the astrocyte population is a 
very heterogeneic one, being divided generally into protoplasmic and fibrous types, the 
former existing within the grey matter, and the latter in the white matter (Wilkin et al., 
1990). There are also further regional variations due to differential gene expressions, for 
example, only cerebellar astrocytes express somatostatin mRNA whereas proenkephalin 
mRNA and enkephalin peptides were present in cortical, striatal and cerebellar astrocytes 
(Shinoda et al., 1989). Marked differences have also been observed in the levels of
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glutamine synthetase and GFAP, as well as neutrotransmiatter receptors and enzymes, in 
astrocytes cultured from different brain regions (Shinoda et al., 1989).
1.2.1.1 Functions under normal conditions
It was originally believed that astrocytes played a merely supporting role for the ‘all- 
important’ CNS neurons, by providing only a structural scaffolding, hence they were 
viewed as a kind of brain ‘glue’, leading to the term neuroglia, meaning nerve glue (Ransom 
et al., 2003). As such, astrocytes form barriers around blood vessels and connections 
between nerve cells. However, experiments carried out in recent years have led to the 
understanding that astrocytes play a role in almost all o f the brain’s functions, both during 
normal and pathological conditions.
Astrocytes function primarily as the housekeeping cells of the CNS, maintaining and 
supporting its normal functions. In this way, they are involved in maintaining tight control 
of pH homeostasis and local ion concentrations, such as K+ and Ca2+, as well as regulating 
the extracellular volume within the CNS (Sykova et al., 1992). They also provide neurons 
with glucose and metabolic substrates, while removing neuronal waste such as metabolic 
byproducts and neurotransmitters, for example glutamate and gamma amino butyric acid 
(GABA), released during synaptic transmission (Schousboe et al., 1992). In addition, 
astrocytic processes interact with endothelial cells of capillaries to form the blood brain 
barrier. This protects the brain from the entry o f numerous large molecules, such as 
proteins and toxic substances, from the blood. Other processes, known as perivascular end 
feet, contact the pia mater, where they seal off the CNS through tight association o f these 
processes, forming the glia limitans.
More recently, however, it has been shown that astrocytes also function to dynamically 
regulate neuronal activity. Astrocytes, along with other CNS glia, are known to envelop 
synapses, in what was presumed to be a passive manner. However, evidence has arisen 
showing that in response to neurotransmitter release, the astrocytes feed back to the 
presynaptic neuron to either enhance or depress the signal, as well as to the postsynaptic 
neuron, producing either excitatory or inhibitory responses (Perea and Araque, 2002; 
Newman, 2003). Evidence also suggests that they may be involved in synaptogenesis,
regulating the formation, maturation and maintenance of such synapses (Slezak and Pfiegar,
2003).
1.2.1.2 Development
Astrocytes are understood to arise mainly from the neuroepithelium, via an intermediate 
radial glial cell. Radial glia are the first cells that can be distinguished from neuroepithelial 
stem cells of the embryonic ventricular zone, first appearing at the onset of neurogenesis. 
They serve as a scaffold for migrating neurons, which are also generated in the ventricular 
zone, before they terminally differentiate into astrocytes (Schmechel and Rakic, 1979; 
Voigt, 1989), and neurons (Tamamaki et al., 2001). However, once development is 
completed, multipotent progenitor cells persist in the adult brain within the subventricular 
zone (SVZ). These are able to form neurons (Doetsch et al., 1997), many of which migrate 
to the olfactory bulb in the rostral migratory stream, as well as forming astrocytes and 
oligodendrocytes (Levison and Goldman, 1993). In fact, these progenitor cells have been 
shown to be the SVZ astrocytes (Doetsch et al., 1999), which may also derive from radial 
glia (Taramontin et al., 2002). These cells may be a source o f tissue replacement following 
injury, thus demonstrating that a fully differentiated glia can act as a stem cell.
An additional progenitor cell which can give rise to astrocytes is the 0-2A, or 
oligodendrocyte-type-2 -astrocyte, progenitor, so named because in vitro it was shown to 
differentiate into both oligodendrocytes, and type-2 astrocytes (Raff et al., 1983). They 
were was discovered in the optic nerve and were shown to develop postnatally, hence 
type - 2  astrocytes were so named to distinguish them from type - 1  astrocytes which 
develop within the embryo. These astrocytes also retain the oligodendrocyte-lineage 
marker A2B5. However, in vivo, the 0 -2 A only gives rise to oligodendrocytes (Fulton et 
al., 1992), and was therefore renamed the oligodendrocyte progenitor cell (OPC). This may 
be due to environmental cues in vivo which either promote oligodendrocyte development, 
or inhibit astrocyte differentiation.
1.2.1.3 Reactive astrocytosis
Following injury, astrocytes undergo many changes becoming what is termed a reactive 
astrocyte (see Figure 1.1). This response occurs rapidly and can be detected within one 
hour of a focal mechanical trauma (Mucke et al., 1991). These astrocytes act to preserve 
the host tissue integrity following injury. This was clearly demonstrated in experiments 
where reactive astrocytes were ablated following spinal cord injury (see section 1 . 1 .3.1). 
Here, the blood brain barrier was not repaired, and further damage to neurons and 
oligodendrocytes occurred (Faulkner et al., 2004). Reactive astrocytes also participate in 
the repair process by forming a scar, re-establishing a glial limiting membrane made up of 
compact astrocytes bound together by gap and tight junctions (Fawcett and Asher, 1999; 
Shearer and Fawcett, 2001). This astrocytic scar protects the CNS from exposure to the 
external, peripheral environment, as well as walling off areas o f tissue necrosis and filling 
space resulting from neuronal loss.
Reactive astrocytes are characterised by many defined changes such as hypertrophy and in 
some cases, proliferation (Eng and Ghimiker, 1994). In addition, they undergo changes in 
gene expression, many of which are used to identify the reactive form, which lead to a 
complex and varied response to injury (Eddleston and Mucke, 1993). The hallmark change 
involved in astrocytosis is a morphological one, with an increase in multi-branched 
processes and astrocyte swelling (hypertrophy), and the upregulation of GFAP 
expression. GFAP is the principle intermediate filament o f mature astrocytes, and has been 
shown to be necessary for the formation of astrocytic processes in response to neuronal 
signals (Weinstein et al., 1991). The precise functions of GFAP are not fully understood as 
yet, although experiments on GFAP knock out mice have suggested important roles in 
normal astrocyte function, such as mediating astrocyte-neuronal interactions and 
modulation of synaptic efficacy in the CNS (McCall et al., 1996). Other protein changes 
occurring during astrocytosis may have obvious biological roles in regulating the 
environment of the injured CNS. These include the upregulation of proteases and pro tease 
inhibitors, which may help remodel the ECM or clear up debris; cytokine production, 
which could regulate the inflammatory response and the blood brain barrier; and the 
production of neurotrophic factors which help protect neurons and other brain cells 
(Eddleston and Mucke, 1993).
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However, the glial scar resulting from reactive astrocytosis also has detrimental effects on 
the ability of the CNS to regenerate. Firstly, this compact scar tissue acts as a mechanical 
barrier preventing regenerating CNS axons from penetrating it. In addition, the scar is also 
rich in a range of ECM components, produced by astrocytes, which are inhibitory to 
axonal outgrowth (Fitch and Silver, 1997a). One such group of proteins are the CS-PGs 
(Fawcett and Asher, 1999), as has been covered in detail (see section 1.1.2.3). GFAP itself 
has also been shown to be involved in axonal inhibition, since astrocytes lacking GFAP 
actually promoted neuronal extension in vitro, rather than inhibiting it (Menet et al., 2000).
The regulation of the astrocytic response is not fully understood in any detail, particularly 
due to the range o f cell types that are involved in the post-injury response and scar 
formation. Within such structures, not only astrocytes, but also inflammatory cells such as 
microglia and macrophages, and OPCs are involved. In addition, they all release many 
cytokines and growth factors which may either be involved in activating the post-injury 
response, or in its maintenance or regulation. Upon invasion of microglia and macrophages 
in the early stages following injury, initial signalling between them and astrocytes probably 
involves IL-1 (Lee et al., 1995; Herx and Yong, 2001). They are also a source of TGFp 
which has been demonstrated to induce astrocytic hypertrophy and increased GFAP 
expression in vivo (Laping et al., 1994) and in vitro (Reilly et al., 1998; Krohn et al., 1999). 
Astrocytes themselves are also a source of TGF(31 (da Cunha et al., 1993), thus is likely to 
be acting as an autocrine or paracrine mechanism. In fact, astrocytes release a range of 
cytokines and growth factors, which have also been shown to induce astrocytic 
hypertrophy or proliferation in culture (Eddleston and Mucke, 1993). For example, FGF-2 
(Menon and Landerholm, 1994) and ciliary neurotrophic factor (CNTF) (Rudge et al 1994), 
are substantially upregulated in injured tissue. FGF-2 has been shown to induce GFAP 
upregulation in cultured astrocytes (Reilly et al., 1998), and CNTF induces hypertrophy 
both in vivo and in vitro (Hudgins and Levison, 1998).
In addition, the astrocytic response is very heterogeneic, with not all astrocytes adopting 
the same phenotype. For example, not all reactive astrocytes are associated with increased 
amounts of ECM molecules, and conversely, in areas o f increased ECM, not all astrocytes
have become reactive (Fitch and Silver, 1997a). Therefore, a lot of work is still required to 
clarify the processes involved in gliosis.
1.2.2 Oligodendrocytes
1.2.2.1 Biological function
Oligodendrocytes are the myelinating cells of the CNS, and along with the astrocytes, are 
the other major class of CNS glia. Due to their ability to produce multiple processes, they 
are able to ensheath and myelinate fifteen axons on average, as well as surround neuronal 
cell bodies in the grey matter. This myelin sheath allows action potentials to pass along the 
CNS axons by saltatory conduction, but following injury, provides one of the major 
sources o f inhibitory molecules (see section 1.1.2).
1.2.2.2 Myelinating disease
In demyelinating diseases, such as multiple sclerosis (MS), it is this myelin sheath that is 
lost, although there is evidence that axonal damage also occurs (Giuliani and Yong, 2003). 
Spontaneous remyelination can occur, for example in experimentally-created demyelinating 
animal models (Blakemore et al., 1977) and in the early inflammatory phases of MS 
(Zamvil and Steinman, 2003). However, with the onset o f chronic demyelination, new 
myelin is no longer produced. It is a matter for debate whether remyelination is due to 
mature oligodendrocytes or OPCs, and whether failure to remyelinate results from a 
depletion in replacement cell stocks, or differentiation and recruitment malfunction 
(Franklin, 2002a).
In models of experimentally-created demyelination both transplanted and endogenous 
mature oligodendrocytes are unable to myelinate (Keirstead and Blakemore, 1999). 
Furthermore, within remyelinated areas of the CNS, there was an enhanced number of 
mature oligodendrocytes observed (Prayoonwiwat and Rodriguez, 1993) despite their 
inability to proliferate (Keirstead and Blakemore, 1999). This has suggested that rather 
than oligodendrocytes, OPCs may be the remyelinating cell, which in turn can give rise to a 
mature population of oligodendrocytes, as has also been supported by lineage labelling 
experiments (Carroll and Jennings, 1994; Gensert and Goldman, 1997).
1.2.2.3 Repair of persistent demyelination
Several approaches have been investigated to enhance remyelination of demyelinated 
lesions. One suggestion has been to enhance spontaneous remyelination through delivery of 
growth factors, such as PDGF and FGF, which may be involved in the recruitment phase 
of remyelination, or insulin-like growth factor 1 (IGF-1), whose levels are enhanced during 
spontaneous remyelination (Hinks and Franklin, 1999, 2000). Alternatively, since MS is 
believed to be a chronic inflammatory disorder, modulation of the inflammatory response 
may prove a more effective method. This is the favoured strategy for dealing with MS at 
present, where the immunomodulatory drugs, interferon beta and glatiramer acetate, 
significantly reduce the inflammatory response and demyelination (Flachenecker and 
Rieckmann, 2003). An additional strategy, would be to replace myelin through 
transplantation of myelin producing cells. This would be beneficial in situations where 
remyelination has failed due to a depletion of endogenous myelinating cell stocks. 
However, there is ongoing debate regarding which stage in the oligodendrocyte lineage is 
best for tranplantation, i.e. whether OPCs, immature or mature oligodendrocytes (Targett 
et al., 1996; Keirstead and Blakemore, 1997; Franklin, 2002b). In addition, these cells may 
not be beneficial within chronic MS lesions where they may continue to be a target of the 
ongoing autoimmune destruction of CNS myelin (Milner et al., 1997). Alternative cells 
with myelinating capacity proposed for transplantation, therefore, include the OEC and the 
Schwann cell, which will be discussed in more detail later (section 1.3.1.4 and 1.4.4).
1.2.3 Microglia
Microglia are the resident phagocytes of the CNS. It has long been debated whether they 
are actually glial cells, or whether they are more related to cells of the mononuclear 
phagocyte lineage. However, it is generally accepted now that they are ontogenetically 
related to mononuclear phagocytes (Kreutzberg, 1996). Resting microglia are small cells 
with short, branched processes that comprise approximately 5% of the glial population of 
the CNS. They show a downregulated immunophenotype which is adapted to the 
specialised microenvironment of the CNS. However, upon injury, they become activated, 
and function mainly as scavenger cells, although they also play other roles involved in 
tissue repair and neural regeneration. Their activation is tightly controlled by the nature of
insult, such that a graded response results. As well as responding to traumatic injury, they 
can respond to subtle alterations in their microenvironment such as imbalances in ion 
homeostasis that precede pathological changes (Kreutzberg, 1996). Their role in gliosis is 
discussed in more detail in section 1.1.2.5.
1.3 Glial cells of the PNS
1.3.1 Schwann cells
The Schwann cell is the major glial cell of the PNS, although others do exist such as the 
teloglia o f somatic motor terminals, satellite cells associated with neuronal cell bodies in 
sensory, sympathetic and parasympathetic ganglia and the enteric glia in the ganglia of the 
gut. In the PNS, all axons are ensheathed by Schwann cells, and these are either myelinated 
or not depending on the diameter of the axon. If the axon is less than 1 pm in diameter, 
several axons, usually in bundles, are ensheathed by one non-myelinating Schwann cell, 
with no myelin protein present (Jessen and Mirsky, 1991). However, for larger axons, one 
myelinating Schwann cell forms a myelin sheath around a single axon, resulting in a signet 
ring appearance. The functions of the Schwann cell include 1) providing an interface 
between the axon and the surrounding tissue, 2) allowing increased saltatory conduction of 
the nerve impulse due to its myelin sheath, and 3) playing important roles in the 
regeneration and development of nerves, particularly after injury.
1.3.1.1 Schwann cell development
The majority of Schwann cells in adult nerves originate directly from the neural crest 
(Jessen and Mirsky, 1992; Le Deourain et al., 1991), along with the other main glial cells of 
the PNS, as well as peripheral neurons and melanocytes. It was suggested that some 
Schwann cells may arise from other sources, such as the ventral neural tube or from 
neuroepithelial cells in the spinal cord after migration o f the neural crest is complete (Lunn 
et al., 1987; Sharma et al., 1995). However, recent experiments have demonstrated that this 
secondary source of Schwann cells is actually derived from boundary cap cells (Maro et al., 
2004; see below), which in turn also have a neural crest origin (Niederlander and Lumsden,
1996). The generation of Schwann cells from the neural crest follows a pathway involving
two main intermediate cell types (Mirsky and Jessen, 1999). First, a Schwann cell 
precursor is formed, and is observed in rat peripheral nerves at embryonic day (E) 14 and 
15. These cells do not express S I00, and do not have a basal lamina. They are also 
dependent upon axonal signals for survival (Jessen et al., 1994). From these precursor cells, 
the immature Schwann cell is formed which can be detected from E l7 until time of birth 
(Jessen et al., 1994; Dong et al 1995, 1999). These cells envelop unmyelinated axons and 
also form a basal lamina. From the time of birth, mature myelinating Schwann cells begin to 
form, although the non-myelinating cell appears later (Mirsky and Jessen, 2002). This last 
step is axon-dependent and also reversible, Schwann cells being able to interchange between 
myelinating and non-myelinating phenotypes. Schwann cell development is believed to be 
regulated in part by the neuregulins, since they influence proliferation and survival of 
Schwann cells (Grinspan et al., 1996; Trachtenberg and Thompson, 1996). The neuregulins 
have also been implicated in myelination since inactivation of the neuregulin receptor 
ErbB3 led to the formation of thinner myelin sheaths (Garratt et al., 2000). Reduced myelin 
sheath thickness also resulted from reducing neuregulin-1 expression too (Michailov et al.,
2004).
The formation of the DREZ is an important aspect o f development since this is a transition 
zone between the permissive PNS and the inhibitory CNS. It is here that Schwann cells and 
astrocytes contact each other, forming an interface which may resemble that which occurs 
following transplantation of Schwann cells into the astrocytic environment o f the CNS (see 
Section 1.5.2). This interface arises during early development as a result of cellular 
interactions between the neural crest and neuroepithelial cells (Golding et al., 1997). Before 
these cells give rise to Schwann cells and astrocytes respectively, a population of cells, 
known as boundary cap cells, cluster at what will later become the axon entry and exit 
points to the spinal cord (Niederlander and Lumsden, 1996). These boundary caps are 
believed to be transient neural-crest-derived structures, which allow the entry and exit of 
axons before the formation of the inhibitory glia limitans. A correlation between the timing 
of boundary cap dispersal, and the loss of capacity for dorsal root axons to enter the spinal 
cord supports this proposal (Carlstedt 1988; Golding and Cohen, 1997), as does the 
observation that neurites can enter CNS-tissue in culture if boundary cap cells are present 
(Golding and Cohen, 1997). Soon after birth in the rat, these boundary cap cells decline in
number and allow astrocyte processes, which are previously hindered by the presence of 
boundary caps, to extend into the dorsal roots and form the DREZ (Carlstedt, 1988; 
Golding et al., 1997). As a result, Schwann cells and astrocytes come into contact over an 
extended area, and the resulting interface is inhibitory to both Schwann cell and axon 
migration. Thus, after the loss of boundary caps, cut axons can regrow through the 
peripheral dorsal root, but this growth is abruptly inhibited at the glial limitans (Liuzzi and 
Lasek 1987; Carlstedt, 1988). The inhibitory effect of the astrocytes can be demonstrated 
following experimental disruption of the spinal cord glia limitans by X-irradiation, which 
allows penetration o f both regenerating sensory axons and Schwann cell populations which 
can enter the astrocyte-free DREZ (Franklin and Blakemore, 1993; Sims and Gilmore 
1994).
1.3.1.2 Myelinating versus non-myelinating phenotype
Schwann cells require axonal contact to drive their differentiation from immature Schwann 
cells to non-myelinating or myelinating mature Schwann cells (Mirsky and Jessen, 1999). 
This mature phenotype, however, remains very plastic, with cells being able to return to a 
cell type similar to the immature phenotype (Mirsky and Jessen, 1996), before 
redifferentiating into either myelinating or non-myelinating cells. This can be demonstrated 
both in culture and after transection of a mature nerve, where developmental regression of 
individual Schwann cells accompanied by myelin breakdown is observed. Reestablishment 
o f appropriate axonal contact, as seen in regenerating nerves or in myelinating co-cultures 
o f Schwann cells and neurons, leads to redifferentiation, and myelination. It is believed that 
cAMP may be involved in the regulation of Schwann cell phenotype, although the exact 
axonal signals have not been fully determined. Schwann cells cultured in the absence of 
axons, which possess an antigenic and morphological phenotype similar to non-myelinating 
Schwann cells, can be induced by addition of cAMP promoting agents such as forskolin, to 
adopt a phenotype more similar to myelinating Schwann cells (Scherer et al., 1994; Morgan 
et al., 1991).
Mature Schwann cells are recognised by the 0 4  antibody (Mirsky et al., 1990), but the 
myelinating and non-myelinating phenotypes can easily by distinguished. Myelinating
Schwann cells express many myelin proteins such as protein zero (PO), MAG, myelin 
basic protein (MBP), and peripheral myelin protein 22kDa (PMP22) (Scherer, 1997). 
They also express the glycolipid galactocerebroside (GalC). In contrast, non-myelinating 
Schwann cells express a diffuse form of GFAP, N-CAM, GAP-43 and p75NTR (Mirsky et 
al., 1986; Jessen et al, 1990; Curtis et al., 1992).
1.3.1.3 Peripheral nerve repair
Following injury to the peripheral nerve, nerve fibres distal to the lesion undergo a process 
called Wallerian degeneration. This leads to the removal and recycling of axonal myelin- 
derived material, and prepares the environment for subsequent axonal growth by the 
regenerating nerve. After the axon and myelin degenerate the remaining Schwann cells are 
stimulated to proliferate within the basal lamina tube that surrounded the original nerve 
fibre; these columns are known as endoneurial tubes or bands of Bungner (Torigoe et al., 
1996; Burnett and Zager, 2004). This tube then acts as a conduit for the re-growing axon. In 
this way, injuries which damage the basal lamina such as a transection, do not repair as well 
as when the basal lamina is left intact, such as in a crush injury. This basal lamina consists 
of collagen, fibronectin and laminin, produced by Schwann cells (Baron von Evercooren et 
al., 1986). Both fibronectin and laminin have been shown to be potent substrates for 
neurite outgrowth (Cohen et al., 1987; Humphries et al., 1988). The proliferation of 
Schwann cells within these bands are believed to be stimulated by both the axonal 
membrane and myelin debris (Salzer and Bunge, 1980; Salzer et al., 1980), as well as 
invading macrophages (Baichwal et al., 1988).
Schwann cells have been shown to be the key component of subsequent axonal regeneration 
in experiments where a length of peripheral nerve has been frozen, killing the Schwann cells 
but leaving the basal lamina intact. If this nerve is grafted on to a proximal stump in a host 
animal, regeneration through it is only possible if migrating Schwann cells accompany the 
nerve (Fawcett and Keynes, 1990).
Schwann cells in the bands of Bungner do not die since they are maintained by an autocrine 
mechanism. This has also been demonstrated in culture, where mature Schwann cells are
able to survive without axonal contact. The active factors involved in this aurocrine survival 
loop, are believed to be IGF-2, PDGF-BB and NT-3 (Meier et al., 1999).
Schwann cells are suited to promoting axonal regeneration since they produce many 
neurotrophins such as neuregulin (Raabe et al., 1996), BDNF and GDNF (Yamamoto et al., 
1993). In addition, they also express several growth stimulatory cell adhesion molecules 
such as integrins, LI, NCAM (Martini et al., 1994) and N-cadherin (Bixby et al., 1988; 
Lakatos et al., 2000). Inhibitory antibodies to L I, beta-1 integrin and N-cadherin have 
highlighted a significant role for these molecules in neurite outgrowth (Bixby et al., 1988). 
Remyelination of regenerating axons is also possible following peripheral injury, occurring 
within 3 weeks (Fawcett and Keynes, 1990).
1.3.1.4 Transplantation studies
Since Schwann cells mediate the axonal-growth-promoting properties of the peripheral 
nervous system, it was investigated whether they could be used to provide a permissive 
environment for CNS regeneration after injury. Many experiments have demonstrated that 
Schwann cells can indeed be used to promote repair of the injured CNS. This was firstly 
done using peripheral nerve grafting (Tello 1911 - cited in Franklin and Barnett, 1997; 
Richardson et al., 1980; Benfrey and Aguayo, 1982), and later by transplantation of 
Schwann cells either in suspension (Rasiman et al., 1993; Brook et al., 1994, 2001) or when 
seeded into channels (Xu et al., 1995b, 1999; Plant et al., 2001). Such experiments have 
shown that the presence of Schwann cells can promote the extension of nerves into grafted 
channels. In addition Schwann cells can induce sprouting of axons (Li and Rasiman, 1994), 
as well as directing subsequent nerve growth (Brook et al., 1994).
However, for such results to be clinically beneficial, the observation o f functional recovery 
is necessary. This has been assessed using behavioural tests or by direct measurement of 
electrical conductivity using electrophysical methods. Fortunately, restoration of nerve 
conduction have been observed following complete transection of the spinal cord (Imazuimi 
et al., 2000). Functional synaptic contacts were also re-established following optic nerve
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transection and subsequent replacement with a segment of peripheral nerve (Vidal-Sanz et 
a l, 1987).
Schwann cells have also been used successfully to remyelinate demyelinated axons. This 
has been shown in experimentally-generated demyelinating lesions, where lesions are 
produced by gliatoxins, such as ethidium bromide and lysolecithin, thus leaving the axons 
intact, and subsequent repair by endogenous glial cells prevented by X-irradiation, known 
as the X-EB model (Blakemore et al., 1977). Following Schwann cell transplantation, 
peripheral myelin was identified, as well as the characteristic one-to-one glia-axon 
relationship, demonstrating remyelination was attributable to the transplanted Schwann 
cells (Blakemore 1977; Blakemore and Crang, 1985). The clinical relevance o f such cellular 
transplantations has been supported by the restoration o f conduction through the lesions 
(Smith and Hall, 1980, Felts and Smith, 1992; Honmouu et al., 1996).
However, despite all this success, there are limitations to the use o f Schwann cells for 
transplantation repair, which will be discussed later (see section 1.5.1).
1.4 The Olfactory System
The primary olfactory system comprises of both CNS and PNS tissue (see Figure 1.2). 
The olfactory bulb is located within the CNS part of the primary olfactory system and is a 
laminated structure, whereas the epithelium exists within the PNS. The outer layer of the 
bulb consists of olfactory receptor neuron (ORN) axons, which extend from the peripheral 
epithelium, and associated glial cells. This layer is known as the olfactory nerve layer. 
Beneath this is the glomerular layer consisting o f round structures, termed glomeruli, which 
are collections of synapses between ORNs, intemeurons and second order neurons.
The ORNs project cilia into the nasal cavity, which contain olfactory receptors, capable of 
binding odorant molecules. These olfactory receptors are a family of G-protein-coupled 
seven-helix transmembrane proteins, and were first cloned by Buck and Axel (1991). The 
oderant receptor family has now been found to be the largest gene family known, due to the 
presence of between 500-1000 genes in the mammalian genome (Buck, 1992). It is also now
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Figure 1.2 Schematic of the prim ary olfactory system.
The olfactory system is composed of both peripheral nervous system (PNS) and 
central nervous system (CNS) tissue. The PNS component contains the olfactory 
mucosa which is subdivided into the olfactory epithelium and lamina propria. The 
olfactory epithelium contains olfactory receptor neurons (ORNs; which project cilia 
into the nasal cavity), sustentacular cells (non-neuronal supporting cells), globose 
basal cells (putative stem cells for the epithelium), horizontal basal cells (putative 
stem cells) and Bowman’s gland and ducts. The lamina propria consists of loose 
connective tissue and olfactory ensheathing cells (OECs), which ensheath bundles of 
olfactory receptor axons extending from the olfactory epithelium. The olfactory 
receptor axons course through the cribriform plate and enter the olfactoiy nerve layer 
of the CNS environment of the olfactory bulb, where they synapse to form glomeruli 
with the second order neurons in the glomerular layer.
apparent that each ORN only expresses one receptor gene (Malnic et a l, 1999). Upon 
binding an odorant molecule, an electrical signal is generated in the ORN which is then 
transmitted from the PNS to the CNS, where the information is processed.
The olfactory system is unique in that, not only is it one of only a few regions of the CNS 
which are capable of spontaneous repair following injury, but ORNs also constantly 
undergo neurogenesis throughout the life of the organism (Graziadei and Graziadei, 1979). 
ORNs are constantly replaced from presumptive stem cells residing at the base of the 
olfactory epithelium, and have an average life span o f between 4-8 weeks depending on the 
environment (MacKay-Sim and Kittel, 1990) and the species (Ramon-Cueto and Avila.,
1998). These newly generated neurons then extend axons through the peripheral part of the 
olfactory system to the glia limitans, where they not only penetrate the CNS part of the 
olfactory bulb, but also form new synapses within the glomerular layers (Valverde et al., 
1992; Treloar et al., 1999). This unique property has been suggested to be due to the 
presence of a novel glial cell within the olfactory system known as the olfactory 
ensheathing cell (OEC). These glial cells were first described by Golgi and Blanes (reviewed 
in Ramon-Cueto and Avila., 1998) at the end of the nineteenth century, when two types of 
macroglial cells were observed in the olfactory bulb. They described stellate cells 
distributed throughout the entire bulb, which are now known to be astrocytes, and fusiform 
cells, which were located in the first two layers of the olfactory bulb, and are now known 
to be OECs.
1.4.1 OEC morphology and antigenic profile
1.4.1.1 In vivo
In the olfactory system, OECs exist in a close relationship with axons, where OECs 
ensheath bundles of unmyelinated axons along the axons’ length, crossing the PNS-CNS 
transition zone, from the epithelium to the outer layers of the olfactory bulb (Doucette, 
1991, Ramon-Cueto and Valverde. 1995). The OEC has a mixture of properties in common 
with both Schwann cells from the PNS, and astrocytes from the CNS (Doucette, 1984;. 
Chuah and Au, 1991). Like the non-myelinating Schwann cell, OECs ensheath bundles of 
axons (Bunge et al., 1986; Jessen and Mirsky, 1991), and express p75NTR (Barnett et al.,
1993), laminin (Liesi et al., 1985) and LI (Miragall et al., 1988). In common with the 
astrocyte, OECs express fibrous GFAP (Barbour and Dahl, 1987), whereas Schwann cells 
express a more diffuse form of GFAP (Jessen et al., 1990). OECs also form part o f the 
olfactory bulb glia limitans at the PNS-CNS transition zone, in a manner resembling the glia 
limitans of astrocytes at other cranial and spinal nerves (Doucette, 1991). Hence, not only 
does the OEC span both the PNS and the CNS within the olfactory system, but it also 
shares properties in common with the glial cells from these two different regions.
However, despite these similarities to both Schwann cells and astrocytes, the OEC is in 
fact a distinct type of glial cell. It differs from the non-myelinating Schwann cell by 
ensheathing bundles of up to 200 axons, opposed to the 20 ensheathed by Schwann cells 
(Franklin and Barnett, 1997). In addition, OECs have a distinct antigenic profile (Barnett et 
al., 1993; Franceschini and Barnett, 1996), for example, unlike both myelinating and non­
myelinating Schwann cells, they lack Gal C (Jessen and Mirsky, 1991). On the basis o f this 
antigenic profile, they can be purified by fluorescent-activated cell sorting (FACS) for 
04+/GalC- (Barnett et al., 1993). They are also distinct from astrocytes, due to their 
ultrastructure, OECs having an electron dense cytoplasm with fewer intermediate 
filaments, in contrast to astrocytes which contain bundles of intermediate filaments in an 
electron lucent cytoplasm (Doucette, 1984, 1990).
Within the bulb, however, OECs appear to exist as a heterogenous population, where the 
0 4  positive olfactory nerve layer (Barnett et al., 1993) can be divided into further layers 
including an inner polysialylated form of NCAM (PSA-NCAM, also known as embryonic- 
NCAM or E-NCAM)-positive layer, surrounded by a p75NTR-positive outer layer 
(Franceschini and Barnett, 1996). In the mouse, the SI 00-positive olfactory nerve layer 
was divided into a GFAP/neuropeptide Y (NPY)-positive inner layer and a p75NTR- 
positive outer layer (Au et al., 2002).
1.4.1.2 In vitro
In accordance with the in vivo observations, OECs in culture also consist of a 
heterogeneous population. The antigenic profile of OECs in culture (purified by FACS
sorting for 04+/GalC-; Barnett et al., 1993) at first resembled those seen in vivo, but with 
time some of these markers change. In serum-containing conditions, OECs lose expression 
of 0 4  and PSA-NCAM, gaining p75NTR and diffuse GFAP, and attaining a flatter 
morphology. However, if OECs are maintained in serum-free conditions supplemented 
with astrocyte-conditioned media (ACM), two morphologically and antigenically distinct 
cell types can be identified. These consist of 1) a flat astrocyte-like/fibroblast-like cell, with 
high levels of PSA-NCAM and filamentous GFAP, but no p75NTR, and 2) a non­
myelinating Schwann cell-like cell, with a spindle morphology, expressing high levels of 
p75NTR but no PSA-NCAM (Franceschini and Barnet, 1996). However, some cells have 
been observed to have a phenotype intermediate between these two phenotypes, 
expressing both p75NTR and PSA-NCAM in culture (Franklin and Barnett, 1997).
The precise relationship between these different cell phenotypes is as yet not fully 
understood, although a clonal OEC cell-line was able to give rise to both astrocyte-like and 
Schwann cell-like OECs, demonstrating that the two cell types are indeed related and share 
a common lineage (Franceschini and Barnett, 1996). Thus, it appears that the OEC is a 
plastic cell which can, depending upon culture conditions, adopt various phenotypes. This 
has been demonstrated clearly in culture where OECs can rapidly adopt different 
morphologies depending upon the culture conditions, and also upon contact with other cell- 
types such as astrocytes and neurons (van den Pol and Santarelli, 2003; Vincent et al., 
2003).
1.4.2 Development
A further distinction between OECs and previously characterised glia is their 
developmental origin. Whereas astrocytes are derived from the neuroectoderm and Schwann 
cells from the neural crest, OECs have been shown to originate, along with the olfactory 
epithelium, from the olfactory placode (Doucette, 1989; Chuah and Au, 1991). The 
olfactory bulb, however, along with other CNS structures, develops from the neural tube 
(Doucette, 1989). Therefore, as the bulb and the epithelium come together during 
embryonic development, primitive olfactory neurons are required to extend axons from 
their origin in the epithelium to where they penetrate the bulb. This is achieved since
neurons migrating forwards are accompanied by a mass of migrating placodal cells, 
including OEC progenitors which are distinguished by their electron-dense ultrastructure 
from the other migrating cells (Doucette, 1989, 1993). As these cells reach the primitive 
bulb, the bulb evaginates and the migrating cells cover it in a thin layer. These then 
penetrate the glia limitans, which at this stage comprises of ventricular layer-derived 
astrocytes, leading to the formation of the olfactory nerve and glomerular layers. It is 
within these newly formed layers, that OECs and astrocytes are then able to intermingle, 
forming a new glia limitans at the bulb surface. This glia limitans is different to that 
surrounding other areas of the CNS, since it remains penetrable to axons throughout 
adulthood.
1.4.3 Role of OECs in olfactory regeneration
Due to the presence of OECs in a tissue capable o f constant neuronal turnover, it was 
proposed that the OECs may play a major role in promoting regeneration (Doucette, 
1989). In fact, since the PNS-CNS entry zone of the olfactory system is continuously 
permissive to the entry of olfactory nerve fibres and has a glia limitans consisting of OECs 
as well as astrocytes, in contrast to other restrictive PNS-CNS interfaces (such as the 
DREZ) consisting of just astrocytes, this seemed a very plausible suggestion. Further 
support for a role for OECs in regeneration came from in vitro studies, showing OECs to 
be a highly conducive substrate for primary olfactory axon outgrowth (Goodman et al., 
1993; Chuah and Au, 1994, Kafitz and Greer, 1998, 1999). Although the precise molecular 
mechanisms by which OECs are able to support axonal growth is not fully understood, 
they do express many molecules suitable for such a task. These include axon growth- 
promoting adhesion molecules such as LI (Miragall et al., 1988) and PSA-NCAM 
(Franceschini and Barnett, 1996). It has been noted that the continued presence of PSA- 
NCAM in the adult olfactory system, indicates a retention of embryonic features, which 
may underlie its remarkable regenerative capacity (Miragall et al., 1988). This is supported 
by the presence of PSA-NCAM in other brain areas which can also generate neurons or 
exhibit morphological or physiological plasticity (Seki and Arai, 1993).
A large array of survival and growth factors which can influence axonal outgrowth, are 
produced by OECs, such as NGF, BDNF, NT-3/4 and neuregulin (Thompson et al., 1999; 
Boruch et al., 2001; Woodhall et al., 2001/ In addition, OECs are immunoreactive for 
PDGF (Kott et al., 1994) and NPY (Ubink et al., 1994). They also produce ECM 
components, which may support axonal growth, such as laminin (Doucette, 1996; Kafotz 
and Greer, 1997), fibronectin and type-IV collagen (Doucette, 1996). Laminin, in particular, 
is seen as a preferential substrate for ORN neurite extension in vitro (Krafitz and Greer, 
1997).
It has also been shown that in a model of olfactory system regeneration where olfactory 
fasicles are destroyed following zinc sulphate treatment of the olfactory system 
(Matulionis, 1975), OECs remain in their original position with processes that ensheath 
axons remaining, suggesting that they may act as a conduit for the regenerating ORN axons 
(Williams et al., 2004).
1.4.4 Role In Transplantation
Due to the potential regeneratory properties o f the OEC, it was a logical step to see how 
OECs could be used to contribute to the repair of CNS pathologies. Following on from the 
hypothesis that it was the presence o f OECs at the glia limitans o f the olfactory bulb that 
might permit the entry of growing axons, their regeneration-promoting properties were 
directly demonstrated in the DREZ (Ramon-Cueteo and Nieto-Sampedro, 1994). Here, 
following injury, the glia limitans prevents dorsal root axons from crossing from the PNS to 
the CNS. However, when OECs were transplanted into the DREZ following dorsal root 
transection, numerous regenerating dorsal root axons could be observed re-entering the 
spinal cord.
This initial success has since been followed by many other examples of OECs apparent 
ability to support axonal regeneration in different experimental models of CNS injury. 
Following a complete transection of the thoracic spinal cord, Ramon-Cueto and co-workers 
followed up their pioneering experiment by showing that transplanted OECs could support 
long-distance regeneration of spinal cord axons (Ramon-Cueto et al., 1998). Likewise,
following a focal lesion of the rat corticospinal tract, OECs inhibited the profuse axonal 
banching (‘abortive sprouts’) and led to a directed elongation of regenerated corticospinal 
axons, both across the lesion site and back into the distal part of the white matter tract (Li 
etal., 1998). Many other experiments have also shown this remarkable capacity of OECs 
to support axonal outgrowth following injury (Smale et al., 1996; Li et al., 1997, 2003; 
McDonald et al., 1999; Navarro et al., 1999; Ramon-Cueto et al., 2000; Lu et al., 2002).
As with Schwann cells, for OEC transplantation to be a therapeutic strategy for treating 
spinal cord injuries, restoration of function needs to be observed, and indeed has been 
demonstrated by many researchers. Recovery of locomotor behaviour in rats following 
complete transection was reported when OECs were transplanted into the spinal cord 
(Ramon-Cueto et al., 2000), even if the transplantation occurred 4 weeks after the injury 
(Lu et al, 2002). In the same way, restoration o f breathing and climbing was demonstrated 
following a hemi-transection of the spinal cord followed by immediate transplantation of an 
OEC-containing endogenous matrix (Li et al, 2003). The restitution o f spinal reflex 
functions has also been reported (Navarro et al., 1999; Taylor et al., 2001), along with 
direct observation of impulse conductions across a transected dorsal column following OEC 
transplantation.
In addition to its success in spinal cord injury repair, the OEC has also shown much 
promise for treatment of persistent demyelinating diseases such as multiple sclerosis. In 
situ, the OEC is associated with small diameter olfactory receptor axons which are not 
myelinated, however, due to its many similarities to the non-myelinating Schwann cell, 
which is also normally engaged with small diameter axons, it was proposed that OECs 
might have the potential to myelinate axons if the diameter was of an appopriate size. This 
was confirmed in vitro where OECs co-cultured with dorsal root ganglions were capable of 
forming a myelin sheath (Devon and Ducette, 1992). In the X-EB model of demyelination 
(see section 1.3.14), where a chemically demyelinated lesion was formed, an OEC cell line 
was also capable of myelinating axons (Franklin et al., 1996). Interestingly, this myelin was 
of a peripheral composition and morphology, such as the expression of P0, further 
supporting the Schwann cell-like nature of OECs. Such models of remyelination have also 
been shown to restore efficient conduction along the axons (Imaizumi et al., 1998).
The clinical potential of OECs for CNS repair has become more possible due to the recent 
observation of a human equivalent cell (Barnett et al., 2000), which shares many properties 
in common with the rat OEC, such as similar growth factor requirement and expression of 
p75NTR. Similar to the rat, human OECs also myelinated demyelinated CNS axons 
following transplantation (Barnett et al., 2000, Kato et al., 2000).
Furthermore, whereas previous OEC cultures have mainly been taken from the bulb 
(Barnett et al., 1993; Smale et al., 1996; Navarro et al., 1999; Plant et al., 2002; Li et al., 
2003), recently OECs have been obtained from the lamina propria, beneath the olfactory 
epithelium (Au and Roskams, 2003). Thus, a peripheral source of OEC may be available 
which would make obtaining such cells for autologous repair of human pathologies much 
safer than the invasive procedures required to gain access to the olfactory bulb.
Whether the different OEC phenotypes (see section 1.4.1.2) fulfil different roles in vivo is 
not known at present. Following transplantation, it has been suggested that the Schwann 
cell-like OEC may ensheath the regenerating fibres, whilst the astrocyte-like OEC, may be 
forming an outer perineurial-like sheath around the regenerating axon and associated 
Schwann cell-like OECs (Raisman, 2001). However, the astrocyte-like OEC observed 
following transplantation may actually be due to contaminant fibroblasts or meningeal cells 
(Lakatos et al., 2003b; Li et al., 2003). However, in the majority of transplantation studies, 
cultures were almost homogenous for p75NTR positive/GFAP diffuse OECs, typical of the 
Schwann cell-like cell (Navarro et al., 1999; Ramon-Cueto et al., 1998, 2000; Verdu et al., 
2001; Plant et al., 2002; Takami et al., 2002), and probably reflecting the popular 
purification technique of p75NTR immunopanning. However, despite the observation of a 
purely p75NTR population, Smale and colleagues (Smale et al., 1996) distinctly saw two 
morphologies following transplantation, one being slender or spindle shaped, and the other 
being large and flat. As previously mentioned, little is known about the relationship 
between the different OEC phenotypes, except their obvious plasticity.
1.5 Comparison of Schwann cells and OECs
It can be summarised, from the previous sections (1.3.1.4 and 1.4.4), that OECs and 
Schwann cells have many general properties in common. First, both OECs and Schwann 
cells are involved in promoting neurogenesis in situ. OECs support neuronal growth, both 
as part of the general turnover of olfactory receptor neurons, and following injury to the 
olfactory system. Likewise Schwann cells are involved in the development of the PNS, and 
facilitate regeneration of peripheral nerves following injury. In addition, they both share 
similar antigenic properties (see Table 1.2), where OECs, like non-myelinating Schwann 
cells, can adopt a spindle-like morphology, and express GFAP and p75NTR. Furthermore, 
they have both been shown to promote axonal regrowth and remyelination upon 
transplantation into models of CNS lesions (see section 1.3.1.4 and 1.4.4). Interestingly, 
not only do OECs express myelin typical of the PNS following remyelination (Franklin et 
al., 1996; Kato et al., 2000), but this remyelination is controlled using similar signalling 
mechanisms as for Schwann cells. It has been shown that the transcription factors, Krox-20 
and SCIP/Oct-6 are involved (Blanchard et al., 1996; Smith et al., 2001), and that desert 
hedgehog, which is implicated in control of peripheral nerve myelination (Bitgood and 
McMahon, 1995) is also expressed by OECs (Parmantier et al., 1999; Smith et al., 2001).
Schwann cells and OECs also display similar growth responses, where proliferation o f both 
cell types is induced following an increase of intracellular cAMP (Wewetzer et al., 2002; 
Ramon-Cuteo et al., 1998; Yan et al., 2001). In addition, both cell types proliferate in 
response to a similar spectrum of growth-promoting molecules -  including heregulin, GGF- 
2, and hepatocyte growth factor (HGF) (Krasnoselsky et al., 1994; Levi et al., 1995; Zhang 
et al., 1995; Pollock et al., 1999; Chuauh et al., 2000; Yan et al., 2001).
However, despite these similarities, there are some differences between OECs and Schwann 
cells, some of which were discussed in section 1.4.1.1. This is particularly seen in their 
interactions with astrocytes, for example, following transplantation.
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1.5.1 Transplantation studies
In order to achieve successful repair following transplantation into injury models, certain 
criteria must be fulfilled by the transplanted cells. Firstly, the cells must be able to survive 
within the host tissue for long enough to promote repair. Secondly, it is important that 
they are able to migrate to areas of damage, rather than remain within the graft. Thirdly, 
they would need to display suitable properties, which would be beneficial for promoting 
repair of the injury site. This could be through the promotion of neuronal regeneration, 
which requires subsequent formation of functional neuronal synapses, or through sparing 
of tissue or promotion of remyelination. In addition, the transplanted cells must not 
contribute to the formation of the glial scar at the injury site to a level which could inhibit 
regeneration.
Both OECs and Schwann cells are candidates for transplant-mediated repair of CNS lesions 
and in different ways meet several o f these criteria. There is still debate as to which might 
be the superior candidate and this will be discussed.
Following transplantation into CNS tissue, regenerating nerves respond differently to 
Schwann cells and OECs. It was shown that whereas Schwann cells stimulated axonal 
sprouting at the lesion site (Li and Rasiman, 1994), axonal sprouting was reduced by 
OECs, which instead caused an increase in growth into the distal part of the transected 
spinal cord (Li et al., 1997, 1998). This ability to promote long distance axonal regeneration 
was also demonstrated by Ramon-Cueto et al (1998), where although axons could enter 
Schwann cell-filled guidance channels, they could not leave the channel and re-enter the 
spinal cord at the distal graft-host interface. The presence o f OECs at the channel/tissue 
interface, however, could promote this. Further evidence that Schwann cells fail to promote 
the exit o f axons from the graft was observed by Plant et al (2001). They speculated that 
this may result from the high concentration of chemoattractant growth factors within the 
graft, such as FGF, which prevent the axons leaving such a favourable environment. 
Alternatively, it could be due to an unfavourable tissue reaction at the distal interface 
leading to astrocytosis and the generation of inhibitory factors, such as the CS-PGs. OECs 
might improve this situation by producing factors favouring long-distance elongation of
axons, or through prevention of such an inhibitory response by the distal host tissue, as 
has been proposed by Verdu et al. (2001).
In contrast, under different experimental conditions, Schwann cells have been demonstrated 
to be a superior candidate for repair than the OEC, for whom limitations were observed. 
Following a contusion injury, Schwann cell transplantation led to an improvement of 
locomotor activity where OEC transplants were o f no benefit (Takami et al., 2002). In 
addition, in vitro myelination assays demonstrated that under conditions where Schwann 
cells could form myelin, OECs failed (Plant et al., 2002). Whether this was due to the OEC 
preparation used remains a possibility. It has recently been shown that pure OEC 
preparations were less efficient at myelinating axons, following tranplantation into models 
of demyelination, than preparations containing contaminant meningeal cells (Lakatos et al., 
2003b). Further in vivo studies have also failed to repeat the initial successes of OEC 
transplantation into experimental CNS injury models (Barnett and Riddell, 2004). For 
example, following dorsal root sectioning and re-anastomosis, OEC transplants did not 
enhance the number of fibres entering the spinal cord in comparison to control samples, nor 
did electrophysiology measurements demonstrate any functional reconnection between 
regenerating fibres and spinal cord neurons (Riddell et al., 2004). Reasons for these 
discrepancies between experiments may be due to any number of reasons from variations in 
cell preparations; such as age of donor tissue, time in culture, and culture conditions of cell 
transplants; to differences in transplantation sites and injury models. It therefore appears 
that there are many factors which determine the efficacy of glial cell transplantations, 
which need to be addressed in order to improve the reliability o f such therapies. One such 
factor is their ability to integrate with the host tissue following transplantation.
1.5.2 Compatibility with host tissue
Many researchers, have reported that OECs are able to migrate and co-exist within host 
tissue (Li et al., 1998; Ramon-Cueto et al., 1998; Gudino-Cabrera et al., 2000), following 
transplantation into the injured spinal cord. In contrast, Schwann cells do not migrate as 
well (Baron von Evercooren et al., 1992; Franklin and Blakemore, 1993; Iwashita et al., 
2000), instead being restricted to the lesion site itself (Iwashita et al., 2000; Shields et al.,
2000). In fact, Schwann cells also exhibited poor survival in these studies (Iwashita et al., 
2000). Such observations are reminiscent of the Schwann cell-astrocyte interface in situ at 
the glia limitans of the DREZ, where Schwann cells and astrocytes exist either side of a 
defined boundary. Interestingly, if the formation of this glia limitans is impeded during 
development by X-irradiation of astrocytes, extensive Schwann cell myelination of CNS 
tracts will occur (Gilmore and Duncan, 1968 -  cited by Franklin and Barnett, 1997), 
demonstrating the inhibitory nature of the astrocytic glia limitans for Schwann cell 
migration. Likewise, the ability of the OEC to integrate with astrocyte-rich tissue reflects 
its co-existence with astrocytes within the glia limitans of the olfactory bulb.
However, in contrast to this, there is evidence that Schwann cells can migrate within the 
CNS, for example, upon grafting into the hippocampus (Brook et al., 1993; Raisman et al.,
1993). However, they may have travelled predominantly along blood vessels and the pia 
mater rather than through astrocyte-rich areas. Whether OECs are capable o f migrating 
extensively within the CNS after transplantation also remains controversial, since some 
studies report extensive migration (Gudino-Cabrera and Nieto-Sampedro, 1996), whereas 
others show that OECs are in fact confined to the graft (Smale et al., 1996). In addition, 
very few direct comparisons have been made between OEC and Schwann cell migratory 
potentials. In one direct comparison, both Schwann cells and OECs displayed limited 
migration within the spinal cord, where they remained in clusters at the transplant site 
(Lakatos et al., 2003a). However, these cells were transplanted into non-injured tissue and 
migration might have been impeded by the lack of space to migrate into, in contrast to 
transplantation studies into experimental lesions (Gudino-Cabrera et al., 2000; Ramon- 
Cueto et al., 1998; Li et al., 1997, 1998). In addition, non-injured tissue may lack many of 
the growth factors which are present following injury, that may influence cellular migration.
In contrast to the results obtained in vivo, the different abilities of OECs and Schwann cells 
to migrate within astrocyte-rich areas in vitro have been clearly demonstrated. In these 
assays Schwann cells cultured with astrocytes formed discrete boundaries, being unable to 
migrate amongst them (Ghimiker and Eng, 1994; Wilby et al., 1999). OECs cultured with 
astrocytes, however, did not form such boundaries (Lakatos et al., 2000), but instead were 
able to interact much more favourably, where they intermingled and migrated extensively 
within astrocyte territories. An additional observation in these in vitro experiments was
that astrocytes in contact with Schwann cells underwent a hypertrophic response, 
becoming enlarged and enhancing their expression of GFAP (Ghimiker and Eng, 1994) and 
CS-PGs (Lakatos et al., 2000). Neither o f these markers were upregulated in OEC- 
astrocyte co-cultures.
This also reflects studies in vivo, where following Schwann cell transplantation, reactive 
astrocytes are observed (Plant et al., 2001; Lakatos et al., 2003a). These astrocytes may 
restrict the efficiency of Schwann cells in subsequent regeneration, a theory supported by 
the observation that Schwann cell remyelination of CNS tissue only occurs in astrocyte- 
free areas (Woodruff and Franklin, 1999; Shields et al., 2000), and also that Schwann cells 
myelinate CNS axons more extensively in situations where the astrocyte-formed glia 
limitans was disrupted (Franklin and Blakemore, 1993). In addition, Schwann cell 
transplantation has led to a greater expression of CS-PGs within the host tissue (Plant et 
al., 2001), than that seen for OEC transplantation (Lakatos et al., 2003a). It has also been 
suggested that OEC transplantations following a photochemical lesion to the spinal cord 
may actually lead to a decrease in CS-PG expression (Verdu et al., 2001). An increase in 
CS-PG expression has been proposed as one of the major factors responsible for the failure 
of axonal regeneration (Fawcett and Asher,1999; Plant et al., 2001; see Section 1.1.2.3).
1.5.3 Molecular mechanisms determining Schwann cell and OEC 
interactions with astrocytes
At present, very little is understood, regarding the molecular mechanisms responsible for 
determining Schwann cell and OEC interactions with astrocytes. The inability o f Schwann 
cells to migrate into astrocyte-rich areas was suggested to be mediated by contact inhibition 
between the astrocyte and the Schwann cell. In particular, evidence from experiments by 
Wilby et al (1999) suggest that N-cadherin may be involved in this process, limiting 
Schwann cell migration through the formation o f strong adhesions with astrocytes. In these 
experiments, inhibitory peptides and antibodies against N-cadherin blocked the adhesion 
and increased the migration o f Schwann cells on astrocyte monolayers. A  similar 
mechanism has also been demonstrated for oligodendrocyte precursors (Schnaedelbach et 
al., 2001). Since OECs migrate more extensively within an astrocyte environment than
Schwann cells, it was originally suggested that OECs may lack N-cadherin, and thus might 
not be restricted by such inhibition. This, however, has been shown not to be the case since 
OECs express N-cadherin at similar levels to Schwann cells (Lakatos et al., 2000). It 
remains to be seen whether N-cadherin does indeed regulate these differences between OEC 
and Schwann cell interactions with astrocytes, and since it is expressed on both, why its 
role in the two cells should be different.
Furthermore, little is known why OECs and Schwann cells should induce different 
astrocytic responses upon contact with astrocytes, both as modelled in vitro, and following 
transplantation. As has been reviewed earlier, we know of several cytokines and growth 
factors capable of inducing an astrocytic reaction (see Section 1.2.1.3), however, this list is 
by no means exhaustive at present, and whether these factors act to induce or maintain 
such a response is still unknown, as are their precise origins. It is known that Schwann 
cells, under certain conditions such as Wallerian regeneration, can produce many of these 
astrocytosis-inducing cytokines, such as IL-1 (Bergsteinsdottir et al., 1991; Skundric et al., 
1997; Rutkowski et al., 1999), IL-6 (Murwani et al., 1996; Rutkowski et al., 1999) and 
T N Fa (Murwani et al., 1996; Wagner and Myers, 1996). Whether these factors are also 
produced by OECs is at present unclear, and may highlight another similarity or difference 
between the two glia. Any induction of astrocytosis by transplanted cells might, not only 
limit the ability of these cells to migrate away from the transplantation site, but also mask 
any benefit and hinder the regeneration of axons. It is also important to assess the degree to 
which Schwann cells contribute to scarring after injury since endogenous Schwann cells can 
penetrate the injured CNS (Bruce et al., 2000) and may contribute to the reactive response 
throughout the CNS.
1.6 Migration and Adhesion
Since OECs and Schwann cells have been shown to have different abilities to migrate into 
astrocytic areas (Gudino-Cabrera and Nieto-Sampedro, 1996; Iwashita et al., 2000; Lakatos 
et al., 2000;), it will be important for this thesis to review some of the processes involved 
in cell migration. Migration requires a coordination o f many events involved in both cell 
propulsion, as well as cellular adhesion, both to the ECM and to other cells. Due to the
proposal that Schwann cell-inhibition upon astrocytes may be due to the function of N- 
cadherin, particular emphasis will be made on cadherin function and regulation.
1.6.1 Integrins
1.6.1.1 Migration
Cell migration is important for many biological and pathological processes, including 
embryogenesis, inflammation, tissue repair and regeneration as well as tumour invasion and 
metastasis. Of particular interest here, migratory processes are involved in axonal 
outgrowth leading to regeneration, and importantly, determine the ability of transplanted 
cells for CNS repair to reach appropriate targets.
Migration can be viewed as a multi-step cycle, involving the extension of a cellular 
protrusion, formation of stable attachments near the leading edge of the protrusion, 
translocation of the cell body forward, release of adhesions and retraction of the rear of the 
cell (Webb et al., 2002; Wehrle-Haller and Imhof, 2003). In this way, coordination of 
adhesion assembly and disassembly is very important, and therefore tightly regulated. The 
actin cytoskeleton is important for driving the initial extension of the plasma membrane at 
the cell front, and can connect to the ECM through a large family of transmembrane 
receptors, known as integrins due to their ability to integrate the extra- and intra-cellular 
skeletons. It is these attraction sites that are believed to function as traction points for the 
propulsive forces that move the cell body forward.
1.6.1.2 Focal adhesions and turnover
The integrins are receptors for ECM proteins such as fibronectin, vitronectin, laminin and 
collagen. They are composed of a  and p families o f transmembrane subunits which can 
heterodimerise to form more than 20 different receptors which exhibit different patterns of 
expression and binding specificity. At integrin adhesion sites, over 50 different proteins 
have been found (Zamir and Geiger, 2001). The classification of these adhesions, including, 
fibrillar adhesions, focal complexes, focal adhesions and podosomes, depends upon the 
morphology and method of formation. Fibrillar adhesions are central a 5 p i integrin-
containing structures, whereas focal complexes are small Rac activated adhesions at the cell 
front (Zamir and Geiger, 2001) which drive rapid cell migration (Beningo et al., 2001). 
Focal adhesions, which are relatively stable structures that may inhibit cell migration, are 
the best studied since they are also involved in other processes such as the formation and 
remodelling of extracellular matrices (Geiger et al., 2001). It has also been observed that 
these different adhesion structures have different molecular compositions. The formation 
and disassembly of adhesions are complex processes and require a coordinated interaction 
of actin or actin-binding proteins, signalling molecules, structural proteins, adaptor 
molecules and microtubules, as well as the integrins (see Figure 1.3).
It appears that adhesion formation is sequential, with recruitment o f individual proteins 
rather than a preformed complex. Upon integrin binding and aggregation, recruitment of 
focal adhesion kinase (FAK) and tensin results, followed by that o f the cytoskeletal 
proteins such as a-actinin, paxillin, vinculin and talin (Miyamoto et al., 1995; Yamada and 
Miyamoto, 1995). Paxillin however, seems to be recruited in a small preformed complex 
with signalling components such as p21-activating kinase (PAK) and PAK-interacting 
factor (PIX) (Matafora et al., 2001).
Dispersion of adhesion occurs both at the cell rear, where retraction of the cell tail occurs, 
and at the cell front, allowing formation of new protusions and adhesions, but the 
mechanisms at these two locations are different. At the rear, integrin remains associated 
with its substrate while the intracellular adhesive components, which are under tension 
from the cytoskeleton, slide along the actin fibres towards the cell body and eventually 
disperse, hence is not a simple reversal of assembly. However, at the front o f the cell, 
turnover o f components by assembly reversal does occur. This difference appears to be 
directed by the presence or absence of a-actinin, whose presence in the adhesions causes 
them to be no longer turned over but instead to slide inwards towards the cell body (Webb 
et al., 2002).
Adhesion turnover is regulated by many different proteins, particularly the Rho family of 
GTPases. Rac is required for the formation of new adhesions at the cell front, whereas Rho 
is required for the maturation of existing contacts, as well as promoting adhesion 
disassembly (Rottner et al., 1999). Other regulatory proteins include FAK. This protein
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Figure 1.3 Integrin signalling and motility
A schematic showing various integrin signals to the cytoskeleton, either directly via a- 
actinin and talin/vinculin, or via complex focal adhesion interactions. FAK acts as a 
multi-protein scaffold of the focal adhesion, and regulates its turnover. Focal adhesion 
turnover is also regulated by calpain and src interactions. Stress fibre formation is 
promoted by myosin light chain kinase (MLCK) phosphorylation of myosin. The 
actions of various inhibitors used throughout this thesis are marked in red.
co-localises to focal adhesions, where it acts downstream of both the GTPases and integrin- 
mediated cell adhesion, to promote both assembly (Richardson et al., 1997) and 
disassembly (Fincham et al., 1995) of focal adhesions. Upon activation, it undergoes 
complex tyrosine phosphorylation at 6 or more sites, allowing it to interact and form a 
complex with src, which is also necessary for migration, and particularly focal adhesion 
turnover (Fincham and Frame, 1998). This FAK-src complex can promote the 
phosphorylation of substrates such as paxillin and Crk-associated substrate (CAS). FAK 
has been shown to be necessary for migration since FAK-deficient cells spread more 
slowly on ECM proteins, and migrate poorly in response to chemotactic signals (Parsons, 
2003). In addition, overexpression of FAK in Chinese hamster ovary cells resulted in 
enhanced cell migration (Cary et al., 1996). The role o f FAK in focal adhesion turnover has 
been suggested to mediate its control of migration due to the need for functional 
interactions between several FAK-interacting proteins, such as paxillin, Cas and src, which 
FAK may scaffold together (Webb et al., 2002). In addition, FAK is also involved in 
mediating signalling pathways necessary for migration, such as the MEK pathway 
(Schlaepfer and Mitra, 2004).
Calpain, a calcium-dependent protease, is also implicated in the regulation of migration, 
particularly through the control of focal adhesion disassembly. Several calpain isoforms 
exist, two of which are ubiquitous (calpain I and II), several are tissue-specific isoforms, 
and one is a small 28-kDA regulatory subunit (calpain 4). Its activity is tightly regulated by 
its endogenous inhibitor calpastatin (Wendt et al., 2004), and it differs from most proteases 
due to its ability for limited cleavage of its protein substrates into stable fragments rather 
than complete proteolytic digestion. It is this cleavage of focal adhesion components, 
including integrins (Du et al., 1995), FAK (Cooray et al., 1996), paxillin (Yamaguchi et al.,
1994) and talin (Beckerle et al., 1997) amongst others, that promotes the disassembly of 
these complexes (Bhatt et al., 2002) resulting in reduced cell adhesion and increased 
migration (Carragher and Frame; 2002). Inhibition o f calpain I function, therefore generally 
reduces migration (Huttenlocher et al., 1997; Carragher et al., 2001), however there are 
some exceptions. For example, inhibition of calpain I function in resting neutrophils 
actually led to an increase in random migration, and resulted in decreased directional 
migration towards chemotactic stimuli (Lokuta et al., 2003). Thus calpain plays a complex
role in regulation o f migration, and may regulate chemotaxis in neutrophils too. The 
function of calpain has been linked to FAK and src regulation of migration since v-src 
activity induces the synthesis of calpain (Carragher et al., 2002), and also induces the 
cleavage of FAK by calpain (Carragher et al., 2001).
1.6.2 Cadherins
As well as integrin adhesion to the ECM, migration is also dependent upon the function of 
cellular adhesion molecules, including immunoglobulin cell adhesion molecules (Ig CAMs) 
and selectins, as well as the Ca2+-dependent cell adhesion molecules, known as cadherins.
1.6.2.1 Cadherin family/structure
The cadherin family is a large superfamily consisting of five subfamilies, the classic types I 
and II, desmosomal cadherins, protocadherins and cadherin-related proteins. The classic 
cadherins include E- (epithelial), N- (neural), P -  (placental), L- (liver), R- (retinal), K- 
(kidney), and M- (muscle) cadherin, named after the tissue in which they were first 
discovered, of which E- and N-cadherin are the most widely studied. The classic cadherins 
are transmembrane glycoproteins with an extracellular region (ectodomain) comprising five 
extracellular homologous domains, a single membrane-spanning region and a cytosolic 
domain. These cadherins have important roles in Ca2+-dependent intercellular adhesion and 
signalling pathways. Adhesion occurs when extracellular cadherin domains from one 
cadherin bind to the extracellular portion of a similar cadherin on an opposing cell, these 
cells can be of the same type (forming homo-typic junctions) or of a different cell-type 
(hetero-typic junction). The role of Ca2+ in mediating these junctions has been studied in 
some detail, where calcium has been shown to bind to two Ca2+ binding sites between each 
cadherin extracellular domain, stabilising their orientation away from the cell (Nagar et al.,
1996) (see Figure 1.4A). This allows cadherin-cadherin cis-dimers to form on the same cell, 
and facilitates interaction with cadherin dimers on opposing cells, forming a trans-dimer. 
Once trans-dimers are formed, the clustering of cadherin at the cell-cell interface can occur, 
through a combination of cis- and trans-dimerisation, resulting in an adherens junction. The 
specificity of classic cadherins is determined by the most N-terminal part of the
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Figure 1.4 C adherin structure and regulation.
(A) Cadherin ectoderms (5 domains) are already clustered on the cell surface due to 
connection to the cytoskeleton (not shown), but have a more globular shape in the absence 
o f Ca2+ ions. Higher concentrations are required for cis interactions between N-terminal 
domain pairs (*). Only at high Ca2+ is cadherin fully activated and can form trans 
interactions with opposing cis dimers (adapted from Koch et al., 1999). (B) Summary of 
localisation and regulation of cadherins. Cadherins connect to the actin cytoskeleton via 
various proteins including (3-catenin, a-catenin and a-actinin. Protein-protein interactions 
are regulated via several phosphorylation and dephosporylation events (adapted from 
Steinberg and McNuff, 1999).
ectodomain, which mediates both cis- and trans-dimerisation, as was shown by its crystal 
structure, leading to the proposal of a zipper-like mechanism (Shapiro et al., 1995).
1.6.2.2 Cadherin function within nervous tissue
Within the nervous system, about 80 different cadherin types have been identified, 
including N-, E- and R-cadherin from the classical family. N-cadherin, the major cadherin 
within the nervous system, has many roles in developmental processes including 
neurulation (Kintner, 1992), neuronal migration (Nakagawa and Takeichi, 1998) and axon 
growth (Bixby and Zhang 1990; Doherty et al., 1991). Recent studies suggest that cadherin 
expression identifies developing neuron populations into organised functional circuits 
(Redies, 1997). During axon growth and target selection, axons of different origins express 
distinct, and often multiple, cadherin types. In fact since axons can express multiple 
cadherins, they can bind to axons with a complementary set, thus the cadherins may 
provide an adhesive ‘code’ for directing the neuronal connections (Ranscht, 2000).
Recently, cadherin subclasses have been identified at different synapse populations on the 
same axon, thus specifying and maintaining specific neuronal connections (Ranscht, 2000). 
This has been demonstrated through the use o f N-cadherin antibodies which disrupted 
synapse formation in specific layers of the retinorecipient tectal layers (Inoue and Sanes,
1997). The cadherins may also be important for regulating synapse function, for example, 
depolarisation of neuronal membranes actually increases N-cadherin stability and adhesive 
function, thus mediating activity-dependent stability of a synapse (Tanaka et al., 2000).
In addition, cadherins can have both stimulatory and inhibitory effects on migration. 
Traditionally, strong adhesion has been associated with a lack of migration. This is reflected 
by observations that tumour cells which progress to a metastatic phenotype are often 
associated with a downregulation of E-cadherin expression (Perl et al., 1998; Christofori 
and Semb, 1999), which presumably allows them to detach from the primary tumour mass. 
However, it has now been shown that N-cadherin is upregulated in invasive cancer cell lines 
(Tran et al., 1999; Hazan et al., 2000) and tumours (Tomita et al., 2000; Li et al., 2001). 
Rather than just reflecting a change in adhesive specificity, N-cadherin actually promotes 
this invasive phenotype, where N-cadherin-expressing breast cancer cells migrated more
efficiently, even when expression of E-cadherin is maintained (Hazan et al., 2000). This is 
contradictory to the role of N-cadherin in glial cells where it has been shown to restrict 
migration (Wilby et al., 1999; Schnaedelbach et al., 2000), but fits with data suggesting that 
whereas E-cadherin promotes only tight cell-cell adhesion, N-cadherin may promote both 
stable and labile cellular interactions that facilitate dynamic processes such as neurite 
outgrowth and cell migration (Bixby and Zhang, 1990; Doherty et al., 1991). Thus N- 
cadherin can play different roles determining migration or adhesion, which presumably 
reflect variability in its regulation.
1.6.2.3 Cadherin regulation
The cytosolic domain of cadherins are associated with proteins known as catenins, 
including p-catenin, y-catenin/plakoglobin and a-catenin. These physically anchor the 
cadherins to the cytoskeleton, through interactions with actinin and then actin, as well as 
mediating signalling pathways (see Figure 1.4B). Other cadherin associated proteins include 
vinculin, the src substrate p l2 0 ctn, IQGAP, and the tumour suppressor protein 
adenomatous polypous coli (APC). Cadherin-catenin interactions are essential for the 
establishment o f functional adherens junctions, where the formation o f a cadherin-catenin 
complex, reflects tight adhesive interactions. Due to the need for both strong, stable 
adhesive contacts in some situations (such as synapse stability and tissue maintenance) and 
also weak interactions in others (such as axonal extension and migration), the adherens 
junction needs to be dynamically and transiently regulated. This can be modulated through 
phosphorylation of the cadherin-catenin complex, particularly though tyrosine 
phosphorylation of p-catenin, which then is lost from the cadherin-catenin complex, thus 
inhibiting cell adhesion (Balsamo et al., 1996). Several tyrosine phosphatases and kinases 
are associated with the regulation of the phosphorylation status, including the small 
GTPases Rac, Rho and cdc42. IQGAP, a Rac and Cdc42 effector, displaces a-catenin from 
the cadherin-catenin complex, as well as interacting directly both with cadherin and P- 
catenin, thus disrupting the association of the complex with the cytoskeleton, and therefore 
inhibiting cell adhesion (Briggs and Sacks; 2003).
The cadherins and catenins, as well as having roles in cell-cell adhesions, have also been 
implicated in cell signalling. Upon being released from the cadherin-catenin complex, p-
catenin is able to bind the lymphoid enhancer binding factor (LEF-1) and the Xenopus 
homolgue XTcf-3 (Behrens et al., 1996; Molenaar et al., 1996). This complex can then 
translocate to the nucleus and lead to transcriptional activation. In this way, p-catenin acts 
downstream of the Wnt signalling pathway, which is particularly important in embryonic 
patterning , including dorsal-ventral axis determination in Xenopus (Itoh et al., 1998).
N-cadherin can also regulate neurite outgrowth through FGFR signalling. N-cadherin and 
FGFR have been shown to co-localise together, and also N-cadherin stimulation was 
necessary for FGFR-dependent neurite outgrowth (Utton et al., 2001). It has been 
suggested that, whereas catenin interaction with cadherins mediates their adhesive 
functions, interaction and activation o f FGFR may be important for their migratory 
functions. This is supported by the dependency o f migratory N-cadherin-expressing 
tumour cells upon FGF signalling, whereby N-cadherin and FGF-2 synergistically 
increased migration and invasion of breast tumour cells (Hazan et al., 2000)
N-cadherin function in neurite growth is also regulated by interactions with receptor 
tyrosine phosphatase p (Burden-Gulley and Brady-Kalnay, 1999), although the 
intracellular signals elicited by this interaction are not as clear as for FGFR signalling. In 
addition, binding of the CS-PG neurocan to an N-cadherin-associated cell surface glycosyl 
transferase exerts negative regulation on N-cadherin, inhibiting both cadherin and integrin 
functions in neurite extenstion (Lilien et al., 1999; Li et al., 2000).
Another mechanism for N-cadherin regulation is through the repulsive guidance cue, slit (as 
discussed in section 1.1.2.6). Upon binding and activating its ligand, Roundabout (Robo), 
slit induces the inhibition o f N-cadherin-mediated cell adhesion (Emerson and Vactor, 2002; 
Rhee et al., 2002). This presumably allows the cells to migrate away from the repulsive 
cue. It appears that activated Robo is able to form a complex with Abelson (Abl) kinase 
and N-cadherin, resulting in phosphorylation of |3-catenin and its loss from the adhesive 
cadherin-catenin complex. However, it is still not understood how all these and additional 
mechanisms cooperate to achieve the concerted action on cadherin-mediated functions.
1.6.3 Communication between integrins and cadherins
Cross-talk between the cadherins and other complexes involved in adhesion and migration 
is a necessary property of the cell, in order to coordinate these events. Communication is 
evident between cadherins and integrins (Monier-Gavelle and Duband, 1997; Gimond et al.,
1999), particularly through the Rho-like GTPases (see Figure 1.5). Activated Cdc42, Rac 
and Rho are necessary for the formation of filopodia, lamellipodia and stress fibres, 
respectively (Hall and Nobes, 2000), and these proteins have also been shown to regulate 
the activation status of each other through a cascade, for example activation of Cdc42 leads 
to a rapid localised activation o f Rac (Nobes and Hall, 1995). As such, the balance between 
GTPase activity is important for determining migratory and adhesive behaviour. Since they 
have been shown to regulate the adhesive strength o f the adherens junctions (section 
1.6.1.3) as well as regulating integrin function (section 1.6.1.2), they therefore bridge 
adhesion and migration. This has been demonstrated in FAK and paxillin-signalling 
impaired cells, where siRNA-mediated knockdown of both FAK and paxillin resulted in 
impaired assembly of N-cadherin-containing cell-cell adhesions in both HeLa cells and 
human fibroblasts (Yano et al., 2004). This effect was reversed by expression o f a 
dominant-negative Racl mutant, and mimicked by constitutively active Racl, suggesting 
FAK and paxillin may normally function to attenuate Racl signalling.
In addition, integrin and cadherin function is balanced through the regulation of, amongst 
others, a nonreceptor tyrosine kinase called fer. This protein coordinates integrin and N- 
cadherin function through its ability to bind to both complexes, whereby its displacement 
from one results in its accumulation at the other (Arregui et al., 2000). This mechanism has 
been observed upon neurocan binding to its receptor GalNAcPTase, in the chick neural 
retina (Li et al., 2000), where fer translocates from the cadherin complex to the integrin 
complex, resulting in inhibition of both N-cadherin- and pl-integrin-mediated adhesion and 
neurite outgrowth.
1.7 Summary
It has long been known that the CNS is unable to regenerate following injury and it is now 
understood that this is due to the interplay between several different mechanisms. These
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Figure 1.5 Schematic of small GTPase regulation of m igration and adhesion.
Communication between the small GTPases, Cdc42, Rac and Rho, coordinately 
regulate migration and adhesion. Adapted from Schmitz et al., 2000.
include the innate state of CNS axons; the presence o f inhibitory myelin components, 
which are not efficiently cleared from the injury site by the immune response; the presence 
of inhibitory guidance molecules and, in particular, the formation of a glial scar. This glial 
scar functions to inhibit regeneration in the CNS both through its formation of an 
impenetrable barrier to repair, and the presence of inhibitory molecules within it, namely 
the CS-PGs. As a result, in order to promote the regeneration of the CNS, a number of 
different methods of intervention are required.
One promising method is the transplantation of cells with regeneration-promoting 
capacities. O f these, OECs and Schwann cells are high on the list o f candidates. Despite 
some of the more obvious similarities between OECs and Schwann cells, they also display 
many different properties which are important when deciding which is the superior 
candidate for transplantation. For example, Schwann cells appear to have a more limited 
ability to survive and migrate within CNS tissue, and may also induce a greater reactive 
response following transplantation than OECs. However, this comparison is not as clear as 
is sometimes reported, since in some models, OECs also show a limited ability both to 
migrate and to promote regeneration, and also induce a degree of reactivity in the host. For 
this reason, Schwann cells are still a potential candidate, and at present remain more 
probable for autologous transplantation due to the ease o f obtaining them and culturing 
them in large numbers.
Thus, a comparison of OEC and Schwann cell interactions with the host CNS, and in 
particular astrocytes, is important in evaluating their transplantation potential. The 
mechanisms which determine the different cellular interactions of OECs and Schwann cells 
with astrocytes remain to be investigated. Such knowledge would allow both a more 
detailed comparison of the candidates to be made, and may also allow the possibility of 
manipulating these cells in order to improve their potential for repair. For example, if  the 
more easily obtained Schwann cell could be made to integrate with astrocytes in a manner 
more similar to OECs, while inducing less reactivity in the host tissue, its scope for 
promoting repair may be enhanced.
1.8 Aims of Thesis
This thesis will address the interactions of OECs and Schwann cells with astrocytes, and 
will aim to highlight the mechanisms involved in regulating these interactions. Firstly, a 
more general comparison of OEC and Schwann cell behaviour in the presence of astrocytes 
will be made. This is in order to evaluate the differences between OECs and Schwann cells, 
to assess how reproducible the published literature is in regards to modelling their 
interactions in vitro, and to establish models by which these can be investigated in more 
detail. Secondly, a comparison of Schwann cell and OEC migration and adhesion capacities, 
both in the presence and absence of astrocytes, will be made to determine the similarities of 
their inherent capacities for migration and adhesion.
Due to the hypothesis that N-cadherin may be a potential candidate for limiting Schwann 
cell migration in the presence of astrocytes, a direct comparison will be made between the 
function of N-cadherin in Schwann cells and OECs, in order to determine whether this may 
give rise to the observed differences in Schwann cell and OEC migration and adhesion in the 
presence of astrocytes. siRNA will be employed to definitively address these issues.
In addition, the role that astroytosis plays in determining Schwann cell and OEC abilities to 
migrate within astrocytes-rich areas will also be studied. Since Schwann cells are reported 
to induce more astrocyte reactivity than OECs, this response could differentially determine 
the ability of these cells to interact with astrocytes. Both factors that determine the 
outcome of the astrocyte response, and the result this has on cellular migration and 
adhesion will be addressed.
CHAPTER 2 
Materials and Methods
2.1 Tissue culture
2.1.1 General tissue culture
Primary cell cultures of astrocytes, Schwann cells and olfactory ensheathing cells (OECs) 
were purified as outlined as below. All cell cultures were grown in T25 (cm3) and T75 
(cm3) culture flasks, 6-well culture plates or on polished borosilicate glass coverslips 
inserted into 24-well culture plates. All dishes and coverslips were coated in poly-L-lysine 
solution (PLL, 13.3 pg/ml in distilled water) in a volume of 2 ml, 4 ml, 1 ml or 0.5 ml 
respectively. PLL was left on the dishes and plates for at least 20 minutes at 37°C, washed 
twice in distilled water (dF^O) and then left to air-dry in a tissue culture hood before use.
All cell cultures were maintained in DMEM-10%, with appropriate growth factors added 
depending on the cell type (see below). Cultures grown in T25 flasks, T75 flasks, 6-well 
plates, or in 24-well plates were fed with 4 ml, 12 ml, 2 ml or 0.5 ml of media respectively, 
and were re-fed two or three times a week, by removing half of the media, and replacing 
with fresh media. All fresh media and tissue culture reagents were filtered through a 0.22 
pm filter.
Cell cultures were passaged when they became confluent, by removing the cells with 
trypsin, and splitting between two flasks (or moving up to a larger size flask). First, cells 
were washed in pre-warmed (37°C) phosphate-buffered saline (PBS), and then pre-warmed 
PBS containing 0.1% trypsin (or 0.2% for astrocytes cultures) added at either 1.5 ml for a 
T25 flask, or 2.5 ml for a T75 flask. Flasks were left at 37°C for 5 minutes, with frequent 
agitation to assist cell detachment. The PBS-trypsin containing the cell suspension was 
then transferred to a 15 ml Falcon tube, and trypsin activity inhibited by addition of 10ml 
DMEM-1%. The suspension was then spun at 1200 rpm for 6 minutes. The resulting 
pellet was resuspended in fresh media and re-plated onto dishes as required. All flasks and 
plates were then maintained at 35°C in a 7% CO2  incubator.
In some instances, the cell suspension was counted before addition of DMEM-1%. This 
was done by placing 10 pi of suspension in a haemocytometer and counting the number of
cells within the grid under a light microscope, and multiplying this by 104 to give the total 
number of cells/ml.
2.1.2 Astrocyte culturing
Neonatal Sprague Dawley rat pups at age 1 -2 days were killed by decapitation (Schedule 1 
procedure). Instruments were sterilised using 100% ethanol, and ethanol was also applied 
to the skin before dissection. The skin was cut away on the head, exposing the skull. The 
brain was exposed by cutting away the skull over the eyes to a point above the nose. Both 
the olfactory bulbs and the cerebellum dissected, allowing the cortices to be removed and 
placed in a small petri dish (90 mm2) containing 200-400 pi L-15 media. The cortices were 
separated from the midbrain, hippocampus and majority o f white matter, before the 
meninges were carefully peeled off using micro-tweezers. The cortices were then pooled (7 
animals per preparation) and stored in ice-cold L I5.
Tissue was chopped with a sterile scalpel into approximately 0.25-0.5 mm pieces in order 
to increase the reactive surface for enzymatic digestion. The tissue was then transferred 
into 0.5 ml of collagenase solution and incubated for 30 minutes at 37°C. After this time the 
enzymatic activity was inhibited by the addition o f 1ml Soybean trypsin inhibitor-DNase 
(SD), followed by trituration in the same solution. Trituration was done gently 5 times 
using a blow-out pipette, followed once with a 21G needle, and then a 23G needle. The 
homogenate was transferred to a 15 ml falcon tube and washed by adding 10 ml DMEM- 
1%, and spun at 1200 rpm for 6 minutes. Cells from the 7 cortices were then resuspended 
and put into two T75 flasks, containing DMEM-10% and incubated for around 1 week, 
after which time astrocytes became fully confluent, and neuronal debris had disappeared.
Once the cells reached confluency, they were re-fed, and the flasks gassed with 5% 
C 0 2/21% 0 2 in N 2 for 20 seconds, and the lids tightly fastened prior to incubation in a 
non-gassed environment. Flasks were then incubated for two days at 37°C, with gentle 
shaking. This brought the contaminant cells, such as oligodendrocyte progenitor cells 
(OPCs), to the surface of the astrocyte monolayer, and many came away into suspension. 
After this time, the flasks were washed in pre-warmed PBS, removing any suspended cells, 
and contaminant cells were selectively removed using a low concentration of trypsin
(0.05%) which left the astrocyte monolayer intact. These contaminant cells were discarded. 
The monolayer was washed in pre-warmed PBS, and passaged using a higher concentration 
of trypsin (0.2%) as outlined in the above section. An aliquot of cells were plated onto 
coverslips to assess astrocyte purity by immunolabelling for glial fibrillary acidic protein 
(GFAP; see section 2.3). Further purification steps were only performed if necessary, such 
as the addition o f the cytotoxic agent cytosine arabinoside (Ara C, 2xlO'5M). This was 
added to the media for two days and killed any rapidly dividing cells. It was added once the 
astrocytes had become confluent and were no longer proliferating, while contaminant cells 
above the astrocyte monolayers were able to continue dividing. After Ara C treatment, the 
astrocytes were washed in PBS, and then passaged as necessary. After purification, 
astrocytes cultures were typically greater than 95% pure (see Figure 3.1).
2.1.3 Schwann cell culturing
Sciatic nerves were dissected from 7-day-old Sprague Dawley neonatal rat pups (killed by 
a Schedule 1 protocol). The skin was sterilised with 100% ethanol, a dorsal incision made 
in the skin along the leg, and the muscles separated to reveal the sciatic nerve. This was 
dissected out and placed in a petri dish. Any remaining muscle tissue was removed and 
then the nerves were chopped finely using a sterile scalpel. As with astrocyte purification, 
small tissue pieces of approximately 0.25-0.5 mm were digested in 0.5 ml collagenase. 
After 15 minutes, 0.5 ml of trypsin was added, and incubated for a further 15 minutes. A t 
the end of this time, the enzymes were neutralised by addition of 500 pi SD. Cells were 
transferred to a 15 ml Falcon, and washed with 10 ml DMEM-1%. The pelleted cells were 
resuspended and approximately 5 sciatic nerves were cultured in each T25 flask. The cells 
were cultured in DMEM-10% until purification was complete. After 24 hours, Ara C was 
added to the flask (at a final concentration of 2x10'5 M) in order to kill the fast proliferating 
fibroblasts. After a further 48 hours, the media containing Ara C was removed, and the 
flasks were washed twice in PBS. Flasks were left for a further 24 hours in DMEM-10% 
to recover before this step was repeated. Following the Ara C treatment, cells were left 
another 24 hours before Schwann cells were selectively removed from the flask using a low 
concentration of trypsin (0.02%). This left the contaminant fibroblasts behind, which were
discarded. The trypsinised cells, were washed in DMEM-1%, and the resulting pellet was 
purified further by complement kill using anti-Thyl.l.
The pellet was resuspended in a mixture containing 50 pi DMEM and 150 pi anti-T hyl.l. 
antibody, which specifically labels fibroblasts, and incubated for 15 minutes at RT, before 
a further 40 pi of rabbit complement was added to the cell suspension. This was then 
incubated for 45 minutes at 37°C, allowing complement-mediated lysis of any remaining 
fibroblasts. Cells were washed twice in DMEM-1%, and re-plated in T25 culture flasks. 
The DMEM-10% culture medium was supplemented with 2 pM  forskolin and 20 ng/ml 
beta-1 heregulin.
Schwann cell purity was assessed by plating an aliquot of cells on to coverslips and 
labelling with anti-p75NTR (see section 2.3, and Figure 3.1). Schwann cell cultures were 
typically over 90% pure, any cultures not meeting this requirement were discarded and 
purification repeated.
2.1 A  Olfactory ensheathlng cell cultures
Olfactory ensheathing cells (OECs) were purified from olfactory bulbs of 7-day-old 
Sprague Dawley rat pups. As with astrocyte purification, the skin was dissected away to 
reveal the skull, which was also removed. Meninges covering the olfactory bulbs were 
removed, and olfactory bulbs excised after cutting the olfactory tracts connecting them to 
the forebrain. Tissue was treated as outlined above in sections 2.1.2 and 2.1.3. Briefly this 
involved chopping into small pieces with a scalpel followed by digestion in collagenase.
The resulting tissue pellet was then purified using the fluorescence-activated cell sorter 
(FACS) as described by Barnett and colleagues (Barnett et al, 1993). Approximately 2xl07 
cells were resuspended in a mixture of 1 ml 0 4  and 1 ml GalC hybridoma supernatants and 
incubated on ice for 1 hour. Cells were washed twice in 10 ml DMEM-1%, and then 
resuspended in 2 ml DMEM-1% containing goat anti-mouse IgM-fluorescein (FITC; 
1:100) and goat anti-mouse IgG3-phycoerythrin (RPE; 1:100). This was incubated for 45 
minutes on ice, and cells were then washed twice in DMEM-1%. The pellet was 
resuspended in 4 ml DMEM-1%, poured through a 70 pm cell strainer to ensure large
pieces of tissue did not cause blockages in the FACS machine, and then transferred to a 
polystyrene round bottom 5 ml tube.
Cell sorting was carried out with the attendance o f  Mr. Tom Gilbey.
A ‘FACVantage SE’ sorter was used to purify the cells according to the protocol by 
Barnett and colleagues (Barnett et al, 1993). Briefly, sorts were carried out by exciting the 
fluorophores with a 488 nm argon laser at 100-150 mW. Since our cells were dual labelled 
with FITC (emission 530 nm) and RPE (emision 578 nm), the compensations (FL-1 and 
FL-2) were set to reduce the spillover of the fluorophores into each channel. This was done 
by running fluorescently-labelled beads, either FITC- or RPE-labelled, through the machine 
prior to sorting, to set the gating. Then the sort windows were set in order to firstly 
separate live cells from dead cells and debris, by size (forward scattering of light) and 
granularity (side scatter), and then to select 04-positive (FITC) GalC-negative (RPE) cells.
Purified cells were collected in a second polystyrene round bottom 5 ml tube (containing 4 
ml of DMEM-1%) and then spun at 1200 rpm. The pellet was resuspended in 20 pi, and 
plated as a strip within a T25 flask, and incubated until the strip became confluent. Cells 
were passaged into an entire T25 flask. Cells were cultured in OEC mitogen media (OM M) 
which has been shown to be a potent mitogen for promoting prolonged growth of p75NTR 
expressing OECs (Alexander et al., 2001). A small aliquot of each purification preparation 
was also plated on to coverslips in order to assess the purity of the cells. This was carried 
out by immunolabelling, using both 0 4  and GalC antibodies, immediately after sorting. 
However, if purity was assessed after the cells had been cultured for any length of time, 
they were immunolabelled for just p75NTR, since OECs lose expression of 0 4  with time in 
culture (Franceschini and Barnett, 1996). All cultures were about 95% pure (see Figure
3.1), as before, any cultures which were not pure enough were discarded, and the process 
repeated.
2.1.5 Hybridoma cells and collection of antibodies
Hybridoma stocks were stored in liquid nitrogen until use. Cells in cryo-vials removed from 
storage were allowed to thaw rapidly in warm water before the cells were removed and
washed twice in 8 ml of DMEM-1%. This removed any residual DMSO which is toxic to 
the cells. After washing, the resultant pellet o f cells was resuspended in 4ml of DMEM- 
10%-1966 and transferred to a T25 flask. The cells were grown at 37°C until confluent 
when they were removed from the flask (no need for trypsin, just agitation) and placed in a 
T75 containing 12 mis DMEM-10%-1966, and again grown until confluent.
When confluent, the cells were pelleted and resuspended in 6 ml of DMEM-10%-1966. Of 
this, 0.5 ml aliquots were placed into two T25 flasks, and allowed to grow to confluency, 
before freezing down to replace hybridoma stocks. The remaining 5 ml were put into a 
T125 which was topped up to 20 ml of DMEM-10%-1966. Cells were grown until 80% 
confluent, at which time they were ready for antibody collection.
For collection of antibody, media was removed from the T125 flask, and the cells washed 
in PBS. 30 mis of DMEM-BS-1966 was then added to the cells, and the flask was 
incubated at 37°C for 2 days. After this time, the media was collected and spun at 1200 
rpm for 6 minutes to remove any cell debris. The antibody was then ready to test, and 1 ml 
aliquots made and stored at -20°C.
2.1.6 Collection of Astrocyte, Schwann cell and OEC
conditioned media (ACM, SCM and OCM).
Conditioned media from Schwann cells and OECs were collected from confluent cultures of 
cells grown in T25 flasks. Flasks were washed twice in PBS and then 4 ml of DMEM-BS 
was added to the flask. Two days later the media was removed and centrifuged at 1200 rpm 
for 6 minutes to remove any cell debris. The collected media was then filtrated using a 0.22 
pm filter, and was then ready for use. Exactly the same procedure was used for generating 
astrocyte conditioned media (ACM), apart from confluent astrocyte cultures were 
maintained in T75 flasks, to which 10 ml of DMEM-BS was added.
Media which was intended for concentrating and 2D electrophoresis analysis was collected 
in BSA-free DMEM-BS, and treated as normal (see Section 2.5).
SCM and OCM were added to cell cultures at a 1:1 ratio with DMEM-10%, except for 
proliferation studies, where media were titrated with DMEM-BS.
2.1.7 Digestion of SCM
SCM was digested in order to assess if its activity was proteinaceous in nature. 2 ml of 
SCM was placed in a falcon tube, to which 100 pi of trypsin-agarose bead suspension was 
added (50:50 suspension beads to PBS; 2.5 units). The beads had previously been washed 
of all storage solution (containing sodium azide). The SCM-trypsin-agarose suspension 
was then put on a rotator at 37°C and left to digest for 24 hours, after which time the 
suspension was spun at 1200 rpm for 6 minutes, and the supernatant collected. The beads 
could then stored in 10 mM acetic acid, pH 3.2 at 4°C, ready for re-use. The digested SCM 
was then filtered through a 0.22 pm syringe filter, and stored at 4°C.
2.1.8 Culturing cells in low Ca2+ media.
For some experiments, cells were cultured in low Ca2+-containing media in order to assess 
the effect o f calcium on cell-cell junctions. Cells were plated onto coverslips as outlined 
above and maintained in DMEM-10% (high Ca2+, 1 mM) until the experiment was 
performed. This media was removed, and the cells washed twice in PBS. 500 pi 
keratinocyte growth media (low Ca2+, 0.03 mM) was then added to each 24-well, and the 
cells maintained at 37°C for a further 4 hours before fixing and immunolabelling.
2.2 Assays
2.2.1 Co-cultures
Astrocytes:OEC and astrocyte:Schwann cell co-cultures were performed by mixing either 
OECs or Schwann cells with astrocytes at a ratio of 1:1 (for N-cadherin immunolabelling) 
or 3:1 (for assessing hypertrophy). Primary cultures were generally maintained for 2-6 
weeks prior to setting up the assays. Trypsinisation, washing and counting o f cells was 
carried out as outlined above (section 2.2.1.1). Cells were mixed in suspension at a total cell 
number of 4x103 per well and then added to PLL coated coverslips in 24-well plates
containing 500 pi of DMEM-10%. Alternatively, for creating cell lysates, a total cell 
number o f 1.6xl04 was added to each well of a 6-well plate, containing 2 ml of DMEM- 
10%.
These cultures were maintained for either 2 days (for N-cadherin immunolabelling, by 
which time cells were in contact with each other) or 14 days (for hypertrophy analysis, by 
which time an astrocytic response had been elicited, Lakatos et al., 2000; Eng and 
Ghimiker, 1994). After this time, cultures grown on coverslips in 24 wells were fixed and 
immunolabelled (as outlined in section 2.3), and cultures grown in 6-well plates were lysed 
for immunoblotting (see section 2.4).
2.2.2 Confrontation assays
In order to investigate cellular responses after contact between populations of different glial 
cells, a ‘confrontation assay’ was set up, as previously described (Wilby et al, 1999). Cells 
were counted as before, and each cell type resuspended to a final concentration of lxlO6 
cells per ml. O f these suspensions, a 10 pi strip (containing 10,000 cells) of astrocytes was 
made at one side of a coverslip, by drawing the cell suspension out using a pipette tip. 
Parallel to this, a second 10 pi strip was made, containing either Schwann cells or OEC, 
such that a cell free area was present between the two cell populations (approximately 
1mm wide). Cells were allowed to attach to the coverslip for 1 hour, before any unattached 
cells were carefully washed in 500 pi DMEM-1%. Cell cultures were then maintained in 
DMEM-10% and allowed to grow and migrate towards each other where they could 
‘confront’ each other. Cultures were maintained for 14 days, by which time they had fully 
interacted with each other (Lakatos et al, 2000). After this time, coverslips were removed 
and immunolabelled as required.
To quantify the number and type of cells which crossed the cellular interface between 
OECs/Schwann cells and astrocytes, coverslips were immunolabelled for p75NTR and 
GFAP. Images were taken at random of the confrontation interaction zone using a Leica 
SP2 confocal microscope at 20x magnification. A boundary distance of 300 pm was 
calculated (using a graticule) and marked on the images, and the number o f OECs or 
Schwann cells which had crossed from the OEC/Schwann cell zone into the astrocyte
domain within this boundary distance were counted. Measurements were carried out in 
triplicate for three separate experiments (n=3), and displayed as the mean number of cells 
crossing the boundary +/- standard error o f the mean (SEM).
2.2.3 Adhesion assay
Cells were labelled for detection with Vybrant (Vybrant CFDA SE (carboxyfluorescein 
diacetate, succinimidyl ester) by incubating them with the dye diluted in PBS (1:500) 
which had been prewarmed, for 15 minutes. Cells were washed in DMEM-1% and 20,000 
labelled cells (Schwann cells or OECs) plated on to coverslips covered with a confluent 
monolayer of either astrocytes, Schwann cells or OECs (maintained in DMEM-10%). 
After 30 minutes at 37°C with gentle shaking on a rotating table, coverslips were removed, 
washed three times in Hanks staining solution and then fixed in 3.7% formaldehyde for 15 
minutes before mounting in Vectashield fluorescent mounting medium. The number o f 
Vybrant labelled cells remaining adhered to the coverslip were counted. All experiments 
were carried out in triplicate, and performed three times (n=3).
2.2.4 Time-lapse migration
In order to assess the migration speeds of Schwann cells and OECs on different substrates, 
coverslips were coated either with PLL (as outlined above) or with confluent astrocytes. 
To generate astrocyte monolayers, cells were plated in suspension at a concentration of
40.000 cells in 500 pi DMEM-10% and left to adhere to PLL-coated coverslips. Cultures 
were maintained in DMEM-10% at 37°C (in a humidified incubator) until they reached 
confluency. For the assay, OECs and Schwann cells were labelled with Vybrant (see above) 
and seeded onto PLL-coated or astrocyte-monolayer-covered coverslips at a density of
10.000 cells per well, and left to adhere overnight. Time-lapse imaging of the cells was 
performed using an Axiovert S I00 microscope connected to an Apple Mac Computer, 
using Open Lab Time Lapse Video Microscopy System. Additional media was added to a 
volume of 1 ml to keep the pH stable, and reduce the effect o f any evaporation. A thin 
layer of mineral oil was placed on top of the media in order to further reduce evaporation, 
and the 24-well plate placed underneath the microscope on a hot plate, set at 37°C.
Fields of view were chosen (at lOx magnification), where healthy cells had adhered and 
spread, showing that Vybrant labelling had no adverse effect on them. Vybrant-labelled 
cells were also demonstrated to still be immunoreactive for p75NTR (data not shown). 
Images were then taken o f the cell at intervals o f 20 minutes, for a period of 3 hours. The 
position of the cell body was measured for each time point, and an average speed of 
migration for each cell calculated. At least 5 measurements were taken for each experiment, 
and experiments performed in triplicate (n=3).
2.2.5 Wound assay
To assess migration, a wound assay was performed where cultures o f OECs or Schwann 
cells were maintained on PLL-coated coverslips until they reached confluency. A single 
scratch wound was made in the middle of the coverslip using a micropipette tip, and 
cultures maintained at 37°C in a humidified incubator for a further 8 hours. Digital photos 
were taken of the wound at time 0 (when the scratch had just been made), and at 8 and 48 
hours after wounding. An inhibitor of calpain 1 (ALLN) was added to the cultures 1 hour 
before wounding at a concentration of 50 pM.
Wounds were analysed by projecting the outline of the average wound size at time 0 
(calculated as 246.4 +/- 12.7 pm, n=3) onto all wound images (see Figure 3.9a). The number 
of cells which had migrated into this wound area were then counted, and presented as an 
average +/- SEM. Stephen Thomson, a BSc honours medical student, assisted with these 
assays, particularly with quantifying the resultant migration.
2.2.6 Use of Inhibitors in assays
2.2.6.1 Time-lapse inhibition
In migration assays, several different inhibitors were used to investigate the mechanism of 
migration (see Figure 1.3 for inhibitor sites of action). PP2 (a src inhibitor), UD and PD 
(MEK inhibitors), and ALLN (calpain 1 inhibitor) were applied to coverslips ready for 
time-lapse imaging. These were applied 1 hour before imaging began, at the relevant 
working concentrations (see Table 2.1). Supplementary media, added to coverslips just
Table 2.1 Inhibitor list, including working concentrations.
Target Inhibitor
Name
Stock 
concentration 
and diluent
Working
concentration
Source Experiment
Protein
synthesis
Emetine 10 mM in 
EtOH
10 pM Sigma,UK Protein lifetime
Calpain 1 ALLN
(MG-101)
100 mM (in 
DMSO or 
EtOH)
50 pM Calbiochem, UK 1) Time-lapse
2) Wound 
Assay
3) Adhesion 
Assay
Src SU6656 10 mM 10 pM Calbiochem, UK Confrontation
Src PP2
(AG1879)
In DMSO 20 pM Calbiochem, UK Time-lapse
MEK U 0126 10 mM in 
DMSO
50 pM Calbiochem, UK Time-lapse
MEK PD98059 In DMSO lOpM Calbiochem, UK Time-lapse
FGFR1 SU5402 10 mM stock 
in DMSO
10 pM Calbiochem, UK SCM
experiments
EGFR AG1478 10 mM 300 nM Calbiochem, UK SCM
experiments
PDGFR AG 1295 10 mM stock 10 pM Calbiochem, UK SCM
experiments
before time-lapse microscopy to protect the cells from evaporation and pH change (section 
2.2.4), also contained inhibitors at the appropriate concentration.
2.2.6.2 N-cadherin peptide inhibitor
To investigate the role o f N-cadherin in interactions between astrocytes, and OECs and 
Schwann cells, a peptide inhibitor of N-cadherin was used in adhesion assays and 
confrontation assays. The cyclic peptide, containing the cadherin adhesion recognition 
(CAR) sequence, His-Ala-Val (HAV; Williams et al., 2000), was added to the 24-wells 
used in adhesion assays at a final concentration of 0.3 mg/ml (from a 10 mg/ml stock), one 
hour before the plating of Vybrant-labelled cells. The assay was then performed as normal.
The cyclic peptide inhibitor was also used in confrontation assays. Here the peptide was 
added to the assay, again at a final concentration of 0.3 mg/ml, after the strips had been 
plated and non-adherent cells washed off. The peptide was reapplied every two days, 
when the assay was re-fed (by removing half of the media, and replacing with fresh 
DMEM-10%), keeping the final concentration constant.
2.2.6.3 N-cadherin peptide agonist
To assess the role of N-cadherin in inducing a hypertrophic response in astrocytes, a 
peptide agonist o f N-cadherin was used. This contained a dimeric version of the 
stimulatory peptide sequence, His-Ala-Val-Asp-Ile (HAVDI; Williams et al., 2002), and 
was applied to low density astrocyte cultures maintained on coverslips, at a final 
concentration of 30 p-g/ml (from a 20 mg/ml stock; Skapa et al., 2004) for 24 hours.
2.2.6.4 Tyrosine Kinase inhibitors
To assess if tyrosine kinases play a role in the mechanism of action of SCM, inhibitors of 
the tyrosine kinase receptors fibroblast growth factor receptor (FGFR), epidermal growth 
factor receptor (EGFR) and platelet-derived growth factor receptor (PDGFR) were used. 
These were applied at the appropriate working concentrations (see Table 2.1) to cultures at 
the time of feeding with SCM, and refreshed 24 hours later.
2.2.6.5 Protein synthesis inhibition with emetine
In order to analyse the lifetime of certain cellular proteins, cultures of OECs and Schwann 
cells were maintained in 6-well plates to a density of around 80% confluency. To these 
cultures, emetine was added at a final concentration of 10 |uM. Protein lysates were 
generated at regular time points, as outlined in section 2.4.1, and immunoblotting 
performed.
2.3 Immunocytochemistry
For details of antibodies and immunocytochemistry, see Tables 2.2 and 2.3
Cells for immunolabelling were grown on coverslips (see sections 2.1.1 and 2.2). These 
coverslips were removed from 24-well plates and any remaining media blotted onto paper. 
Coverslips were washed twice in PBS. Between all steps, any excess liquid remaining on 
the coverslips was blotted on paper. Cells were fixed by addition of 3.7% formaldehyde 
before covering and incubating for 10 minutes at RT. After this time, coverslips were 
washed in PBS and permeablised with 0.5% Triton-X 100/1% BSA in PBS, and incubated 
for 15 minutes at RT in the dark. After washing, the cells were incubated in blocking 
solution (10% FBS in PBS) for 30 minutes at RT. For some extracellular antibodies, the 
coverslips were blocked straight after fixation, followed by the extracellular antibodies. 
Permeablisation was then performed before applying the intracellular antibodies.
Primary antibodies were diluted in blocking solution at the appropriate dilutions (Table
2.2). and added to the coverslips for 1 hour at RT. Washes were performed three times in 
0.025% Tween 20 for 15 minutes. The appropriate secondary antibodies were diluted 
1:100 in blocking solution, and this was then added to the coverslips for 45 minutes, before 
further washing. Secondary antibodies of the appropriate class specificity were either 
FITC- (green) or TRITC- (red) conjugated as needed. After washes, coverslips were rinsed 
once in distilled water (dH20 )  and mounted on slides, using Vectashield mounting medium 
for fluorescence, supplemented with 4’,6’-diaminidino-2-phenylindole (DAPI) to aid 
detection of cell nuclei. Finally, the edges of the coverslips were sealed using nail varnish.
Table 2.2. Primary antibody list.
PRIMARY ANTIBODIES
ANTIBODY CLASS USE ! DILUTION SOURCE
N-cadherin IgGl Immunolabelling
Immunoblotting
Immunoprecipitation
1:100
1:1000
BD Transduction 
laboratories, Lexington, 
KY, USA
(3-catenin 4 4 Immunolabelling
Immunoblotting
Immunoprecipitation
1:100
1:1000
4 4
p l2 0 c“ 4 4 Immunolabelling
Immunoblotting
Immunoprecipitation
1:100
1:1000
4 4
E-cadherin 4 4 Immunolabelling
Immunoblotting
1:100
1:1000
4 4
P-cadherin 4 4 Immunolabelling
Immunoblotting
1:100
1:1000
4 4
vinculin 4 4 Immunolabelling
Immunoblotting
1:100
1:1000
4 4
paxillin 4 4 Immunolabelling
Immunoblotting
1:100
1:1000
4 4
GFAP anti-rabbit
polyclonal
Immunolabelling 1:100 Dako, Bucks, UK
actin IG2A Immunoblotting 1:100 Sigma, UK
BrdU IgGl Immunolabelling 1:20 Dako, Bucks, UK
actin phalloidin- 
conjugated 
to TRITC
Immunolabelling 1:200 Sigma, UK
Laminin anti-rabbit
polyclonal
Immunolabelling 1:100 Sigma, UK
Fibronectin anti-rabbit
polyclonal
Immunolabelling 1:50 Dako, Buck, UK
Neurocan
(IG2)
IgG Immunolabelling
Immunoblotting
1:2
1:20
Gift from Dr Oohira, 
Japan
CS-56 IgM Immunolabelling
Immunoblotting
1:100 Sigma, UK
473HD 4 4 Immunolabelling 1:25 Gift from Dr Faissner, 
Germany
0 4 4 4 Immunolabelling 1:4 Hybridoma; Sommer and 
Schachner, 1981
p75NTR IgGl Immunoblotting 
FACS sorting
1:4 Hybridoma; Yan and 
Johnson, 1987
Gal-C IgG3 FACS sorting 1:5 Hybridoma; Ranscht et 
al., 1982
Thy 1.1 IgM Complement killing 1:4 Hybridoma; ECACC, UK
Table 2.3. Secondary antibody list.
SECONDARY ANTIBODIES
ANTIBODY CLASS USE DILUTION SOURCE
IgGl
(anti-mouse)
Goat Immunolabelling 1:100 Southern Biotechniques, 
Cambridge Bioscience, 
Cambridge, UK
IgG2a
(anti-mouse)
4 4 Immunolabelling 1:100 4 4
IgG3
(anti-mouse)
4 4 Immunolabelling 
FACS sorting
1:100 4 4
IgM
(anti-mouse)
4 4 Immunolabelling 
FACS sorting
1:100 Jackson Labs
Anti-rabbit 4 4 Immunolabelling 1:100 Southern Biotechniques, 
Cambridge Bioscience, 
Cambridge, UK
Anti-mouse HRP - Immunoblotting 1:7000 Jackson Labs
Anti-rabbit HRP - Immunblotting 1:7000 Jackson Labs
For CS-56 immunolabelling, cells were first washed in solution A (see appendix 6.3ii) and 
then fixed with 4% paraformaldehyde (in solution A) for 10 minutes at RT. After fixation 
the cells were incubated in 0.5% triton x-100 (in solution A) for 1 minute also at RT. 
Solution A was also used for all washing steps as a substitution for PBS.
For BrdU labelling, cells were pre-treated with 20 |iM  BrdU (diluted in warmed PBS) 
while the cells were while still in culture. BrdU, which is intercalated into synthesised 
DNA, was left to incorporate into the cells for 16 hours. After this time, coverslips were 
removed and fixed in methanol at -20°C for 20 minutes and then washed in PBS. Further 
fixing was performed in 0.2% paraformaldehyde diluted in Hanks staining solution, for 
exactly 1 minute, followed by washing. 0.07 M NaOH was added to the coverslip and 
incubated for 7-10 minutes at RT. After further washing, BrdU antibody (1:20) was 
incubated on the cells or 45 minutes at RT in the dark. As with other staining protocols, 
the coverslips were washed before addition of the appropriate secondary for 30 minutes, 
followed by mounting, as previously described.
2.3.1 Microscopy
Confocal microscopy was carried out using a Leica SP2 confocal microscope at 10, 20 and 
40x magnification. Other fluorescent microscopy was carried out using Axioshop and 
Axioplan microscopes, at 10 and 20x magnification.
For measurements of astrocytic area, images were taken at lOx magnification. These images 
were visualised using NIH Image software, and direct measurements were taken of the 
astrocyte area, and calibrated using a graticule. At least 5 cells were measured per image, 
and 3 images taken per experiment. Experiments were performed in triplicate (n=3).
BrdU immunolabelling was performed (as outlined above in section 2.2.3) to quantify the 
number o f proliferating cells in culture. The BrdU positive cells were identified using 
indirect fluorescent microscopy. Briefly, random areas containing at least 200 cells per 
view were chosen, and the number of BrdU positive cells counted and displayed as a 
percentage of total cells in view. At least 5 fields of view were counted per experiment, and 
experiments performed in triplicate (n=3).
2.4 Immunoblotting
2.4.1 Preparation of protein extracts
Whole cell lysates were prepared using ice-cold lysis buffer. Confluent flasks or dishes 
were rinsed twice with ice-cold PBS. The culture vessels were inclined and allowed to drain 
to minimise the amount of residual PBS on the cells. Ice-cold lysis buffer was added to the 
cells (100 pi for a T25 flask, or 25 pi per 6 well) and lysis occurred over 10 minutes on ice, 
after which time lysates were collected, using a disposable cell scraper, into micro­
centrifuge tubes. Typically, lysates from at least 2 wells of a 6-well plate were pooled.
The lysates were sonicated, using a Soniprep 150 sonicator, and cleared of insoluble cell 
debris by centrifugation at 12,000 rpm at 4°C for 10 minutes. The total protein 
concentration of the lysates was estimated by adding 200 pi o f 2% CuS04 in Bicinchoninic 
acid to lOpl o f protein sample (at various dilutions) in a 96 well. This was incubated for 30 
minutes at 37°C before measuring the absorbance o f the samples at 562 nm using a 
microplate reader. Experimental values were compared to a standard curve (obtained using 
BSA, from a 2 mg/ml stock) and the total protein concentration in each sample calculated.
Protein extracts for immunoblotting with antibodies against the chondroitin sulphate 
proteoglycans (CS-PGs), were pretreated with chondroitinase, in order to remove GAG 
chains which can give a smeary blotting profile (McKeon et al., 1999; Asher et al., 2000).
0.2 U chondrotinase was diluted 1:10 with chondroitinase activating buffer. Of this, 0.02 
U/ml was added to protein extract, before incubation at 37°C for 3 hours.
2.4.2 Protein electrophoresis
Lysates were standardised for total protein content (maximum 15 pg protein per sample) 
before adding 4X sample buffer containing 4% p-mercaptoethanol. The lysates were boiled 
for 10 minutes, spun at 12,000 rpm for 30 seconds, and allowed to cool before loading onto 
SDS-polyacylamide gel electrophoresis (PAGE) gels for electrophoresis. Protein samples 
were separated on NuPAGE Bis-Tris 4-12% gels in NuPAGE MOPS buffer. Gels were 
run at 150V and 200mA for approximately 1 hour until the dye-front had reached the
bottom of the gel. All gels were run with SeeBlue molecular weight markers, and either 
stained directly (2.4.7) or the protein blotted on to nitrocellulose for immuno-probing 
(2.4.3).
2.4.3 Immunoblotting
After electrophoresis, proteins were transferred onto a 0.45 mm pore-size nitrocellulose 
membrane by electrophoretic semi-dry blotting. Briefly, the nitrocellulose membrane was 
soaked in methanol followed by dry blot buffer, and 12 pieces of 3MM paper were soaked 
in dry blot buffer alone. The SDS-PAGE gel and nitrocellulose membrane was sandwiched 
with 6 sheets of 3MM paper on each side, such that the membrane was on the cathode side 
of the gel. After gently excluding air bubbles from the paper/gel/membrane stack, by rolling 
a 1 ml pipette over the top, the proteins were transferred for 1 hour at a maximum current 
of 200 mA and a maximum voltage of 20 V for a gel of 140 cm2.
2.4.4 Antibody incubation and detection by ECL
Following the transfer, the nitrocellulose membrane was blocked in the appropriate 
blocking solution (PBS containing 0.2% Tween-20 (PBS/Tween) supplemented with either 
5% (w/v) milk powder or 3% (w/v) bovine serum albumin (BSA)) for 1 hour at RT on a 
shaker. After blocking, the blots were probed with primary antibody (1:1000 see Table
2.2) diluted in blocking solution for either 3 hours at RT or overnight at 4°C. After this, the 
blots were washed 3 times in PBS/Tween (15 minutes per wash) and were incubated in 
horseradish peroxidase (HRP)-conjugated secondary antibody (1:7000; anti-mouse IgG) for 
30 minutes at RT. After further washing in PBS/Tween, the blots were drained and 
incubated in ECL reagent for 1 minute with gentle agitation and wrapped in Saran-wrap. 
The blots were placed in contact with X-ray film, in an x-ray film holder in a dark room, for 
a period o f time sufficient for a signal from the enhanced chemiluminescence (ECL) to be 
detected and the film then processed in a Kodak automated processor.
2.4.5 Removing bound anti-sera from immunoblots
It was necessary to remove bound anti-sera from blots prior to reprobing with a different 
antibody. First, the blot was washed in PBS/Tween to remove spent ECL reagent, and then
incubated in stripping buffer (Reblot, 1:10 dilution) for 15 minutes at RT with shaking. At 
the end o f this incubation, the blot was washed again and blocked as above, prior to 
incubation with the appropriate antibodies.
2.4.6 Immunoprecipitation of extracted proteins
Lysates for immunoprecipitation were prepared in RIPA buffer. These lysates were then 
standardised for total protein content (ideally 1.0 mg per sample). Antibody against the 
protein o f interest was then incubated with the lysate (2 |ig Ab to >0.5 ml protein) 
overnight at 4°C to form IgG complexes. These complexes were then collected by 
incubation for 1 hour at 4°C with 50 jil o f a 50% slurry of protein-A sepharose beads 
against rabbit antibodies, or a slurry of IgG- or IgM-agarose beads against mouse 
antibodies. The collected immuno-complexes were washed 3 times in RIPA lysis buffer 
before resuspending in 20 jil of 4X sample buffer and boiling for 10 minutes at RT. 
Electrophoresis and blotting was performed as outlined in section 2.4.2.
2.4.7 Labelling of protein within the gel
Several staining methods were used to visualise the proteins in the gel depending on the 
sensitivity required.
If only a general view of protein components was required, following electrophoresis, the 
gel was stained in coomassie blue solution. Coomassie blue was added to the gel and shaken 
gently at RT for 30 minutes, before destaining in 7% acetic acid/5% methanol solution over 
night. The gel was then scanned.
Alternatively, when a more sensitive method was required, the gel was stained with 
Brilliant Blue Colloidal. Following electrophoresis, the gel was fixed by incubating in 7% 
acetic acid/40% methanol for 30 minutes. Brilliant blue stock solution (produced by adding 
800 ml deionised water to the bottle, mixing by inversion, and storage at 4°C) was then 
mixed 4:1 with methanol. This solution was incubated with the gel for 2 hours. After this 
time, the solution was removed and the gel destained in 10% acetic acid/25% methanol for
60 seconds, followed by a wash with water for 1 hour. The gel was then scanned at 600 
nm.
For staining o f two dimensional (2D) gels (Section 2.2.5) Sypro Orange was used. This was 
diluted 1:5000 in PBS and the gel was incubated for 30 minutes in the solution in the fridge. 
The fluorescent stain could then be detected at 580 nm using Typhoon software on a 
Typhoon 9400 transilluminator.
2.4.8 Densitometry reading of protein bands
To assess relative densities of immunoblotting bands, images were measured using 
QuantiOne Software by Biorad. Readings were normalised to the background, and also to 
the densities o f a loading control (actin or vinculin).
2.5 2D protein electrophoresis
2.5.1 Sample collection
SCM and OCM intended for 2D electrophoresis were collected as outlined in section 
2.2.1.6 but using DMEM-BS lacking BSA, in order to reduce contaminant protein levels. 
All media were concentrated using Centricon Plus-20 (centrifugal filter devices) tubes with 
a cut off o f 5,000 kDa, by centrifugation at 4,000 rpm for approximately 10 minutes. The 
filtrate was then discarded, and the concentrated sample was collected. This was carried out 
by inserting a collection tube, inverting the centricon tube, and spinning at 1,000 rpm for 1 
minute. The final solution was approximately 20 times more concentrated than the original 
solution.
2.5.2 Sample preparation
1/100 volume o f 2% Na-deoxycholate was added to lOOpg of protein and left on ice for 30 
minutes. To this, 1/10 volume of trichloric acetic acid (TCA) was added and left on ice for 
1-2 hours, after which the precipitated protein was collected by centrifugation for 15 min 
at 15,000 rpm at 4°C, before washing in -20°C acetone, and incubating on ice for a further 
30 minutes. The wash was repeated and the sample left on ice for 20 minutes. The sample
was then centrifuged for 15 minutes at 15,000 rpm at 4°C, left to air dry and resuspended 
in 125 (il of 2D gel sample buffer 1.
2.5.3 First dimension
Firstly, the IPGphor unit strip holders were placed on top of the IPGphor unit. The 
protein sample was then added dropwise along the groove in the strip holder (avoiding 
bubbles) and the immobilise dry strip placed on top of the sample. The pointed end (or 
marked *+’) o f the dry strip was pushed to the top of the groove. The sample and dry strip 
were then covered with 1 ml Dry Strip Cover Fluid.
The lid of the IPGphor unit was closed and the programme started, using a 12 hour 
rehydration step of the IPG strip, followed by 6-8 hours polarisation of the sample at 
5000 V.
2.5.4 Second dimension
The strip was removed from the electrode and rinsed in dH20, followed by a 15 minute 
incubation in 1 ml 2D gel sample buffer 2, with shaking. The strip was rinsed again, and 
then incubated for 15 minutes in 1ml 2D gel sample buffer 3, while shaking. After a further 
rinse, the strip was loaded onto a pre-cast gel (containing an IPG loading well). The gel was 
run as for ID  gels at 150 V and 200 mA for about 1 hour until the dye-front had reached 
the bottom of the gel, with SeeBlue molecular weight markers in parallel.
2.5.5 Fixation and staining
Following electrophoresis, the gel was fixed overnight at RT in 30% ethanol/5 % acetic acid, 
followed by 30 minutes in 0.05% SDS in PBS. Staining was performed using either Brilliant 
Blue Colloidal or Sypro Orange protein gel stain (Section 2.2.4.7).
2.6 Mass Spectrometry
2.6.1 Sample preparation -  with assistance from Chris Ward (proteomics 
manager, Beatson Institute)
Bands or spots o f interest in the gels were carefully excised using a scalpel on a clean glass 
plate, carried out in a fume cupboard, while wearing gloves, to minimise keratin 
contamination. Care was taken to minimise the gel size, avoiding excess gel. The gel piece 
was then cut into small pieces and placed in a sterile 1.5 ml microcentrifuge tube. The 
pieces were washed in 300 pi Milli-Q water for 15 minutes and the supernatant removed.
The gel pieces were then washed with 300 pi 100 mM NH4H C 0 3/CH3CN (50:50 v/v) for 
15 minutes and the supernatant removed, followed by a 15 minute wash with 300 pi 100 
mM NH4C 0 3 for 15 minutes, and removal of supernatant. If the gel pieces were still blue, 
these steps were repeated once or twice to remove the stain. After a final wash in 
NH4H C 0 3/CH3CN, 100 pi CH3CN was added for 10 minutes to dehydrate the gel. The 
supernatant was removed, and the pieces dried in a Speedvac for 5 minutes, before storing 
at -20°C.
Trypsin digestion of the protein sample was performed by addition of 10 pi of digestion 
buffer (25 pg/ml of modified trypsin in 20 mM NH4H C 0 3) per band. This was left for 20- 
30 minutes to rehydrate the gel pieces. If necessary, more 20 mM NH4H C 03 (without 
trypsin) was added to cover the pieces (although keeping the volume to a minimum). The 
sample was then incubated at 30°C for a minimum of 4 hours, before storage at -20°C until 
needed.
Samples were analysed (by Chris Ward) by mass spectrometry. Briefly, ID gel samples 
were ionised by electrospray ionisation (ESI) and then analysed by Q-star. 2D samples 
were ionised using matrix-assisted laser desorption ionisation (MALDI) and analysed by 
time-of-flight analysers (MALDI-TOF). These allow the production of trypsin digest 
spectras giving a peptide mass fingerprint which were then compared to University 
databases for identification
2.7 RNAi
2.7.1 Design of nucleotides
Twenty-one nucleotide double-stranded RNA sequences were designed against N-cadherin 
mRNA as recommended (ref:
http://www.mpibpc. gwdg.de/abteilungen/100/105/sima.htmlL 
The following rules were applied:
1. Sequences were chosen in the coding region of the mRNA with a GC ratio as close 
to 50% as possible
2. Regions within 50-100 nt of the AUG start codon or 50-100 nt o f the termination 
codon were avoided
3. Poly G sequences (more than 3 guanisines in a row) were avoided
4. Target sequences were chosen which started with two adenosines
5. Target sequences underwent a BLAST search to ensure that no unwanted genes 
with similar sequences were silenced
6. dTdT overhangs were used instead of UU since they were easier and cheaper to 
synthesise, as well as being more protected from nucleases
Sequences were ordered from Dharmacon Research in a ready annealed form. These were 
diluted in diethyl pyrocarbonate (DEPC; 0.1%) treated water to a concentration of 20 pM. 
Successful sequences used were:
sense siRNA: 5’ AAGAUGUUUACAGCGCGCGGU 
anti-sense siRNA: 5’ACCGCGCGCUGUAAACAUCdTdT
Scrambled RNAi were also designed for control experiments and subjected to a BLAST 
search to check that they did not correspond to any known RNA sequences. Sequences 
used were:
sense siRNA 5’ AAGCUAUCGCUACGUGCACGU 
anti sense siRNA 5’ ACGUGCACGUAGCGAUAGCdTdT
2.7.2 RNAi Transfection
Cells were set up for transfection by trypsinizing cells and then plating them on PLL- 
coated 6 wells at a density o f 40-60% confluency 24 hours before transfection.
Transfection was performed using both FuGENE and oligofectamine transfection protocols 
(according to manufacturers instructions). A transfection mixture containing 3 pi siRNA 
and 8 pi FuGENE was made in 200 pi DMEM-BS and added to each 6 well, already 
containing 2 ml of culture medium.
Alternatively, a mixture containing 12 pi siRNA and 12 pi Oligofectamine was made in 
400pl serum-reduced OPTIMEM, before adding to 6 wells containing only cells and no 
media. Cells were incubated for 4 hours at 37°C before adjusting the final culture volume 
with DMEM-10% to 2 ml. For both protocols, cells were left for 48 hours before making 
lysates, or being used in experiments.
2.8 Statistics
Statistical analyses were performed using either a 2-tailed t-test, where 2 samples were 
compared and assuming unequal variance, or using the one-way ANOVA test with 
Tukey’s post hoc analysis, where more than 1 group was being compared.
Data was expressed as the mean +/- SEM, and p-values were rounded to 3 digits. P-values 
below 0.05 were considered significant, and all experiments were performed at least in 
triplicate.
CHAPTER 3
Characterisation and comparison of Schwann cell 
and OEC migratory and adhesive properties
3.1 Introduction
In recent years olfactory ensheathing cells (OECs) and Schwann cells have both been 
proposed as candidates for transplant-mediated repair of central nervous system (CNS) 
lesions (Franklin and Barnett, 2000; Raisman, 2001; Wewetzer et al., 2002). Both cells 
have a similar repair repertoire, being able to remyelinate experimentally demyelinated 
lesions (Franklin et al., 1996; Barnett et al., 2000; Imaizuimi et al., 2000), and permit rapid 
saltatory conduction to take place (Imaizumi et al., 1998; Honmou et al., 1996) using 
similar transcriptional mechanisms (Smith et al., 2001). In addition, both OECs and 
Schwann cells can support axonal outgrowth, in experimental models of spinal cord injury 
(Ramon Cueto et al., 1994, 2000; Li et al., 1997, 2003a, 2003b).
Despite these similarities, there are significant differences between the two cell-types 
which may affect their candidature for transplant-mediated repair. For example, Schwann 
cells may have a limited potential to repair CNS damage due to their inability to migrate 
and survive within the CNS environment after transplantation (Baron von Evercooren et 
al., 1992; Franklin and Blakemore, 1993; Iwashita et al., 2000). This inhibitory 
environment is characterised by the presence o f reactive astrocytes (Norenberg, 1994; Eng 
and Ghimikar, 1994), which may be a restrictive component of CNS tissue since 
remyelination by Schwann cells is only observed in astrocyte-free areas (Woodruff and 
Franklin 1999; Shields et al., 2000). This propensity of Schwann cells to avoid astrocyte- 
rich areas was also demonstrated in vitro where Schwann cells cultured with astrocytes 
formed discrete boundaries being unable to migrate amongst them (Ghimiker and Eng, 1994; 
Wilby et al., 1999). In contrast to Schwann cells, OECs interact much more favourably 
with astrocytes and are able to intermingle and migrate amongst co-cultured astrocytes 
(Lakatos et al 2000), perhaps due to their inherent ability to exist in situ alongside 
astrocytes within the olfactory system (Doucette, 1991, 1993).
Another difference between Schwann cells and OECs is seen in the reactive response 
elicited when either cell-type is co-cultured with astrocytes (Lakatoes et al., 2000). When 
in contact with Schwann cells, but not OECs, astrocytes became enlarged and enhanced 
expression of the hypertrophic marker glial fibrillary acidic protein (GFAP), and
chondroitin sulphate proteoglycans (CS-PGs), an inhibitory component of the glial scar 
(Norenberg, 1994). This may be an important consideration when trying to minimise glial 
scarring, as supported by in vivo studies demonstrating that transplanted Schwann cells 
within the CNS induced a greater host tissue inhibitory response to axon regeneration by 
upregulating expression of CS-PGs and astrocytic GFAP compared to that associated with 
OEC transplantation (Plant et al., 2001; Lakatos et al., 2003).
It has been reported in the literature that there are migrational differences between OECs 
and Schwann cells when they come into contact with astrocytes in vitro. For instance, in 
co-cultures with astrocytes OECs can migrate into astrocytic areas, but Schwann cells 
cannot (Lakatos et al., 2000). At present, it is not known whether these migrational 
differences are intrinsic to the glial cells, such as relating to their inherent motility and their 
regulatory mechanisms of migration, or whether they are a result o f differential interactions 
with astrocytes, such as their adherence. The aim of this chapter, is to investigate some of 
the mechanisms which may explain how Schwann cells and OECs differ in their migration 
and adhesion. In order to achieve this, the adhesive and migratory properties of OECs and 
Schwann cells will be characterised on various substrates. In addition, the expression and 
localisation of molecular components associated with adhesion and migration will be 
investigated to assess if there are any substantial differences between how the cell types 
organise the machinery necessary for these processes. Since migration and adhesion are 
related phenomena (see Introduction, section 1.6.1.1), it is hoped that these functions can 
be dissected in order to assess the contribution o f each to the resultant behaviour of OECs 
and Schwann cells in the presence of astrocytes.
As previously described in the introduction (section 1.4.1.2), OECs can exist as a 
heterogenous population, consisting of a Schwann cell-like and an astrocyte-like 
phenotype. In order to simplify the comparison between OECs and Schwann cells in this 
thesis, OECs were cultured in conditions (Alexander et al., 2004) which favoured the 
Schwann cell-like phenotype (see Figure 3.1Aii). This preparation also reflects the cells 
used in the majority of reported transplantation experiments which were p75NTR-positive 
(Ramon-Cueto et al., 1998, 2000; Navarro et al., 1999; Plant et al., 2002).
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Figure 3.1. Cell purity of different cultures.
(A) Immunocytochemistry (i, ii, iii; co-labelled for GFAP-TRJTC, p75NrR-FITC and 
DAPI) and phase (iv, v, vi; different fields of view) of astrocytes (i, iv) cultured in DMEM- 
10%, Schwann cells (ii, v) cultured in DMEM-10% supplemented with heregulin and 
forskolin, and OECs (iii, iv) cultured in OEC mitogen media (OMM). Scale bar = 100 pm.
(B) Average purity o f cultures used in experiments (percentage of GFAP-positive cells 
(astrocytes) or p75NTR-positive cells (Schwann cells and OECs), total cell number was 
indicated by DAPI-labelling). n=6.
3.2 Results
3.2.1 The Confrontation assay models in vivo observations
To examine the ability o f Schwann cells and OECs to intermingle with astrocytes, we have 
used a previously demonstrated in vitro assay, termed the confrontation assay, and have 
confirmed its reproducibility (Wilby et al., 1999; Lakatos et al., 2000). The assay consisted 
o f strips o f OECs or Schwann cells which were plated on a coverslip opposing a strip of 
astrocytes. These were then maintained in culture for up to 14 days and the resulting 
cellular interactions analysed by immunocytochemistry. The cultures were immuno- 
labelled for p75NTR, to identify both OECs and Schwann cells, and GFAP, to distinguish 
astrocytes by their strong and fibrous GFAP expression from the weak and diffusely- 
expressing Schwann cells and OECs. The purity of the cells used in these experiments was 
also confirmed using these markers (Figure 3.1 A), and was above 90% for all cell types 
used (Figure 3.IB).
The confrontation assay demonstrated that Schwann cells were less able than OECs to 
mingle with astrocytes (Figure 3.2). Schwann cells typically formed discrete boundaries 
against the astrocytes (Figure 3.2B and 3.2D), and in addition, induced the astrocytes to 
become enlarged (see asterisk), a morphology characteristic of hypertrophy. It could also 
be seen that Schwann cells possessed an ordered alignment amongst themselves which was 
absent amongst the OECs. This may be suggestive of strong adhesions between Schwann 
cells. These phenomena reflect the in vivo observations following transplantation of OECs 
and Schwann cells into astrocyte-rich areas (Plant et al., 2001; Lakatos et al., 2003) and 
therefore allowed the use o f a simplified, in vitro approach to elucidate any molecular 
differences between the two glial cells in their ability to interact with astrocytes.
3.2.2 OECs and Schwann cells similarly express and localise 
components associated with migration and adhesion
Immunocytochemistry using antibodies against proteins typically associated with both 
migration and adhesion was performed in order to investigate their expression and
OEC:Astrocyte Schwann cell:Astrocyte
Figure 3.2. Schwann cells, but not OECs, form a boundary upon interacting with
astrocytes.
A confrontation assay was set up between OECs and astrocytes (A, C) and between 
Schwann cells and OECs (B, D). Cells were immunolabelled after 10 days, and phase 
microscopy (A, B) and confocal microscopy (C, D) was performed. OECs and Schwann 
cells were labelled in green (p75NTR-FITC), and astrocytes in red (GFAP-TRITC). 
Schwann cells formed a clear boundary against the astrocyte domain (arrows), whereas 
OECs have intermingled with astrocytes. An enlarged hypertrophic astrocyte can be 
seen, marked with an asterisk. Scale bar = 100 pm.
localisation in Schwann cells, OECs and astrocytes (Figures 3.3 and 3.4). The intention was 
to characterise the arrangement of these in order to highlight any gross differences between 
the different glia, such as the absence or inappropriate positioning of known proteins 
necessary for adhesion and migration. Structures investigated were focal adhesions (paxillin 
and vinculin), adherens junctions (N-cadherin, vinculin and (3-catenin), the cytoskeleton 
(actin) and the extracellular matrix (ECM; fibronectin and laminin).
Paxillin and vinculin were located as expected at focal adhesions, clearly seen at the tips of 
cellular processes. N-cadherin and (3-catenin were both associated with the cell-cell 
junctions where they are likely to mediate adhesion between cells. Astrocytes had more 
distinct junctions, compared to Schwann cells and OECs, which occurred on all surfaces, 
reflecting the astrocytes ability to form monolayers and syncytium (Shearer and Fawcett, 
2001), whereas OECs and Schwann cells were similar in that they had only short, often 
patchy, contact areas. For all glial cells, clear actin stress fibres were observed. In addition, 
both fibronectin and laminin were detected on all cells, with a particularly diffuse pattern 
around astrocytes, reflecting where they were secreted.
In summary, OECs, Schwann cells and astrocytes all contain the appropriate protein 
structures associated with migration (focal adhesions) and adhesion (adherens junctions), 
and at correct cellular locations for them to function appropriately. In addition, they all 
expressed distinct actin stress fibres. OECs and Schwann cells both appeared to have a 
similar ability to secrete ECM. However, it is also noteworthy that Schwann cells 
displayed a more polarised morphology than both OECs and astrocytes, suggestive of 
greater motility.
3.2.3 Migration
3.2.3.1 Schwann cell migration is impeded on astrocytes
To compare the abilities of Schwann cells and OECs to migrate, migration assays were 
performed on both PLL and astrocyte substrates, using time-lapse microscopy, where the 
distance moved by Schwann cell and OEC cell bodies at regular time intervals was 
measured. On PLL, OECs and Schwann cells migrated at similar speeds (18.16 +/- 2.81
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Figure 3.3. Astrocytes, OECs and Schwann cells form normal focal adhesions and 
adherens junctions.
Immunocytochemistry of astrocytes (A, D, G, J), OECs (B, E, H, K) and Schwann cells 
(C, F, I, L) showing molecular localisation o f components associated with migration and 
adhesion, such as focal adhesions (paxillin (A, B, C) and vinculin (D, E, F), solid arrows) 
and adherens junctions (vinculin, N-cadherin (G, H, I) and (3-catenin (J, K, L), open 
arrows). Scale bar = 50 pm.
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Figure 3.4. Astrocytes, OECs and Schwann cells have distinct actin stress fibres, and 
secrete fibronectin and laminin.
Immunocytochemistry of astrocytes (A, D, G), OECs (B, E, H) and Schwann cells (C, F, 
I) showing molecular localisation of components associated with migration and adhesion, 
including components of the cytoskeleton (actin; A, B, C) and the extracellular matrix 
(fibronectin (D, E, F) and laminin (G, H, I)). Arrows indicate leading edge of polarised 
Schwann cells. Scale bar = 50 pm.
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pm/hour and 19.57 +/- 3.08 pm/hour, respectively; Figure 3.5). However, upon astrocyte 
monolayers (AS), OEC migration was equivalent to that assessed upon PLL (21 +/- 2 
pm/hour) whereas Schwann cell migration was significantly reduced by approximately 40% 
(to 11.47 +/- 0.87 pm/hour, p<0.01). Thus, Schwann cell migration, although comparable to
OEC migration upon PLL, is inhibited when cultured upon astrocytes. This inhibition is 
not seen for OECs. Therefore, Schwann cell migration is comparable to OEC migration, 
unless astrocyte-mediated inhibition is occurring. This suggests that an inhibitory factor 
from astrocytes is acting upon Schwann cell migration.
3.2.3.2 OECs and Schwann cells are dependent upon similar signalling 
pathways to regulate migration
In order to compare and contrast the mechanisms controlling migration o f OECs and 
Schwann cells, a number of components of signalling pathways associated with migration 
were inhibited (see Figure 1.3 in Introduction), and the resulting effects on migration 
measured. MEK and src signalling pathways were targeted since they have been shown to 
be important for the regulation o f migration (Klemke et al., 1997; Fincham and Frame, 
1998). Cells were incubated in MEK inhibitors (UD and PD), and a src inhibitor (PP2), and 
migration was assessed by time-lapse microscopy. All inhibitors, reduced migration 
significantly in both Schwann cells and OECs (Figure 3.6; p<0.001). Thus both Schwann 
cells and OECs use similar MEK and src signalling pathways to regulate migration.
3.2.4 OEC and Schwann cell focal adhesion turnover is not 
regulated by astrocyte contact
A reduction in cell migration can be associated with a reduced turnover o f focal adhesions 
(see Introduction, section 1.6.1.2). This can be identified by an enlargement of the focal 
adhesions, resulting from the build-up of proteins at these sites which are no longer being 
disengaged and disassembled, and in particular, the formation of exaggerated rod-like 
adhesions due to the contraction o f the associated actin-cables (Raghavan et al., 2003). To 
investigate whether such a mechanism results from the contact-mediated inhibition of 
Schwann cell migration, following interaction with astrocytes, any change in focal adhesion
30
Figure 3.5. Schwann cell m igration is inhibited upon astrocyte monolayers.
OEC and Schwann cell migration rates upon poly-l-lysine (PLL) and astrocyte 
monolayers were measured using time-lapse microscopy. The migration speeds of 
OECs on both PLL and astrocytes monolayers were similar, whereas Schwann cell 
migration was significantly decreased upon an astrocyte monolayer (*p<0.01, n=15).
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Figure 3.6. Both Schwann cells and OECs require M EK and src signalling 
pathways for migration.
Relative migration speeds of OECs and Schwann cells were measured using time-lapse 
microscopy after addition of MEK (UD and PD) and src (PP2) inhibitors. Migration 
was reduced in both OECs and Schwann cells by the presence of all these inhibitors. * 
p<0.001, n=15.
size was analysed following co-culture of Schwann cells and OECs with astrocytes. Double 
immunolabelling with an antibody against paxillin was used to label focal adhesions, 
together with anti-GFAP to identify astrocytes. All cells (astrocytes and either Schwann 
cells or OECs) were identified by DAPI-staining of cell nuclei. Immunofluorescence 
demonstrated that focal adhesion size was not significantly changed between cells in mono- 
and co-cultures, when assessed qualitatively by eye (Figure 3.7), suggesting that focal 
adhesion turnover as unaffected by astrocyte contact and was therefore not a mechanism 
through which Schwann cell migration was decreased.
3.2.5 Schwann cells have stronger adhesions than OECs
An adhesion assay was employed to compare the relative adhesive strengths of Schwann 
cells and OECs to both monolayers o f themselves (homo-typic adhesion) and to astrocyte 
monolayers (hetero-typic adhesion). In this manner, Schwann cell inhibition (as 
demonstrated in the confrontation assay, Figure 3.2) could be explained either as a result of 
enhanced adhesion to astrocytes, preventing Schwann cells from migrating further into 
astrocytic areas, or due to strong mutual adhesion to themselves, which in turn prevents 
them from migrating away from Schwann cell areas. The adhesion assay was performed by 
counting the number of Schwann cells and OECs (labelled with Vybrant to aid detection) 
which had adhered to a monolayer of Schwann cells or OECs (respectively), or to an 
astrocyte monolayer.
Schwann cells displayed a greater adhesion than OECs to astrocytes (Figure 3.8; p<0.001), 
where 1197 +/- 75 Schwann cells adhered to astrocyte monolayers, compared to 469 +/- 38 
OECs. Schwann cells also had greater adhesion to themselves (681 +/- 46 Schwann cells to 
Schwann cell monolayers), than OECs (114 +/- 9.9 OECs to OEC monolayers; p<0.001). 
This shows that Schwann cell adhesion is greater than OEC adhesion, both homo- and 
hetero-typically. Additionally, despite OEC adhesion being less strong than Schwann cells 
to either substrate, both Schwann cells and OECs adhered more strongly to astrocytes than 
to monolayers o f themselves (p<0 .0 0 1 ).
Schwann cellAstrocyte
OEC:Schwann cell Astrocyte:Schwann cell
Figure 3.7. Focal adhesion size is unchanged in OECs and Schwann cells co-cultured 
with astrocytes.
Immunocytochemistry of paxillin (FITC) in cells both in mono-culture (OECs, A; astrocytes, 
B; Schwann cells, C) and co-cultured with astrocytes (astrocyte:OEC, D; astrocyte:Schwann 
cell, E), showing that OEC and Schwann cell focal adhesion sizes are unchanged when in 
contact with astrocytes, as assessed qualitatively by eye. Cell nuclei are labelled with DAPI, 
and astrocytes for GFAP (TRITC). Scale bar = 100 pm.
A dherent cells: Schwann cell OECs Schwann cells OECs
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Figure 3.8. Schwann cells form stronger adhesions than OECs.
Schwann cells are capable of stronger adhesions than OECs, to both themselves (homo- 
typic) and astrocytes (hetero-typic). To assess adhesion, Vybrant-labelled cells were 
plated onto a confluent cell monolayer and left to adhere for 30 minutes with shaking at 
37°C. The number of adherent cells that remained attached were then counted. * p values 
between every pair <0.001, n=6.
3.2.6 Role of calpain in migration and adhesion
Calpain is a protease involved in the regulation and degradation of components associated 
with migration and adhesion (see Introduction, section 1.6.1.2; Figure 1.3). It has been 
demonstrated to play different roles in various cell types, and therefore may be a 
determinant of the different migratory and adhesive behaviour observed in Schwann cells 
and OECs. In most cell types it functions to enhance migration, thus its inhibition reduces 
the motility of a cell (Huttenlocher et al., 1997; Carragher et ah, 2001). In neutrophils, 
however, its inhibition actually led to a more migratory phenotype (Lokuta et al., 2003). 
The role of calpain in Schwann cell and OEC migration and adhesion was therefore 
investigated, to see how it affected the two glial cells. Cell viability was assessed for the 
calpain inhibitor (ALLN) before selecting the optimal concentration for experiments. This 
was performed, following cell-treatment with a range of inhibitor concentrations for 24 
hours, by both propidium iodide labelling (50 (Lig/ml in PBS) and qualitatively assessing the 
cellular appearance by phase microscopy (data not shown). Stephen Thomson assisted 
with some of the optimisation. A working concentration of 50 p,M was chosen since this 
was the highest concentration where cell viability appeared unaffected by treatment, and 
within the suggested effective concentration range.
3.2.6.1 Both Schwann cells and OECs are dependent upon calpain for 
migration
Migration assays were set up, and speeds o f cells plated upon PLL and astrocyte 
monolayers were measured both in the presence and absence of an inhibitor of type - 1  
calpain, ALLN. In all experiments, in which Schwann cells and OECs were pre-incubated 
for 1 hour with ALLN, migration was reduced (Figure 3.9; OECs p<0.05, Schwann cells 
p<0.01). Therefore, no differences were seem in the dependency of Schwann cells and 
OECs upon calpain for efficient migration. This similar dependency upon calpain was also 
demonstrated using an additional assay for assessing migration, the wound assay, where 
confluent cultures were scraped with a pipette tip to create a ‘wound’. Again, ALLN was 
pre-incubated for 1 hour with confluent OEC and Schwann cell cultures, prior to wounding 
the cultures with a micropipette. Images were taken of the cultures at 0, 8  and 48 hours 
after wounding (Figure 3.10). After 8  hours, cells could be seen migrating into the wound in
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Figure 3.9. Schwann cells and OECs both require calpain function for migration.
Relative migration rates, as measured by time-lapse microscopy, were calculated for 
OECs and Schwann cells (SC) plated on PLL (A) and on astrocyte monolayers (B), 
both with and without treatment with the calpain 1 inhibitor (ALLN) (n = 10; *p<0.05,
**p<0.01).
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Figure 3.10. OEC and Schwann cell wound healing requires calpain activity.
Phase contrast images of wound assays were taken using confluent OEC (A to F) and 
Schwann cell (G to L) monolayers on PLL. Inhibition of migration is seen after treatment 
with the calpain 1 inhibitor (ALLN) by 8  hours (B, E, H, K) and which still occurs at 48 
hours (C, F, I, L), compared to controls (A, D, G, J). Scale bar = 100 pxn.
untreated cultures (Figure 3.1 OB and 3.1 OH), whereas both Schwann cell and OEC 
migration was prevented in the treated experiment (Figure 3.10E and 3.1 OK). This 
inhibition was seen further at 48 hours, where untreated Schwann cell and OEC cultures 
had almost reached confluency again (Figure 3.IOC and 3.101), whereas the wound was still 
clearly observable in the treated set (Figure 3.1 OF and 3.10L). These differences were 
quantified by taking images of the wounds at the various time-points following wounding. 
The number of cells migrating into the wound area (as designated by projecting an outline 
o f the average wound size onto images) were counted and presented in a graphical form 
(Figure 3.11). Schwann cell migration into the wound following ALLN treatment was 
significantly reduced at 48 hours following wounding (257.6 +/- 42.4 cells per wound 
(untreated) to 74 +/- 16.7 cells per wound (ALLN-treated); p<0.01), as was OEC migration 
(238.75 +/- 24.1 cells per wound (untreated) to 101.5 +/- 23.4 cells per wound (ALLN-
treated); p<0.01). It can therefore be concluded that Schwann cells and OECs are both 
dependent upon calpain activity for migration, and dependency is to a similar level.
3.2.6.2 OEC and Schwann cell adhesion are not dependent upon calpain 
activity
An adhesion assay was performed to measure the adhesion of Vybrant-labelled OECs and 
Schwann cells to astrocyte monolayers with and without the preincubation of ALLN for 1 
hour (Figure 3.12). OEC adhesion appeared to increase upon inhibition of calpain, but this 
difference was not significant. Schwann cell adhesion was unaffected by the presence of 
ALLN.
3.3 Discussion
3.3.1 General comparison of Schwann cells and OECs
Many similarities between the cellular and molecular properties of Schwann cells and 
OECs were observed in the experiments performed in this chapter. These included the 
localisation of complexes associated with migration and adhesion, and the ability of 
Schwann cells and OECs to migrate upon PLL. These similarities therefore add to the
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Figure 3.11. ALLN treatment significantly decreases the number of OECs and 
Schwann cells migrating into a wound.
(A) Phase contrast images demonstrating the projection of wound divisions to allow 
quantification o f cells migrating into the wound space. Defined boundary edges 
(based on average wound size of 246.4 +/- 12.7 pm, n=6 ) were overlaid onto images, 
and the numbers of cells which migrated into this space were counted, (i) OECs 
immediately after wounding, and (ii) OECs 4 hours after wounding demonstrating 
migrating cells into wound area. Scale bar = 100 pm. (B) Quantification of number of 
cells migrating into scratch wound. A significant decrease in OECs and Schwann cells 
migrating into the wound was seen after ALLN treatment (48 hours). *p<0.01, n=6 .
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Figure 3.12. Calpain inhibition does not significantly affect OEC or 
Schwann eell adhesion to astrocytes.
Relative adhesion of OECs and Schwann cells (SC) to astrocyte monolayers, 
both with and without treatment with a calpain inhibitor (ALLN). Adhesion was 
measured using the adhesion assay, whereby the number of Vybrant-labelled 
cells adhering to an astrocyte monolayer after 30 minutes were counted. n=6.
plethora of evidence that Schwann cells and OECs share many properties in common, 
despite being derived from developmentally distinct regions, the neural crest and olfactory 
placode respectively.
However, significant differences are also seen between the two cell-types when it comes to 
the nature of their interactions with astrocytes, as has been highlighted both in vitro and in 
vivo. Thus, the data showing that Schwann cells form distinct boundaries upon interaction 
with astrocytes, and induce characteristics typical of hypertrophy in astrocytes, whereas 
OECs intermingle freely with astrocytes, confirms the published literature (Lakatos et al., 
2000, 2003; Plant et al, 2002). This boundary formation property of Schwann cells may 
well influence their ability to integrate within the astrocyte-rich CNS tissue after 
transplantation.
As previously mentioned at the beginning of this chapter (Section 3.1), OECs for these 
experiments were cultured in conditions favouring the spindle-shaped, Schwann cell-like 
phenotype rather than the flatter, astrocyte-like phenotype. Despite the fact that these 
OECs adopted a morphology very similar to the Schwann cell, which may suggest similar
migratory behaviour between them due to their shared polarity, they were still very 
different in function. This suggests that the cellular behaviour of the cells are probably not 
determined by their morphology alone, but may reflect more fundamental biological 
differences between them. However, how the astrocyte-like OEC behaves under the 
conditions of these assays still remains an interesting question.
3.3.2 Expression and localisation of proteins associated with 
migration and adhesion
These data indicate that there are no inherent structural problems with the abilities of 
OECs and Schwann cells to migrate and adhere since there were no obvious differences 
detected in the expression and localisation of proteins associated with focal adhesions, 
adherens junctions and the cytoskeleton. The deposition of ECM was also investigated, as 
this has been shown to promote integrin-mediated adhesion and subsequent integrin- 
dependent migration. These data suggest that Schwann cells do not have any inherent
defects to explain a lack of migration. In agreement with these results, it was found by 
time-lapse microscopy that Schwann cells could migrate as efficiently as OECs on PLL. 
This is also supported by the observation that Schwann cells are very polarised with 
respect to their direction of movement indicative of a motile phenotype. In contrast, the 
presence of distinct actin stress fibres might suggest a less migratory phenotype, resulting 
from stable adhesion to the substratum, where focal adhesions associated with these fibres 
are involved in long term anchorage rather than dynamic protrusion and traction processes 
at the cell front (Kaverina et al., 2002). Despite this, all three glial cells had similar fibres 
and suggest that these are unlikely to be mediating a functional difference between the cell 
types. Indeed, OECs and Schwann cells appeared more alike when compared to astrocytes, 
since they both had short, patchy adherens junctions, reflecting their polar morphologies. 
In addition, OECs and Schwann cells appeared to have secreted similar amounts of ECM, 
which was less than that produced by astrocytes. Cultured astrocytes have been 
previously described as sources of fibronectin and laminin (van der Laan et al., 1997), 
which may reflect a role for astrocytes in maintaining the cytoarchitecture of the CNS 
(Rutka et al., 1988). This further highlights the Schwann cell-like properties of the OECs 
used in these assays.
3.3.3 Regulatory pathways o f migra
Taken together, the migration data show that Schwann cell and OEC migration is regulated 
in a similar manner, requiring the efficient functioning of both MEK- and src-dependent 
pathways, as well as calpain regulation. This calpain dependency may reflect the similar 
dependency upon src, in that calpain and src may be acting on similar pathways, Indeed, 
calpain and src are both required for focal adhesion regulation, where src activity is 
necessary for calpain-mediated cleavage of focal adhesion components such as FAK 
(Carragher et al., 2001), leading to their disassembly. Differences were, however, observed 
in calpain-dependency for adhesion, although these were not statistically significant. The 
lack of effect o f calpain inhibition, which would act to reduce adhesion turnover, was 
probably due to the higher degree of adhesion observed in Schwann cells, compared to 
OECs, to astrocytes. Since adhesion was already so high, and thus turnover probably very 
low, inhibition of calpain had no extra effect. OECs, however, exhibited a lower cellular 
adhesion capacity which might reflect a more dynamically regulated adhesion process.
Calpain inhibition, and therefore an increased stability of adhesion complexes, could 
therefore exert an effect. The low statistical significance in these experiments may be 
increased by using a higher concentration of inhibitor, or increased incubation time, 
although the parameters used were suitable for migration inhibition. Why would these be 
different in migration and adhesion? A key difference between migration and adhesion could 
be due to the dual role of calpain as a regulator o f both integrin- and cadherin-mediated 
adhesion. Migration on PLL would require only integrin-mediated adhesion to ECM laid 
down by the cells, whereas adhesion to astrocytes would also involve both integrin and 
cadherin complexes. Both complexes are substrates for calpain (Covault et al., 1991; Bhatt 
et al., 2002; Rios-Doria et al., 2003) although they may be regulated differently.
3.3.4 Migration versus Adhesion
Despite the many similarities between OECs and Schwann cells, differences were apparent 
in their migration capacity, as assessed by time-lapse microscopy. Although OEC and 
Schwann cell migration is indistinguishable upon PLL, they demonstrate very different 
abilities upon astrocyte monolayers, where Schwann cells have greater adhesion than OECs 
and display less migration. The slower migration of Schwann cells on an astrocyte 
monolayer may reflect their strong adhesion to astrocytes. Cell migration is the result of 
many coordinated events involving changes in the actin cy to skeleton, as well as the 
controlled formation and dispersal o f adhesion sites between cells and their substrates. 
Thus, since OECs adhere less strongly to astrocytes, this may be why they are able to 
migrate more freely upon astrocyte monolayers. Conversely, Schwann cells adhere much 
more strongly to astrocytes, providing an explanation of why they are more restricted in 
their ability to migrate on this substrate.
However, it can not be determined at present whether it is Schwann cell adhesion to 
themselves or to astrocytes which might be playing a greater role in restricting Schwann cell 
migration, as seen in the confrontation assay. Schwann celkSchwann cell adhesions were 
greater than OEC:OEC adhesions, and may suggest that Schwann cells were not able to 
migrate away and be released from contact with other Schwann cells in order to enter 
astrocyte-rich areas. Conversely, Schwann cell:astrocyte adhesions were also greater than 
OEC:astrocyte adhesion, possibly implying that Schwann cells formed strong contacts
with the first astrocytes they encountered, impeding further migration. Since adhesion to 
astrocytes was greater than adhesion to other Schwann cells, the latter is probably playing 
a more inhibitory function.
Different conclusions from mine have been drawn from time-lapse studies of Schwann cell 
migration upon astrocyte monolayers when the total distance moved was measured, rather 
than speed (Lakatos et al., 2000). Here Schwann cells and OECs had similar migration 
profiles. Other researchers have also reported an ability of Schwann cells to migrate over 
the surface of astrocytes (Franklin and Blakemore, 1995; Baron von Evercooren et al, 
1996), although not through them (Xu et al., 1996; Iwashita et al., 2000). This supports the 
idea that migration upon astrocytes is fundamentally different from migration through 
astrocyte-rich areas.
One possible explanation for this is that although Schwann cell migration may be slowed 
down significantly upon astrocyte monolayers, with enough time they are still able to 
travel some distance. In contrast, migration through an astrocytic environment also requires 
the space to move into. Alternatively, if repulsive cues are presented by astrocytes, then 
cells in a confrontation assay would be restricted from entering the astrocyte domain. 
However, cells plated upon an astrocyte monolayer could respond by migrating away from 
this astrocyte contact, only to form new contacts with astrocytes, eventually reaching an 
astrocyte patch that may be expressing fewer o f these signals. In addition, the reactive 
response of astrocytes to Schwann cells may provide a greater physical barrier to their 
migration, an effect not apparent when Schwann cells migrate upon a monolayers. This is 
supported by the lack of migration observed by both OECs and Schwann cells when 
transplanted into intact and uninjured tissue (Iwashita et al., 2000; Lakatos et al., 2003a), 
where they both may not have had any room to move. In contrast, cells injected into 
injured tissue were able to migrate further (Li and Raisman, 1994; Ramon-Cueto et al., 
1998). For this reason, although the migration assay can give a lot o f information regarding 
adhesion and migration, the confrontation assay was felt to be a better assay for modelling 
interactions with astrocytes in a way that best reflected the transplantation scenario.
3.3.5 Schwann cell invasion versus migration
The degree to which Schwann cells can actually migrate within the CNS is still an area of 
controversy. Many researchers have reported an inability of Schwann cells to migrate 
within astrocyte-rich areas, both in vitro (Wilby et al., 1999; Lakatos et al., 2000) and in 
vivo (Ramon-Cueto et al., 1998; Iwashita et al., 2000; Plant et al., 2001). However, upon 
disruption to the glia limitans, Schwann cells from the peripheral nerves beyond the dorsal 
root entry zone can invade the CNS environment of the spinal cord very easily (Bmce et 
al., 2000), although this tissue is typically damaged. Transplanted Schwann cells have also 
been shown to migrate within the CNS in some experiments (Brook et al., 1993; Li and 
Raisman, 1994), although due to the identification of these cells by expression of p75NTR, it 
was not possible to confirm that these cells were all o f transplant origin. In addition, upon 
transplantation of peripherally derived OECs into the injured CNS, endogenous Schwann 
cells were recruited to the site of injury by the transplanted cells (Ramer et al., 2004a). It is 
for these reasons that better labelling techniques are being developed to distinguish the 
repair attributed to the transplanted cells themselves, and that resulting from endogenous 
glia (Lee et al., 2004). Why in some instances Schwann cells can migrate within the CNS, 
and in others they can not is not fully understood. Since the migration observed for 
transplanted Schwann cells occurred predominately along blood vessels, epydyma and 
meninges (Brook et al., 1993; Baron van Evercooren et al., 1994, 1996; Li and Raisman, 
1994), it has been speculated that endogenous Schwann cells which invade the CNS may 
also be migrating along these pathways, thus actually avoiding direct contact with 
astrocytes.
Despite the controversy, when comparing Schwann cell and OEC compatibilities with 
astrocytes, using both in vitro confrontation assays (which test the ability of cells to 
migrate through astrocytes) and migration assays (which test the ability of cells to migrate 
upon astrocytes), clear differences are apparent. These suggest fundamental differences in 
the biology of these glia which are of interest, both in improving our understanding of these 
cells and determining which might be the superior candidate for transplantation, but also in 
understanding possible regulatory mechanisms involved in the inhibition of transplant cell 
migration.
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3.3.6 Conclusions
It remains to be seen what the molecular mechanisms are that govern the different OEC and 
Schwann cell migratory and adhesive potentials when in contact with astrocytes. Adhesion 
strength appears to be a key process, as demonstrated by the adhesion assay, where 
migratory differences may result from the greater Schwann cell adhesion to astrocytes. This 
appears to be supported by the lack of migratory defects seen on PLL, where Schwann 
cells possessed a motile phenotype and were capable o f migration speeds equivalent to 
OECs.
In addition, the mechanism by which Schwann cells induce hypertrophy in astrocytes may 
also be important. Reactive astrocytes were observed only in Schwann cell:astrocyte 
confrontation assays and not in OEC:astrocyte cultures, also confirming the published 
literature (Ghimiker and Eng, 1994; Lakatos et al., 2000; Plant et al., 2001). What causes 
this differential reactivity, and also the degree to which it influences subsequent Schwann 
cell-astrocyte interactions, remains unanswered. It could be that enlarged astrocytes, 
resulting from initial Schwann cell-astrocyte interactions, provide a greater adhesive 
substrate for Schwann cells, thus restricting their migration away from this junction.
In order to answer these questions, Chapter 4 will focus more on the role of adhesion 
molecules in Schwann cells and OECs, with particular emphasis on their interactions with 
astrocytes. In particular, the role of the adhesion molecule N-cadherin will be assessed. In 
Chapter 5, I will investigate in more detail the astrocytic response, and how this 
contributes to the varying abilities of OECs and Schwann cells to migrate within astrocytic 
areas.
CHAPTER 4
N-cadherin differentially determines Schwann cell 
and OEC interactions upon contact with astrocytes
4.1 Introduction
It was shown in the previous chapter that Schwann cells and OECs are similar in their 
ability to migrate upon PLL-coated substrates, and in their expression of molecules 
associated with the processes of migration and adhesion. However, they differ in the way 
they interact with astrocytes, where Schwann cell, but not OEC, migration was reduced 
upon astrocytes. In addition, Schwann cells were shown to have stronger adhesions than 
OECs to both astrocytes and to themselves.
It has been previously suggested that the restriction o f Schwann cell migration into 
astrocyte-rich regions may be mediated by contact inhibition, perhaps via N-cadherin. This 
was borne out by the experiments o f Wilby et al (1999), where an N-cadherin inhibitory 
peptide blocked the adhesion and increased the migration o f Schwann cells on astrocyte 
monolayers. Since OECs migrate more extensively within an astrocyte environment than 
Schwann cells, it was originally suggested that OECs may lack N-cadherin, although this 
has been proved not to be true, by both immunocytochemistry and immunoblotting (Figure 
3.3 and 4.1; also Lakatos et al., 2000).
Thus the role o f N-cadherin in both Schwann cell and OEC migration and adhesion requires 
further investigation. Specifically, I have addressed by precise molecular intervention 
whether i) N-cadherin is present and similarly functional in both OECs and Schwann cells 
and ii) if silencing N-cadherin using RNA interference (RNAi) has similar, or distinct, 
biological effects on the interactions of the two glial cells with astrocytes in vitro.
4.2 Results
4.2.1 N-cadherin is the major cadherin molecule for Schwann 
cells, OECs and astrocytes
To confirm previous data that N-cadherin was present on OECs and Schwann cells, 
immunoblotting was performed using lysates from astrocytes, OECs and Schwann cells. N- 
cadherin levels were similar for all three cell types, compared to total protein concentration 
(Figure 4.1 A). To assess whether N-cadherin was forming functional adherens junctions,
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Figure 4.1. Astrocytes, OECs and Schwann cells all express N-cadherin to 
sim ilar levels
(A) Immunoblot showing N-cadherin levels in the different glial cells, with a-actin 
loading control. (B) Immunocytochemsitry showing no redundancy in expression 
of the classical cadherins, since they all express N-cadherin (ii, v, viii) but not E- 
(i, iv, vii) or P-cadherin (iii, vi, ix). Scale bar = 100 pm.
cellular localisation and Ca2+ dependency was monitored by immunofluoresence. Ca2+ is 
necessary for the rigidification of N-cadherin ectoderms, which promote stable interactions 
between both trans and cis N-cadherin molecules (Figure 1.4), and thus modulation of Ca2+ 
concentration can be used to monitor if cadherins are functional with regards to cell-cell 
contacts (Nagar et al., 1996; Steinberg and McNutt, 1999). In all three glial cell types, cell­
cell junctions were seen, and N-cadherin was clustered between opposing cells (Figure 4.2). 
Upon reducing Ca2+ from 1 mM (high Ca2+, Figure 4.2A, C and E) to 0.03 mM (low Ca2+, 
(Figure 4.2B, D and F) for 4 hours, the junctions disassembled and N-cadherin was no 
longer visible at regions o f contact. Schwann cells in low Ca2+ appeared to have dispersed 
N-cadherin on the cell surface and the cells lost their highly polar alignment, becoming 
disorganised in appearance.
Immunocytochemistry against E-cadherin and P-cadherin demonstrated that all three glial 
cell types did not express either of these cadherin family members, indicating that these 
cadherins could not provide similar functions with regard to contact formation between glial 
cell-types (Figure 4.1).
Since N-cadherin junctions between both Schwann cells and OECs, were not typical in 
morphology of classic cadherin junctions, being only visible on small localised areas of cell 
surface where contact was visible (Figure 4.1; see also Figure 3.3), immunocytochemistry 
was performed on cells which had been plated down on PLL for only 1 hour. The reason 
for this was that these cells retained a morphology which was very similar to epithelial and 
Madin-Darby Canine Kidney (MDCK) cells, in whom cadherin function (E-cadherin) has 
been well characterised (Price et al., 2004; Boucher et al., 2005). At this time point, 
Schwann cells and OECs were still very rounded and had just begun to adhere to the 
substrate, thus resembling epithelial cells. N-cadherin immunolabelling of these cells 
showed cell-cell junctions (Figure 4.3; arrows) which were shorter and rounder, and 
therefore resembled classic epithelial E-cadherin junctions, indicating that they may be 
similarly functional.
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Figure 4.2. Astrocytes, OECs and Schwann cells form C a2+ dependent N- 
cadherin junctions.
Astrocytes (A, B), OECs (C, D) and Schwann cell (E, F) in the presence o f high 
(1 mM; A, C, E) and low (0.03 mM; B, D, F) Ca2+ were immunolabelled for N- 
cadherin. In high Ca2+, these junctions were clearly formed (arrows), but upon 
reducing the level of Ca2+ the junctions began to breakdown, with an apparent 
loss o f Schwann cell alignment. Scale bar = 100 pm.
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Figure 4.3. OECs and Schwann cells can form cadherin junctions with typical 
morphologies.
N-cadherin junctions in OECs (A, B) and Schwann cells (C, D) were analysed by 
immunolabelling 1 hour after initial plating on laminin (A, C) and fibronectin (B, 
D). At this time point, when they had just started to sit down their adherens 
junctions had morphologies typical o f the classical E-cadherin junctions of 
epithelial cells. Scale bar = 50 pm.
4.2.2 N-cadherin turnover is similar in OECs and Schwann cells
Since the N-cadherin present on Schwann cells and OECs was indistinguishable in terms of 
its localisation and Ca2+ dependency, a potential difference could be its turnover within the 
cell. In order to measure the lifetime of N-cadherin from protein synthesis until it was 
degraded, emetine, a protein synthesis inhibitor, was added to Schwann cell and OEC 
cultures, and lysates made at regular time intervals. As for the calpain inhibitor, the optimal 
working concentration was chosen following titration and cell viability assessment (see 
Section 3.2.6). Based on this, a working concentration of 10 pM was selected. Emetine 
treatment allowed the persistence of N-cadherin following a block in its production to be 
measured and compared. For both Schwann cells and OECs, N-cadherin persisted in cells 
for almost 24 hours following protein synthesis inhibition, before levels began to decrease 
(Figure 4.4). This was in contrast to the lifetime of actin, which had started to decrease in 
Schwann cells and OECs at 4 hours, and was almost completely degraded by 8  hours. This 
data suggests N-cadherin turnover occurs at a similar rate in both Schwann cells and OECs.
4.2.3 N-cadherin is localised to heterotypic junctions
To determine if N-cadherin is involved in the interaction of Schwann cells or OECs with 
astrocytes, the localisation of N-cadherin was examined injunctions between the different 
glial cell types. Using immunocytochemistry, where all cells are identified by nuclear DAPI 
staining and astrocytes were identified by their intense fibrous glial fibrillary acidid protein 
(GFAP) immunoreactivity, the localisation of N-cadherin was examined (Figure 4.5). N- 
cadherin-associated junctions were visible between cells of the same type (homo-typic 
junctions, Figure 4.5A, B and C, broken arrows), and between different cell types (hetero­
typic junctions, Figure 4.5D and 4.5E, unbroken arrows). These data suggest that both 
Schwann cells and OECs are capable of forming cadherin-associated inter-cellular contacts 
at their interface with astrocytes.
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Figure 4.4. N-cadherin protein turnover is equivalent in both OECs and 
Schwann cells.
Western blot of N-cadherin and actin protein levels at 0, 2, 4, 8 , and 24 hour time 
intervals following emetine (protein synthesis inhibitor) treatment.
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Figure 4.5. Both OECs and Schwann cells can form hetero-typic N-cadherin junctions 
to astrocytes, as well as homo-typic junctions.
OECs and Schwann cells were co-cultured for several days with astrocytes and then 
immunolabelled for GFAP (TRITC) denoting astrocytes, and N-cadherin (FITC). Nuclei 
were visualised with DAPI (blue). Distinct junctions were visualised between cells of the 
same type (OECs, A; astrocytes, B; Schwann cells, C; broken arrows), and also between 
different types (astrocyte:OEC, D; astrocyte:Schwann cell, E; unbroken arrows). Scale bar 
= 50 pm.
4.2.4 Cyclic peptide inhibition of N-cadherin
4.2.4.1 A cyclic peptide inhibitor of N-cadherin reduced Schwann cell, but not 
OEC adhesion
In order to assess the function of N-cadherin in Schwann cell and OEC interactions with 
astrocytes, a cyclic peptide inhibitor of N-cadherin was initially used. This contains the 
common cadherin cell adhesion recognition sequence motif, His-Ala-Val (HAV; Williams et 
al., 1999). An adhesion assay was performed where Vybrant-labelled OECs and Schwann 
cells were incubated on confluent glial monolayers, and cells that adhered were counted, in 
the presence and absence of the peptide inhibitor. Addition o f the inhibitor reduced 
Schwann cell adhesion to both astrocytes (1222 +/- 145 to 864 +/- 56, p>0.04; Figure 
4.6A) and to a confluent monolayer of Schwann cells (881.5 +/- 73 to 445 +/- 22, p>0.05). 
This effect, though modest, was statistically significant. However, the peptide had no 
significant effect on OEC adhesion to either astrocytes or to confluent monolayers of 
OECs. As was seen in the previous chapter (Figure 3.7), Schwann cells had stronger 
adhesions than OECs to both themselves and astrocytes (homo- and hetero-typic), and 
both Schwann cells and OECs adhered more strongly to astrocytes (hetero-typic) than 
themselves (homo-typic). These data imply that N-cadherin mediates the adhesion of 
Schwann cells, but not OECs, to themselves and to astrocytes.
4.2.4.2 A cyclic peptide inhibitor did not affect boundary formation
The role N-cadherin played in the development of boundaries was assessed using the 
confrontation assay (see Section 3.2.1), in which parallel strips of either OECs or Schwann 
cells were plated facing astrocytes. These were allowed to proliferate and migrate towards 
each other, both with and without the N-cadherin peptide inhibitor, and their resulting 
interactions visualised. The peptide inhibitor was added to the cultures at 2 day intervals 
over the 10 day period of the assay. The addition o f the peptide inhibitor had no effect on 
either Schwann cell or OEC interactions with astrocytes (Figure 4.6C and 4.6E).
The difference in peptide inhibition seen between the adhesion assay and the confrontation 
assay may reflect the peptide’s mode of action and also differences in the time course or
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Figure 4.6. Cyclic peptide inhibitor of N-cadherin reduces Schwann cell adhesion to 
astrocytes, but did not affect boundary formation.
(A) An adhesion assay was performed using Vybrant labelled cells to aid detection, and 
were left to adhere to confluent monolayers of either astrocytes or OECs/Schwann cells for 
30 minutes. Schwann cell adhesion was reduced to both astrocytes (*p<0.05) and Schwann 
cells (**p<0.02), n=6 . OEC adhesion was unaffected by the presence of the peptide 
inhibitor. (B) Confrontation assays, where a strip of either OECs (i, ii) or Schwann cells (iii, 
iv) were allowed to grow towards a strip of astrocytes and the resulting interactions analysed 
by immunocytochemistry. The peptide inhibitor was added (ii, iv) at a concentration of 10 
pg/ml and supplemented every two days over the duration of the assay. After addition of the 
peptide, a boundary still formed between Schwann cells and astrocytes, whereas OECs 
migrated amongst the astrocyte domain. Astrocytes are immunolabelled for GFAP (TRITC), 
and Schwann cells and OECs for p75NTR (FITC). Scale bar = 100 pm.
duration of the assays. The adhesion assay is a short term assay lasting only 30 minutes, 
whereas the confrontation assay takes longer, occurring over several days. Although the 
peptide can reversibly inhibit dynamic N-cadherin junctions during their formation, as 
measured in the adhesion assay, it might not be able to actively disrupt stable junctions 
after they have formed. Thus over the time scale of the confrontation assay, these more 
stable adhesions might still accumulate. For this reason, a more precise method of N- 
cadherin inhibition by preventing protein synthesis using RNAi technology was used.
4.2.5 RNA interference
4.2.5.1 RNAi reduced N-cadherin expression in Schwann cells and OECs
To clearly define the role of N-cadherin in these cellular interactions, the expression of N- 
cadherin in Schwann cells and OECs was reduced using linear, double-stranded small 
inhibitory RNA (siRNA). siRNA transfection leads to the degradation of RNA with 
complementary coding sequences. In this way, sequence-specific gene silencing can be 
performed (Elbashir et al., 2001a, 2001b). Introduction of siRNA against N-cadherin (Ncad 
siRNA) and a scrambled sequence (scramble siRNA) was carried out using two different 
protocols (FuGENE and Oligofectamine) to test efficiency. Forty-eight hours after 
transfection with siRNA, protein lysates were made and immunoblotting performed to 
assess the reduction in steady-state levels of N-cadherin. For both transfection protocols, 
N-cadherin was reduced by Ncad siRNA, but was unaffected by scramble siRNA (Figure 
4.7A). However, a complete reduction in N-cadherin protein levels was not always 
achieved, presumably reflecting the variable transfection efficiency.
Immunocytochemistry was performed to visualise N-cadherin expression after siRNA 
transfection (Figure. 4.7B). Due to the nature o f Schwann cell and OEC junctions, which 
are only visible on small, localised areas of cell-cell contact (Figure 3.3), it was difficult to 
quantitatively judge the absence of junctions, although disruption was clearly seen (Figure 
4.7Biv and v). However, in astrocytes, Ncad siRNA-induced disruption of N-cadherin 
junctions in large areas of the culture was clearly visible (Figure 4.7Bvi). This is because 
astrocytes have a larger contact area with which N-cadherin junctions can form with other 
astrocytes (Figure 3.3). Junctions were not absent on all astrocytes, reflecting the
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Figure 4.7. Ncad siRNA reduces N-cadherin expression in glial cells.
(A) Western blot demonstrates a reduction in N-cadherin expression following 
transfection with N-cadherin specific siRNA (Ncad siRNA) using both 
oligofectamine (lane 1), and FuGENE (lane 2). Control (untreated) cells and cells 
transfected with scrambled siRNA expressed similar levels of N-cadherin. (B) 
Immunocytochemistry for N-cadherin on Ncad siRNA-treated Schwann cells (iv), 
OECs (v) and astrocytes (vi) illustrated the reduction of N-cadherin on the cell surface 
in a proportion of cells, compared to untreated Schwann cells (i), OECs (ii) and 
astrocytes (iii). Cells were co-labelled with DAPI (Schwann cells and OECs) and 
GFAP (astrocytes). Scale bar=  100 pm.
transfection efficiency of the siRNA and the immunoblotting results. However, it was not 
independently confirmed which cells were transfected. One method to achieve this would 
be to transfect cells with vector-based siRNA. Thus, a vector encoding both siRNA and a 
reporter gene such as GFP, could simultaneously reduce protein expression and give 
information as to which cells were successfully transfected (Yoon et al., 2004, Kojima et 
al., 2004).
4.2.5.2 Effect of Ncad siRNA treatment on Schwann cell and OEC proliferation 
and migration
To assess if Ncad siRNA had any adverse biological effects on Schwann cells and OECs 
which could influence boundary formation and adhesion, their proliferation capacity was 
assessed using bromodeoxyuridine (BrdU) uptake. There was no significant change in the 
BrdU uptake o f either OECs or Schwann cells after siRNA treatment (Figure 4.8). This 
data demonstrated that changes in cell proliferation could not explain any observed 
differences in cellular migration.As was noted in Chapter 3, Schwann migration was 
impeded upon astrocyte monolayers, when compared to migration upon PLL, whereas 
OEC migration was equivalent on both substrates (Figure 3.4). To investigate whether N- 
cadherin mediates these differences, OECs and Schwann cells were treated with Ncad 
siRNA and migration speeds on PLL and astrocyte monolayers were calculated. (Figure 
4.9A and B). siRNA treatment had no significant effect on either OEC or Schwann cell 
migration upon PLL (OEC = 18.16 +/- 2.81 pm/hour, OEC siRNA = 19.23 +/- 2.52 
pm/hour, SC = 19.56 +/- 3.08 pm/hour, SC siRNA = 20.78 +/- 7.86 pm/hour). However, 
differences were seen in migration speeds of cells plated on astrocyte monolayers. As 
shown in Figure 3.4, untreated Schwann cell migration was slower on astrocytes, when 
compared to untreated OECs migration on astrocytes (Figure 4.9B). Treatment with 
siRNA did not have a significant effect on OEC migration speeds (OEC = 21.6 +/- 2.17 
pm/hour, OEC siRNA = 19.44 +/- 1.49 pm/hour), but there was an increase in Schwann 
cell migration on astrocyte monolayers (SC = 11.47 +/- 0.87 pm/hour, SC siRNA = 18.56 
+/-1.42 pm/hour). This difference may have been greater were it not for the case that not 
all cells take up siRNA after transfection, as seen in Figure 4.7. Therefore the average may 
under-represent the effect of Ncad siRNA. This is demonstrated in Figure 4.9B where the 
migration speeds of individual cells are plotted, showing a greater spread of migration speed
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Figure 4.8. Ncad siRNA treatm ent does not affect OEC and Schwann cell 
proliferation.
BrdU incorporation into OECs and Schwann cells cultured in FCS, with and 
without Ncad siRNA treatment, was assessed using indirect immunoflourescence. 
siRNA treatment had no significant effect on proliferation as assessed by BrdU. 
n=6.
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Figure 4.9. Ncad siRNA treatment increases Schwann cell migration upon astrocyte 
monolayers.
Migration on PLL (A) and on astrocyte (AS) monolayers (B) were measured by time-lapse 
microscopy, both with and without Ncad siRNA treatment. The individual migration speeds 
were plotted, along with the median for each set. Following siRNA treatment, there was no 
change in the observed migration speeds of either OECs or Schwann cells on poly-l-lysine. 
OEC migration upon an astrocyte monolayer was unaffected by siRNA treatment, but for 
Schwann cells, a proportion of the population o f treated cells were able to migrate much faster 
(*p<0.01). This proportion reflects the transfection efficiency seen in Fig. 4.7.
J - possible population clustering
compared to the untreated set. This spread appears to reflect the transfection efficiency 
with siRNA (Figure 4.7) where a proportion of successfully transfected cells may be 
exhibiting the more migratory phenotype. This, however, could not be confirmed due to the 
lack of direct detection of which cells had successfully incorporated siRNA. However, even 
when the 2  populations are averaged, the difference in mean migration speeds between the 
untreated and the siRNA-transfected sets is significant, p<0.01. Thus, N-cadherin may 
mediate the slower migration speeds of Schwann cell on astrocytes, compared to OECs or 
to their migration on PLL.
4.2.5.3 Ncad siRNA treated Schwann cells, but not OECs, have reduced 
adhesion
To assess if N-cadherin mediates heterotypic adhesion (to astrocytes) and homotypic 
adhesion (to themselves) using an adhesion assay (Figure 4.10), Schwann cells and OECs 
were transfected with Ncad siRNA. Untreated cells and cells transfected with a scrambled 
siRNA sequence were used as controls, and yielded similar results to each other. OECs 
treated with Ncad siRNA adhered to astrocytes and OECs to a similar extent as controls. 
Thus, reducing expression of N-cadherin in OECs did not alter either hetero-typic or homo­
typic adhesion. In contrast, adhesion of Schwann cells to both monolayers of astrocytes (4 
fold decrease, p<0.001) and Schwann cells (5.5 fold decrease, p<0.002) was significantly 
reduced by N-cadherin siRNA treatment. These data indicate that Schwann cells but not 
OECs were dependent upon N-cadherin for homotypic and heterotypic cell-cell adhesion, 
in agreement with the N-cadherin peptide inhibitor results (Figure 4.6A). These data 
support N-cadherin mediation of cellular adhesion for Schwann cells, but not OECs, 
despite the latter expressing similar levels of N-cadherin, and suggest that the function of 
N-cadherin is different between the two cell types.
4.2.5.4 Ncad siRNA treated Schwann cells no longer form boundaries when in 
contact with astrocytes
To determine if N-cadherin plays a role in the formation of a cellular boundary between 
astrocytes and Schwann cells or OECs in confrontation assays, Ncad siRNA was used to 
transfect OECs and Schwann cells, and the subsequent boundary formation assessed.
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Figure 4.10. siRNA treatm ent reduces Schwann cell, but not OEC, adhesion.
An adhesion assay was performed using untreated, scramble RNAi-transfected and N- 
cadherin RNAi-transfected OECs and Schwann cells. These cells were Vybrant labelled 
to aid detection and left to adhere to a confluent monolayer of either astrocytes or 
OECs/Schwann cells. N-cadherin siRNA reduced Schwann cell adhesion to both 
astrocytes (*p<0.001) and Schwann cells (**p<0.002), whereas adhesion of OEC to both 
astrocytes or OECs was unaffected. n=6.
Confrontation assays were also performed using untreated and scramble siRNA-treated 
Schwann cells and OECs as controls (Figure 4.11 A). Treatment with scramble siRNA did 
not affect the intrinsic properties of the glial cells, where Schwann cells, but not OECs, still 
formed boundaries against astrocytes. In contrast, Schwann cells treated with Ncad siRNA 
no longer formed these boundaries (Figure 4.11Aix and x), and instead intermingled with 
astrocytes in a similar manner to OECs. This was quantified by counting the number of 
Schwann cells crossing the astrocyte-Schwann cell boundary into the astrocyte domain 
(Figure 4.1 IB). For Schwann cell/astrocyte cultures there was an increase in the number of 
cells after Ncad siRNA treatment (22 +/- 1.75; p<0.01), compared to control levels 
(untreated = 4.33 +/- 0.76 cells, scramble siRNA treated = 5.33 +/- 0.76 per 300 jam 
boundary). Ncad siRNA-treated OECs, behaved as untreated OECs, migrating amongst 
astrocytes. These data demonstrate a role for N-cadherin in the formation of a cellular 
boundary between Schwann cell and astrocytes.
4.2.5.5 Ncad siRNA treatment of Schwann cells or OECs does not alter their 
hypertrophy-inducing properties, as measured by astrocyte area
Initial studies using co-cultures demonstrated that astrocyte area increases on contact with 
Schwann cells (Ghimiker and Eng, 1994; Lakatos et al., 2000). To assess if N-cadherin 
mediated this measurement of hypertrophy, the average area of astrocytes in contact with 
Schwann cells treated with siRNA (Figure 4.12) was calculated using NIH Image. The area 
of astrocytes in contact with Schwann cells, whether untreated or siRNA-treated, was 
increased two-fold, compared to astrocytes cultured in monolayers. This suggested that the 
treatment of Schwann cells with Ncad siRNA did not influence hypertrophy in these 
cultures as measured by astrocyte area, implying that regulation of these two glial 
properties may not be linked.
4.2.6 Downstream signalling from N-cadherin is unchanged 
between Schwann cells and OECs
Since N-cadherin functionality appears to be different between Schwann cells and OECs, as 
demonstrated by their different dependency upon N-cadherin for normal adhesion and 
migration (Figures 4.9 and 4.10), the next step was to investigate the regulation of N-
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Figure 4.11. N-cadherin is required for Schwann cell/astrocyte boundary formation.
(A) Confrontation assays were performed with untreated (i to iv), scramble siRNA-treated 
(v to viii) and N-cadherin siRNA-treated (ix to xii) Schwann cells (i, ii, v, vi, ix, x) and 
OECs (iii, iv, vii, viii, xi,xii). Phase and confocal images (OECs and Schwann cells, 
p75NTR-FITC; astrocytes, GFAP-TRITC) are of different fields of view. Schwann cells 
formed distinct boundaries against astrocytes in both untreated and scramble siRNA- 
treated cells (open arrows). However, N-cadherin siRNA-treated Schwann cells no longer 
formed boundaries but were able to intermingle with astrocytes, in a manner similar to 
OECs. OECs intermingled with astrocytes, whether untreated, scramble siRNA-treated, or 
N-cadherin siRNA-treated. Migrating cells indicated with solid arrows. Scale bar = 100 
pm. (B) Quantification of the confrontation assays. The number of cells that crossed the 
boundary was significantly higher in Schwann cell/astrocyte confrontation assays when the 
Schwann cells were treated with the siRNA to N-cadherin (*p<0.01) but not scramble 
siRNA. n=6 .
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Figure 4.12. Ncad siRNA treatm ent does not affect astrocytic hypertrophy.
Astrocyte area was measured using NIH Image from astrocytes cultured alone 
(control), or co-cultured for 7 days with either OECs, OECs treated with N-cadherin 
siRNA, Schwann cells (SC), or Schwann cells treated with N-cadherin siRNA. 
Astrocyte area is increased a small amount upon co-culturing with OECs but is 
increased significantly when co-cultured with Schwann cells (two-fold increase; * 
p<0.05, ** p<0.001 compared to control). Treatment of cells with N-cadherin 
siRNA had no effect on this assessment of astrocyte hypertrophy (n=30).
cadherin by downstream regulators, with particular emphasis on members of the catenin 
family, p-catenin and p l2 0 ctn. The catenins are immediate downstream regulators which 
connect N-cadherin to the actin cytoskeleton, and are therefore are suited to regulating N- 
cadherin-dependent migration and adhesion (see Introduction 1.6.2.3).
To assess if these downsteam candidate effectors were interacting with N-cadherin 
differently, immunoprecipitations were performed to measure the relative amounts of 
catenin bound to N-cadherin in Schwann cells and OECs, both when in mono-cultures and 
after co-culturing with astrocytes (Figure 4.13A). Co-cultured OECs and Schwann cells 
were removed from astrocyte monolayers with low levels of trypsin before making lysates 
to avoid astrocyte contamination. No visible difference in p-catenin or p l2 0 ctn co­
precipitation with N-cadherin in Schwann cells and OECs was found, whether in cultures 
alone, or with astrocytes (Figure 4.13 A). This, therefore, indicates no difference in catenin 
association with N-cadherin in either cell type. We also looked at the phosphorylation 
status of P-catenin in both mono- and co-cultures. Again, p-catenin was similarly 
phosphorylated in both Schwann cell and OEC cultures (Figure 4.13B). This reflects the 
lack of difference seen for catenin association, since phosphorylation is a mechanism for 
regulating cadherin-catenin interactions. Thus, at the immediate downstream level o f N- 
cadherin regulation, there were no obvious differences which would readily explain the 
differences in N-cadherin functionality observed in earlier experiments.
4.2.7 Identification of N-cadherin interacting proteins
Since there was no apparent difference in catenin regulation of N-cadherin, a more general 
approach was taken to identify any possible candidates which may be differentially 
interacting with or regulating N-cadherin function. This was carried out by 
immunoprecipitating Schwann cell and OEC lysates with an anti-N-cadherin antibody, and 
staining all the co-precipitated proteins, after electrophoresis, with Brilliant Blue G- 
Colloidal (Figure 4.14A). N-cadherin is denoted with an asterisk. One major protein 
difference was apparent, marked with an arrow. In OEC cultures, both in mono- and co­
culture with astrocytes, a protein with an approximate molecular weight of 54kDa was 
present. The band was excised from the gel and underwent Mass Spectrometry, identifying 
it as vimentin. Western blot analysis showed that vimentin was indeed present in OEC IPs
Mono-cultures Co-cultures
N-cadherin IP 
 A_ Total Protein  a_____
B
Uco
Uw
O
S' ,55
 _
h h m » -  •
u
co
UUJO
N-cadherin IP
A .
co
<
U
CO
A
CO
<
U
CO
CO
<
UwO
Total Protein
C/5
<
U
CO
CO
<
UwO
-••x#
P-catenin
p 12 0 ctl
Total protein 
WB: anti- p-catenin
P-catenin IP
WB: anti-phospho-tyrosine
Figure 4.13. Catenin signalling is unchanged in OECs and Schwann cells following 
contact with astrocytes.
(A) Immunoprecipitation and Western blotting were performed to show p-catenin and 
p l20ctn levels (Total Protein) and their co-precipitation with N-cadherin (N-cadherin IP). 
This was carried out using Schwann cell (SC) and OEC lysates, as well as lysates made 
from cells which had been allowed to adhere to astrocytes for 30 minutes before trypsin 
treatment and generation of lysates (SC:AS and OEC: AS). (B) Phosphorylation of p- 
catenin was unchanged following adhesion to astrocytes.
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Figure 4.14. Vimentin is non-specifically ‘pulled down’ in OEC 
immunoprecipitations.
(A) N-cadherin IPs were stained with Brilliant Blue G-colloidal, of OEC and Schwann 
cell lysates, and also OEC:AS and SC:AS lysates. A control was performed with no 
anti-N-cadherin antibody, which pulled down the band (indicated by arrows) non- 
specifically in OEC lysate. Mass spectrometry of the band identified the protein as 
vimentin. N-cadherin protein is denoted by *. (B) Immuno blot of IP confirming 
vimentin being pulled down in OEC, but not Schwann cell lysates. (C) Immuno blot 
showing vimentin is pulled down non-specifically in OEC lysates.
and not in Schwann cell IPs, despite being present equally in the total lysate before 
immunoprecipitation (Figure 4.14B). However, both Western blotting (Figure 4.14C) and 
whole gel stain (Figure 4.14A) of OEC lysates without N-cadherin antibody showed that 
vimentin was being non-specifically pulled down in these IPs and did not reflect a 
preferential association with N-cadherin in OECs rather than Schwann cells. However, 
vimentin is present in both Schwann cell and OEC lysates, so why it should be ‘stickier’ in 
OECs than Schwann cells remains a question. No other candidates for differential N- 
cadherin interactions, and thus regulation, were apparent at this level of investigation.
4.3 Discussion
This study illustrates that OECs and Schwann cells both express functional N-cadherin, as 
demonstrated by its presence at cell-cell junctions and Ca2+ dependency, yet N-cadherin is 
apparently functioning differently in the two glial cells. For example, Schwann cells 
adhered more strongly to an astrocyte monolayer and migrated more slowly on astrocyte 
but not PLL substrates when compared to OECs. Using siRNA to reduce N-cadherin 
expression, the inhibition of Schwann cell migration on astrocytes was removed and their 
adhesion to astrocytes was reduced. On the other hand, Ncad siRNA transfection into 
OECs had little effect on their migration and adhesion when cultured with astrocytes. 
Taking the migration and the adhesion data together, these results show that the OECs and 
Schwann cells differ in how they use N-cadherin for adhesion and migration, highlighting a 
further distinction between the two cell types (Ramon-Cueto and Avila, 1998; Wewetzer 
et al., 2002; Barnett and Riddell, 2004).
4.3.1 Inhibition of N-cadherin
In previous studies, a role for N-cadherin was proposed for Schwann cell migration and 
adhesion based on competitive inhibition by the classical cadherin cell adhesion recognition 
sequence His-Ala-Val (HAV; Wilby et al., 1999), but no direct evidence was available for a 
role for N-cadherin in OEC migration (Lakatos et al, 2000). In this study the cyclic peptide 
was initially used, which is probably less resistant to degradation than the linear peptide 
(Williams et al., 2000), to demonstrate differences in the adhesive characteristics of OECs 
and Schwann cells. However, as there is no way of confirming its mechanism of action, and
due to its limited effect on the confrontation assay which may arise from different N- 
cadherin junction dynamics in short term (adhesion) and long term (confrontation) assays, 
it was decided to use the more precise method of N-cadherin inhibition by preventing 
protein synthesis with siRNA.
In this way, N-cadherin expression was successfully reduced in both Schwann cells and 
OECs. This resulted in the ability of Schwann cells to overcome the astrocyte-induced 
inhibition, as measured by adhesion, migration and confrontation assays, while not 
affecting OEC behaviour. As has been discussed earlier (Section 3.2.4), adhesion and 
migration are related processes, and therefore the slow migration of Schwann cells upon 
astrocyte monolayers may result from their strong adhesion to astrocytes. Likewise, the N- 
cadherin dependency of Schwann cell migration upon astrocytes may result from the N- 
cadherin-dependent adhesion of Schwann cells to astrocytes.
4.3 N-cadherin and hypertrophy
Reducing N-cadherin expression with Ncad siRNA also allowed the perturbation of the 
boundary formed in confrontation assays between Schwann cells and astrocytes. A 
predominant feature of the inhibitory astrocyte domain is the presence of greatly enlarged 
astrocytes (Eddleston and Mucke, 1993; Ghimikar and Eng, 1994; Lakatos et al., 2000). 
These hypertrophic astrocytes are seen only in Schwann cell/astrocyte cultures, where 
Schwann cell migration is impeded, and not in OEC/astrocyte cultures. This leads to the 
speculation that the inhibition o f Schwann cell migration amongst astrocytes could be 
determined by either the increase in astrocyte size, which would act as a physical barrier, 
changes in Schwann cell proliferation or by the strength of adhesion mediated by N- 
cadherin upon cellular contact. The reduction of N-cadherin by siRNA allowed more 
Schwann cells to successfully overcome this contact-induced inhibition, and penetrate the 
astrocyte domains but did not affect proliferation as assessed by BrdU uptake. Therefore, 
using Ncad siRNA, it was assessed if removal of N-cadherin reduced the increase in 
astrocyte area. These studies demonstrated that Ncad siRNA treatment of Schwann cells 
and OECs did not affect astrocyte area, and thus N-cadherin was not required for the 
induction of hypertrophy. Although a caveat for this result may be that a proportion of 
Schwann cells still express N-cadherin, due to incomplete transfection (Figure 4.7), and
thus may be able to induce astrocytic hypertrophy. However, the strong correlation of N- 
cadherin reduction and disruption of astrocyte/Schwann cell boundary formation suggests 
that strong Schwann cell adhesion to astrocytes is more likely to prevent their migration 
amongst astrocytes and not astrocytic hypertrophy.
4.3.4 Possible N-cadherin mechanisms
The question remains why do OECs express N-cadherin if it is not used in their adhesion 
to astrocytes? It may be that OECs require N-cadherin for interactions with other cell 
types. For example, N-cadherin is necessary for the adherence and alignment of Schwann 
cells to axons (Wanner and Wood, 2002) and is necessary for the initiation of myelination 
as has been demonstrated for oligodendrocytes (Schnadelbach et al., 2001).
Furthermore, simple adhesion models cannot readily explain the diverse functions of 
cadherins, and some cadherin functions might be better explained by their ability to activate 
signal transduction cascades rather than adhesion per se (Skaper et al., 2004). For example, 
N-cadherin is able to activate a fibroblast growth factor receptor (FGFR) signalling cascade 
(Williams et al., 1994) and an interaction between N-cadherin and the FGFR has been 
implicated in both developmental and pathological processes. In addition, neurite 
outgrowth stimulated by N-cadherin is inhibited by a wide variety of agents that inhibit 
FGFR function in neurons (Williams et al., 1994), including expression of a dominant- 
negative FGFR (Utton et al., 2001; Williams et al., 2002). More recently, N-cadherin has 
been reported to promote the motility of cancer cells, with evidence that FGFR might be 
involved (Nieman, et al., 1999; Hazan et al., 2000).
In the immunoprecipitation experiments presented in this study, no differences between N- 
cadherin interacting proteins were seen in Schwann cells and OECs (Figure 4.14A). 
However, the sensitivity o f this approach may be questionable. This is highlighted by the 
only faint detection of the well characterised N-cadherin-interacting protein, p-catenin 
(Figure 4.14), which we know was successfully co-precipitated with N-cadherin due to its 
clear detection using immunoblotting (Figure 4.13). Therefore a more sensitive approach, 
such as silver staining or using more protein, might be more suitable.
N-cadherin may have different functions depending upon how it is presented, for example 
it may function differently when expressed in different cell types. This is demonstrated 
where Schwann cells presented with N-cadherin on a neurite do not have impaired 
migration, in contrast to when they are presented with N-cadherin on an astrocyte (Bixby 
et al., 1988; Wilby et al., 1999). This demonstrates that N-cadherin alone might not 
determine the migratory outcome, but rather that it is in conjunction with other signals or 
N-cadherin-interacting molecules that the decision to form either stable or dynamic 
junctions is made. For example, the association of N-cadherin with the catenins mediates 
their adhesive functions, whereas interaction with FGFR can promote migration (see 
Introduction 1.6.2.3). It would therefore be important to investigate both upstream and 
downsteam signals from N-cadherin to see how they compare between the two cell types. 
An initial investigation of downstream catenin signalling pathways from N-cadherin did not 
highlight any differences which readily explain the different N-cadherin functions observed 
between OECs and Schwann cells. It still remains to be investigated how upstream signals 
influence N-cadherin function in these assays. Since N-cadherin presentation or 
accompanying signals might vary between cellular targets, such as between neurites and 
astrocytes, differences may also arise depending upon the reactive status of the astrocyte. 
In other words, the astrocytic N-cadherin encountered by an OEC might actually be 
biochemically different in some way from the astrocytic N-cadherin encountered by a 
Schwann cell, due to the varying effects of Schwann cells and OECs on astrocytosis (Figure 
4.12; Lakatos et al., 2000). Many potential N-cadherin-interacting candidates exist, and 
some are induced in reactive astrocytes, such as neurocan, (McKeon et al., 1999; Asher et 
al., 2000), which interacts with N-cadherin via its receptor, GalNAcPTase (Li et al., 2000).
4.3.5 Vimentin
One potential N-cadherin interacting protein identified in this study, which was present in 
OEC cultures but not in Schwann cell cultures, was vimentin. Under normal conditions, 
vimentin expression is associated with the developing CNS (Bignami et al., 1982), whereby 
astrocytes switch from a vimentin-based cytoskeleton to a GFAP-orientated one upon 
maturation. This process occurs alongside the transformation of astrocytes as a permissive 
environment to one that restricts axonal growth (Smith et al., 1990). In the OEC, however, 
vimentin remains as a major intermediate filament constituent in the adult (Franceschini and
Barnett, 1996; Ramon-Cueto and Avila, 1998), providing evidence that OECs retain an 
‘immature’ phenotype, and may confer the cell’s axonal growth-promoting properties. 
Schwann cells have also been reported to express vimentin (Jessen and Mirsky, 1983), as 
was confirmed here by both immunoblotting and immunocytochemistry. Vimentin has also 
been associated with motile cells, particularly due to its upregulation in the epidermal- 
mesenchymal transition associated with the metastatic progression of tumourous skin cells 
(Kirschmann et al., 1999; Avizienyte et al., 2004). This might explain a role for vimentin in 
the motile, or even ‘invasive’ OECs. However, due to the lack o f specificity in vimentin 
precipitation, this may not be a significant observation. Why it should be pulled down in 
OECs but not Schwann cells is still unexplainable, but may involve different vimentin 
interactions with the cell.
4.3.6 Conclusions
In summary, in this chapter it has been demonstrated that silencing N-cadherin using 
siRNA had distinct biological effects on the interactions of OECs and Schwann cells with 
astrocytes. This suggests that N-cadherin functions differently in these cells and may have 
dual functionality, promoting either adhesion or migration. In this way, N-cadherin may be 
a potential target for pharmacological intervention in order to make Schwann cells behave 
more like OECs upon transplantation. However, due to the role of N-cadherin in mediating 
Schwann cell adhesion to neurons, it would not be advantageous to prevent Schwann cells 
from actually binding to their therapeutic targets. An understanding of N-cadherin 
regulatory pathways in Schwann cells, particularly upon astrocyte-interaction, might 
highlight appropriate specific targets for modulation which would not disrupt the essential 
functions of N-cadherin necessary for axonal regeneration or myelination.
CHAPTER 5
Effect of Schwann cell-conditioned media on 
astrocytes, and olfactory ensheathing 
cell/astrocyte interactions
5.1 Introduction
In the previous chapters it has been established that the inhibition of Schwann cell 
migration within astrocytic areas can in part result from the ability of Schwann cells to 
form strong cellular adhesions. This has been demonstrated by comparison of Schwann cell 
and olfactory ensheathing cell (OEC) adhesion and migration when interacting with 
astrocytes, and also from a detailed investigation of the role of N-cadherin in these 
processes. In addition, it has been hypothesised that Schwann cell migration may also be 
impeded by the inhibitory astrocytic environment, as indicated by the presence of enlarged 
hypertrophic astrocytes, which may occur as a result o f Schwann cell interactions with 
astrocytes.
However, the influence of hypertrophic astrocytes upon cellular migration has not been 
thoroughly investigated. It has been previously established in the published literature that 
both Schwann cells and OECs elicit an astrocytic response in vivo (Plant et al., 2001; 
Takami et al., 2002; Lakatos et al., 2003a) as indicated by an increase in the expression of 
both glial fibrillary acidic protein (GFAP) and the chondoitin sulphate proteoglycans (CS- 
PGs). However, the astrocytic response to OECs appears to be much less than that to 
Schwann cells (Verdu et al., 2001; Takami et al., 2002; Lakatos et al., 2003a). This may 
correlate with the enhanced inherent ability of OECs to migrate within the astrocyte 
environment o f the CNS compared to Schwann cells (Guidino-Cabrera and Nieto- 
Sampedro, 1996, Iwashita et al., 2000). In vitro studies have also confirmed these in vivo 
results where astrocytes co-cultured with Schwann cells became enlarged and hypertrophic 
(Ghimiker and Eng, 1994; Lakatos et al., 2000), but again the astrocytic response to co- 
cultured OECs was much less (see Chapter 4, Figure 4.12)
However, it remains to be determined what the specific role this astrocytic response plays 
in determining the different migration patterns seen between OECs and Schwann cells upon 
interacting with astrocytes, particularly following transplantation. In addition, a rather 
limited understanding of what factors might be inducing this hypertrophy exists at present. 
If it is possible to increase our knowledge of these processes, it might enable us to advance 
transplantation therapies. Generally, this might allow us to reduce the glial scarring that 
results following spinal cord injury, but more specifically, we may be able to enhance the
ability of transplanted cells to reach appropriate targets of repair, while keeping the host 
response to these cells to a minimum.
In this chapter, the approach will be taken to examine the effect of factors secreted by 
OECs and Schwann cells on astrocytes, in order to determine some of the signals involved 
in the induction o f astrocytosis. In addition, the role that the resulting astrocytic reactivity 
plays in determining Schwann cell and OEC abilities to migrate within astrocytic areas will 
be addressed.
5.2 Results
5.2.1 Schwann cell-conditioned media (SCM) induces boundary 
formation in OEC/astrocyte confrontation cultures
Since downstream N-cadherin signalling was unchanged between OEC and Schwann cells 
(Chapter 4), it was hypothesised that signalling upstream from N-cadherin may differ 
between the cell types, for example, variations in cell-secreted factors which may regulate 
N-cadherin differently. Therefore, the effect of Schwann cell-conditioned media (SCM) on 
OEC/astrocyte interactions was investigated using the confrontation assay. SCM was 
collected from confluent Schwann cell cultures in DMEM-BS after 2 days incubation. This 
was then applied, as a 50% SCM/50% DMEM-10% solution (SCM-50%), to 
OEC:astrocyte confrontation cultures which had been cultured in DMEM-10% for 10 
days. After 2 days in the presence of SCM, distinct boundaries began to form at the 
interface between OECs and astrocytes, in a similar manner detected for Schwann 
cell/astrocyte interactions (Figure 5.1 A and B). It could also be seen that expression o f glial 
fibrillary acidic protein (GFAP) was higher in astrocytes at the SCM-induced boundary 
interface than in astrocytes which were further away from OEC contact. An upregulation 
of GFAP expression in astrocytes contacting OECs was not observed in OEC:astrocyte 
confrontations maintained in only DMEM-10%.
It could also be seen in these cultures that following SCM treatment, OECs became much 
more aligned with each other. In this way, their alignment resembled that seen in Schwann
FCS SCM
Figure 5.1. SCM induces boundary formation in OEC/astrocyte confrontation
assays.
Confrontation assays were cultured in either DMEM-10% (FCS; A, C), or switched 
after 10 days culturing in FCS to 50% SCM/50% DMEM-10% (SCM; B, D) for 2 
days, after which time clear boundaries (open arrows) were formed. Images were taken 
using either light microscopy (A, B) or immunocytochemistry (C, D) with p75NTR 
(OECs, FITC) and GFAP (astrocytes, TRITC). Images are of different fields of view. 
Scale bar = 200 pm.
cell cultures (Figure 3.2; Wanner et al., 2002). However, this response was very variable 
following SCM treatment, being apparent in some cultures but not all.
5.2.2 Fibroblast growth factor receptor inhibition disrupts SCM- 
induced boundary formation in OEC/astrocyte cultures
5.2.2.1 Inhibitors used
Inhibitors o f various tyrosine receptor kinases were added to the confrontation assays in 
order to try and elucidate which signalling pathways were activated by addition of SCM. 
These inhibitors included epidermal growth factor receptor (EGFR; A G 1478), platelet- 
derived growth factor receptor (PDGFR; AG1295), and fibroblast growth factor receptor 
(FGFR; SU5402). In addition, an inhibitor of the non-receptor tyrosine kinase src 
(SU6656) was also included. Concentrations were selected based upon the published 
literature for SU6656 (Src inhibitor; Bowmann et al., 2001; Blake et al., 2000), PP2 (Src 
inhibitor; Blake et al., 2000; Nam et al., 2002), U0126 (Zheng et al., 2003; Jadeski et al., 
2003, PD98059 (MEK inhibitor; Reiling et al., 2001), SU5402 (FGFR inhibitor; Skaper et 
al., 2000; Mahommadi et al., 1997), AG1478 (EGFR inhibitor; Shushan et al., 2004; Zhao 
et al., 2003) and AG1295 (PDGFR inhibitor; Banai et al., 1998; Zhao et al., 2003). 
However, it does remain a possibility that the concentrations used for the different 
inhibitors may be at different positions on the dose-response curve, thus inhibiting targets 
with different efficiencies.
A degree of cross-reactivity is detectable with some of these inhibitors, where AG1295, in 
addition to inhibiting PDGFR (IC5 0  = 500 nM), also weakly inibits EGFR (IC 5o = 2.5 
mM). AG1295 inhibits PDGFR at high doses (IC 50 > 1 0 0  mM) as well as the intended 
target EGFR (IC 50 = 3 nM). SU6656 inhibits several closely related kinases such as Fyn 
(IC50 = 170 nM), Yes (IC50 = 20 nM) and Lyn (IC50 = 1 3 0  nM) in addition to Src (IC50 =  
28 nM), and SU5402 only weakly inhibits PDGFR but not EGFR, in addition to its 
intended target FGFR (IC 50 = 1 0  mM). However, for the screening purposes here, the 
inhibitors selected are suitable. By using the above combination of inhibitors, the functional 
target can be deduced, i.e. the PDGFR inhibitor can identify whether FGFR-mediated 
inhibition is actually due to residual PDGFR inhibition.
5.2.2.2 Effects of inhibitors
Control cultures consisted of both DMEM-10% (FCS) alone or SCM-50% without the 
addition of inhibitors (SCM). Inhibitors were added to OEC:astrocyte confrontation 
cultures at the same time that SCM was applied, which, as before, was added to cultures 
which had been maintained for 10 days. After 2 days, cultures were immunolabelled for 
GFAP (astrocytes) and p75NTR (OECs; Figure 5.2).
As demonstrated in Figure 5.1, it was seen that OEC:astrocyte confrontations maintained 
in DMEM-10% were able to intemingle with each other, whereas upon addition of SCM a 
clear boundary was formed (Figure 5.2Aii). The presence of hypertrophic astrocytes, 
identified by their enlarged appearance, could also be seen along the boundary in SCM- 
treated cultures. In the presence of EGFR and PDGFR inhibitors (Figures 5.2Aiii and 
5.2Aiv), no differences were seen in comparison to cultures in SCM-alone, since 
boundaries and hypertrophic astrocytes were present in all cultures. However, inhibition of 
src caused a morphological change in both OECs and astrocytes (Figure 5.2Av). Here, the 
cells became elongated, presumably due to a decrease in focal adhesion turnover in the 
lagging portion of the migrating cells such that as they moved they could not detach the rear 
of the cell and thus became stretched. However, despite their interdigitated appearance, 
OECs did not cross into astrocyte domains, suggesting that despite a change in the 
alignment o f the cellular boundary, OECs did not regain the ability to invade and migrate 
within the astrocytic domains.
In the presence o f an FGFR inhibitor (Figure 5.2Avi), this SCM-induced boundary was 
again not as defined as in SCM alone, where astrocytic processes appeared to stretch into 
the OEC domain and interact with OECs. Enlarged astrocytes were also not as apparent.
Some OECs were observed entering into the astrocyte domain itself (arrows), although not 
as many as in FCS treated cultures, suggesting that FGFR inhibition did not abrogate all 
effects of addition of SCM, but may have prevented any morphological changes in the 
astrocytes cultures, such as hypertrophy. The confrontation assays were quantified by 
counting the number o f cells which crossed the astrocyte-OEC boundary into the astrocyte
A
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Figure 5.2. FGFR inhibition prevents OEC/astrocyte boundary formation, following 
SCM treatment.
(A) Tyrosine kinase inhibitors were applied to OEC:astrocyte confrontation assays to 
examine their effects on SCM-induced boundary formation. Astrocytes were cultured with 
FCS (i), SCM (ii) and SCM supplemented with inhibitors of EGFR (iii), PDGFR (iv), src (v) 
and FGFR (vi). In addition, FGF-2 was added to cultures at a concentration of 50 pM (vii) 
and 100 pM (viii). Boundaries were not disrupted by the presence of EGFR and PDGFR 
inhibitors (in), although astrocytes became very elongated in the presence of the src inhibitor. 
In the presence of an FGFR inhibitor, OECs and astrocytes formed a weaving interlay, with 
some intermingling. Migrating cells are indicated with a white arrow. Scale bar = 200 pm.
(B) Quantification of confrontation assays, the number of cells which had crossed into 
astrocyte territories were counted over an astrocyte/OEC boundary distance of 300 pm. 
FGFR inhibition increases the number of cells migrating into astrocytic territories 
significantly compared to SCM treated. However, FGF-2 treatment did not mimic SCM (N.S. 
= not significant). n=6 ; *p<0 .0 1 .
territory (Figure 5.2B). FGFR inhibition o f the SCM-treated OEC/astrocyte confrontations 
significantly increased the number of cells crossing this boundary from 14.2 +/- 1.47 cells 
per 300 pm boundary to 23.7 +/- 2.36 (p<0.01). This was no longer significantly different 
from the untreated OEC/astrocytes boundary with 30.2 +/- 3.24 cells crossing per 300 pm 
boundary. However, application of FGF-2 to OEC/astrocyte confrontation assays, at both 
50 ng/ml and 100 ng/ml, did not induce a similar effect to SCM, with OECs being able to 
migrate efficiently into astrocyte-rich areas. This suggests that FGF-2 might not be 
responsible for the effect of SCM.
5.2.3 SCM treatment of astrocyte monolayers does not affect 
OEC or Schwann cell migration and adhesion upon them
Confluent astroycte cultures were maintained in DMEM-10%, and then switched to SCM- 
50% for 2 days. These were then used to perform both migration and adhesion assays. 
Vybrant-labelled OECs and Schwann cells were allowed to adhere to control and SCM- 
treated astrocyte monolayers overnight and then their migration speeds measured using 
time-lapse microscopy. As has been seen earlier (Figure 3.5. and 4.9), Schwann cells 
migrated at slower speeds than OECs on astrocyte monolayers (Figure 5.3A), 
demonstrating astrocyte-induced inhibition of Schwann cell migration, but not that of 
OECs. The treatment of astrocyte monolayers with SCM did not affect the ability o f either 
Schwann cells or OECs to migrate upon them.
Adhesion assays were also performed, in which Vybrant-labelled cells were allowed to 
adhere to astrocyte monolayers for 30 minutes while on a shaking platform. The 
monolayers had been previously treated for 2 days with DMEM-10%, SCM-50% or 
OEC-conditioned media (OCM), again in a 50% dilution with DMEM-10% (OCM-50%). 
The number o f cells which adhered after 30 minutes to the astrocyte monolayers were then 
quantified. As seen previously, the addition of SCM and OCM to astrocyte monolayers 
did not significantly affect the ability o f either OECs or Schwann cells to adhere to 
astrocytes.5.2.4 SCM-treatment increases astrocyte proliferation
To assess if SCM treatment affected astrocyte proliferation, the uptake of BrdU was 
measured by BrdU immunofluorescence. The number of astrocytes which took up BrdU
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Figure 5.3. SCM treatment of astrocyte monolayers does not affect Schwann 
cell (SC) or OEC migration and adhesion.
(A) Schwann cell and OEC migration upon astrocyte monolayers, as assessed by 
time-lapse microscopy, are not significantly affected by SCM treatment. n=15. (B) 
SCM and OCM does not significantly affect SC or OEC adhesion to astrocytes. 
Adhesion assays were performed where the number of Vybrant-labelled Schwann 
cells and OECs adhering to an astrocyte monolayer after 30 minutes were counted. 
n=6 .
over 16 hours following treatment were counted. Astrocytes were treated for 12 hours 
before addition of BrdU, with either serum-free media (DMEM-BS supplemented with 
heregulin and forskolin; DMEM-BS H/F), or with SCM or OCM which were diluted 1:1 
with DMEM-BS. Serum-free DMEM-BS H/F was used as control media since this is the 
media used to collect the conditioned media, and allowed proliferation changes to be 
measured without being masked by the overriding effect of serum. Under these conditions, 
astrocyte proliferation was unaffected by addition o f OCM, but was increased 2.5 fold by 
SCM (p<0.001), and the percentage of cells taking up BrdU increased from 10.2 +/- 0.8% 
to 24.9 +/- 3.1% (Figure 5.4A). Treatment with tyrosine receptor kinase inhibitors (EGFR, 
PDGFR and FGFR) did not significantly reduce SCM-induced proliferation, suggesting 
that the proliferative response was not induced via signalling dependent upon these 
receptors (Figure 5.4B). Likewise, application of EGF and FGF (at lOng/ml, based on 
Bansal et al., 2003; Asher et al., 2000; Williams et al., 1994; Araujo and Cotman, 1992), did 
not increase astrocyte proliferation significantly, again suggesting that they were not 
responsible for the increase in proliferation observed following SCM treatment. In addition, 
the astrocytic proliferation response to SCM was concentration-dependent as 
demonstrated by a concentration-response assay in which SCM was titrated from 1:50 to 
1:1 SCM:DMEM-BS H/F (Figure 5.4C). A significant proliferative response could be 
detected when SCM was diluted at 1:10, and had reached a plateau by 1:5.
5.2.5 Both OEC contact and Schwann cell-secreted factors are 
necessary for induction of astrocytic hypertrophy and 
upregulation of GFAP expression
In order to assess the effect o f SCM on astrocytic hypertrophy (indicated by an increase in 
astrocyte area), low density astrocyte cultures were set up as mono-cultures or co-cultured 
with OECs or Schwann cells. These were maintained in either DMEM-10% or SCM-50%
for 2 days prior to immunolabelling for GFAP (astrocytes) or p75NTR (OECs or Schwann 
cells; Figure 5.5A). Astrocyte area was measured using NIH Image programme and the 
mean values calculated (Figure 5.5B). Astrocytes cultured in DMEM-10% with Schwann 
cells were greatly enlarged in comparison to astrocytes cultured alone (increasing from 2495 
+/- 218 pm 2  to 5438 +/- 615 pm2, p<0.001), in agreement with Figure 4.12. Astrocytes
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Figure 5.4. SCM induces astrocyte proliferation.
(A) Astrocytes were treated with DMEM-BS H/F, OCM and SCM, and incubated 
with BrdU overnight, before staining. The percentage o f BrdU positive cells after 16 
hours were estimated. (B) Astrocytes were incubated with SCM in the presence or 
absence of receptor tyrosine kinase (EGFR, PDGR, FGFR) inhibitors. In addition, 
EGF (10 ng/ml) and FGF-2 (10 ng/ml) were added, but did not mimic SCM addition. 
(C Different titrations of SCM in SATO H/F (1:50, 1:10, 1:5 and 1:1). n=6 , *p>0.001.
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Figure 5.5. Both SCM and OEC contact are required for astrocytic 
hypertrophy.
(A) The effect of culture conditions upon astrocytic area was assessed by 
immunocytochemistry (astrocytes, GFAP-TRITC; OECs or Schwann cells, 
p75NTR-FITC). Conditions included culturing astrocytes for 2 days in FCS (i), co­
culture with OECs (ii) or Schwann cells (iii), SCM-treatment (iv) co-culture with 
OECs and SCM-treatment (v), and treatment with both SCM and OCM (vi). 
Hypertrophic astrocytes are marked with a white asterisk. Scale bar = 100 pm.(B) 
Quantification of astrocytic area using NIH Image analysis. * p<0.001, n=25.
cultured with OECs and mono-culture astrocytes treated with SCM did not increase in 
area. In contrast, astrocytes cultured with OECs with concomitant SCM treatment became 
enlarged (4872 +/- 413 fim2, p<0.001), to a similar degree as Schwann cell:astrocyte co­
cultures. To assess whether this increase in astrocyte area was a result o f synergy between 
Schwann cell-secreted factors, present in SCM, and OEC-secreted factors, produced by the 
OECs in culture, astrocyte mono-cultures were treated with both SCM and OCM. This did 
not result in hypertrophy, suggesting that both SCM and an OEC-contact mediated signal, 
as opposed to an OEC-secreted signal, are necessary for the induction of hypertrophy.
A similar result was seen when expression of GFAP was assessed (Figure 5.6). After 
mono- and co-cultures had been treated with SCM-50% for 2 days, lysates were made and 
subjected to immunoblotting for GFAP, using vinculin as a control. GFAP expression was 
significantly upregulated in Schwann cell/astrocyte co-cultures, and in astrocytes cultured 
with OECs when treated with SCM, but not when cultured with OECs in the absence of 
SCM, or when treated with SCM alone. Once more, this demonstrates that both OEC 
contact and SCM are necessary for the hypertrophic response as assessed by GFAP 
upregulation.
To assess if FGFR signalling was involved in the induction of hypertrophy in these 
models, an inhibitor of FGFR was employed. This was added to cultures over the same 
time course, either at the time of SCM treatment, or two days before immunolabelling in 
non-SCM-treated cultures, and reapplied every day for two days. Coverslips were then 
immunolabelled for GFAP and p75NTR (Figure 5.7A), and astrocyte areas were measured 
and quantified (Figure 5.7B). As before, both astrocytes in co-culture with Schwann cells 
alone, and those cultured with OECs and treated with SCM, were enlarged (from 1939 +/- 
150 pm2 (control) to 5286 +/- 302 pm2 (Schwann cell co-culture) and 5524 +/- 377 pm2 
(OEC co-culture with SCM)). Inhibition of FGFR significantly reduced this effect, 
although not to control levels (OEC co-culture with SCM plus FGFR inhibitor, 2468 +/-
396 pm2; Schwann cell co-culture plus FGFR inhibitor, 3632 +/- 499 pm2). This suggests 
that both Schwann cell-induced and OEC/SCM-induced hypertrophy requires the function 
of FGFR.
cP Ov  cy O
B
vinculin
GFAP
G_o4) C/3> C/3•p: 4)cq i—a.Tj xk.«<—i 4)o CU
n®o ' <
a
600
500
400
300
200
1 0 0
0
OEC SC OEC
+
co-culture
SCM
Figure 5.6. Both SCM and OEC contact are necessary for GFAP upregulation.
(A) Western blot showing GFAP expression after treatment of astrocytes. Treatments 
included astrocytes cultured in FCS (control), co-cultured with OECs and Schwann 
cells (SC), 50% SCM, and co-cultured with OECs with 50% SCM treatment. 
Vinculin was used as a protein loading control. (B) Densitometry of GFAP 
expression, relative to vinculin. GFAP was up-regulated in Schwann celhastrocyte co­
cultures, and OEC:astrocyte co-cultures only following treatment with SCM.
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Figure 5.7. FGFR inhibitor treatm ent reduces Schwann cell- and OEC with 
SCM -induced hypertrophy.
(A) Astrocyte cultures were treated for 2 days by culturing in FCS (i), co-culturing 
with OECs and SCM treatment (ii), co-culturing with OECs and SCM treatment 
with FGFR inhibition (iii), co-culturing with Schwann cells (iv), and co-culturing 
with Schwann cells with FGFR inhibition (v). Cultures were immunolabelled for 
GFAP (astrocytes, TRITC) and p75NIR (OECs and Schwann cells, FITC), with 
nuclear staining (DAPI). Hypertrophic astrocytes are marked with a white asterisk. 
Scale bar=  200 pm. (B) Quantification of astrocyte area using NIH Image analysis. 
* p<0.001, ** p<0.02, n=22.
To test whether OECs were inducing astrocytic hypertrophy through N-cadherin 
stimulation, a cyclic N-cadherin agonist peptide was added to astrocyte cultures which 
were also treated with SCM (Figure 5.8). Addition of the agonist peptide did not 
compensate for the presence of co-cultured OECs since astrocytes did not become enlarged 
(astrocytes with SCM and peptide, 1199 +/- 30; astrocytes co-cultured with OECs and 
SCM treatment, 2565 +/- 185; p<0.001), but remained with a similar area as astrocytes 
treated with FCS or SCM alone (1284 +/- 76 and 1263 +/- 30 respectively). As a positive 
control, agonist peptide from the same batch was used in neurite outgrowth assays (Skaper 
et al., 2003) in Professor Doherty’s laboratory.
5.2.6 SCM and OCM increase astrocyte chondroitin sulphate 
proteoglycan expression, particularly neurocan
In order to assess the effect of SCM and OCM on other markers of astrocytic reactivity, 
the expression of the inhibitory molecules chondroitin sulphate proteoglycan (CS-PGs) 
was investigated. Astrocyte cultures were maintained as mono-cultures in DMEM-10% 
(FCS), SCM-50% (SCM) or OCM-50% (OCM), or co-cultured with Schwann cells. As a 
positive control for astrocyte reactivity, astrocyte monolayers in DMEM-10% were 
wounded with a pipette tip and either immunolabelled immediately or left for 24 hours 
before immunolabelling. All cultures were immunolabelled for GFAP and also CS-PGs 
using either a pan-CS-PG antibody (CS-56 and 473HD) or a neurocan-specific antibody 
(Figure 5.9). CS-56 staining was enhanced in SCM-treated cultures (Figure 5.9C), and 
possibly in OCM-treated cultures (Figure 5.9D) although this was difficult to judge 
subjectively by eye. It was clearly upregulated in the positive controls, both immediately 
after wounding where cells adjacent to the wound edge wound were immunoreactive (Figure 
5.9E), and also 24 hours after wounding in which strongly immunoreactive astrocyte 
processes could be seen throughout the cultures (Figure 5.9F). However, immunoreactivity 
of control (FCS) cultures was much higher than expected (Lakatos et al., 2000) and did not 
appear to differ significantly with astrocytes co-cultured with Schwann cells, as has been
reported previously. A similar immunoreactivity pattern was observed with the 473HD 
antibody. Similar to the CS-56 antibody, 473HD also labels many different types of CS- 
PGs, although it recognises a different epitope. An increase in CS-PG expression was
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Figure 5.8. N-cadherin stimulation does not compensate for OEC 
contact on astrocytic area.
Low density astrocyte cultures were treated for 2 days with SCM, SCM and 
N-cadherin agonist peptide, and OEC co-culture with SCM treatment. The 
bar chart illustrates the average area of astrocyte size as quantified using 
NIH Image. *p<0.001, n=18.
Figure 5.9. CS-PG expression is upregulated in astrocytes following SCM treatment.
Immunocytochemistry o f astrocytes after various treatments was performed for different CS- 
PG epitopes. Treatments included FCS (A, G, M), co-culture with Schwann cells (SC; B, H, 
N), treatment with SCM (C, I, O) or OCM (D, J, P), or wounding astrocytes by scratching 
confluent monolayers and then fixing coverslips either immediately (E, K, Q) or after 24 
hours (F, L, R). Astrocytes were labelled for GFAP (TRITC) and CS-PG (CS-56 (A-F), 
473HD (G-L) and neurocan (M-R) antibodies; TRITC). CS-PG expression was enhanced 
following SCM treatment, as detected by each antibody used. White arrows indicate areas o f 
upregulated CS-PG expression. Scale bar = 200pm.
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Figure 5.9. CS-PG expression is upregulated in astrocytes following SCM treatm ent.
particularly obvious with 473HD in the wound controls, again with immuno-reactive cells 
present at the wound edge immediately (Figure 5.9K), and along astrocytic processes after 
24 hours (Figure 5.9L). An increase was also apparent in SCM-treated cultures (Figure 
5.91), although as with the CS-56 antibody Schwann cell-co-cultured and mono-cultured 
astrocytes were unchanged. An antibody against the CS-PG, neurocan, was also used and 
showed the most dramatic upregulation following SCM treatment (Figure 5.90). In 
addition, neurocan levels were increased following OCM treatment (Figure 5.9P). The 
negative control (FCS) for this antibody was much lower than for both CS-56 and 473HD, 
but, as before, positive scratch controls were highly immunoreactive (Figures 5.9Q and 
5.9R).
To measure the effect of SCM treatment on CS-PG expression in more detail, lysates of 
treated cultures (24 hours after scratching, 2 days after SCM or OCM treatment, or 10 
days after co-culturing) were made and subjected to immunoblotting. Vinculin was used as 
a loading control, and both pan-CS-PG antibodies (CS-56 and 473HD) and the neurocan 
antibody were used to measure CS-PG levels (Figure 5.10). Before probing with anti­
neurocan, lysates were digested with chondrotinase (see Materials and Methods, section
2.4.1), in order to resolve neurocan into discrete bands for identification and quantification 
(McKeon et al., 1999; Asher et al., 2000). Both the CS-56 and 473HD antibodies did not 
give a clear immunoblotting profile, producing bands with varying apparent molecular 
weights (data not shown), preventing a comparative analysis. However, using the neurocan 
antibody, full length neurocan (275 kDa) was identified. Quantification clearly showed an 
increase in neurocan expression following SCM treatment (12 fold), and also following 
OCM treatment (10.5 fold). Levels were also elevated in the wound control (10.7 fold). 
Interestingly, unlike the immunocytochemistry study, neurocan levels were upregulated 
following astrocyte co-culture with Schwann cells (6.3 fold). In conclusion, SCM and 
OCM treatment causes astrocytes to upregulate expression o f CS-PGs, and in particular 
neurocan.
To determine which signalling pathways were required for the upregulation of CS-PG 
expression, tyrosine receptor kinase inhibitors were added to SCM-treated cultures at the 
time of treatment and reapplied every day for two days before cultures were 
immunolabelled. The addition of the FGFR inhibitor had no effect on SCM-induced
vinculin
neurocan
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Figure 5.10. Neurocan expression increases in astrocytes after SCM and OCM  
treatm ent
(A) Immunoblotting showing effect of astrocyte treatment on expression of neurocan. 
Astrocyte treatments include FCS (control), co-culturing with OECs (+ OEC) and 
Schwann cells (+ SC), 50% SCM, 50% OCM, and wounding astrocyte monolayers as a 
positive control (lysates made 24 hours later). Vinculin was used as a protein loading 
control. (B) Quantification of neurocan expression, relative to vinculin. Neurocan 
expression is raised in Schwann cell/astrocyte co-cultures, and after SCM and OCM 
treatment.
expression of either the CS-56 epitope or neurocan (Figure 5.11). Similarly, addition of 
EGFR and PDGFR inhibitors had no effect on CS-PG expression in these cultures (data 
not shown). This suggests that SCM does not activate essential FGFR, EGFR or PDGFR- 
dependent signals necessary for upregulation of CS-PGs.
5.2.7 N-cadherin expression is upregulated by SCM
Lysates were made from astrocytes, cultured in DMEM-10% (FCS), SCM-50% (SCM) or 
OCM-50% (OCM) for 2 days, or co-cultured for 10 days with OECs or Schwann cells. 
Positive controls were made by wounding astrocyte monolayers with a pipette tip and 
leaving for 24 hours. N-cadherin levels were examined by immunoblotting, and compared to 
vinculin as a loading control (Figure 5.12). The levels were highly upregulated in SCM- 
treated cultures (17.4 fold), but only slightly increased in Schwann cell co-cultures, OCM- 
treated and scratched cultures (3.8, 3 and 5 fold respectively).
5.2.8 SCM-treatment does not alter other astrocyte markers, 
nestin, vimentin and PSA-NCAM
To assess if other markers of hypertrophy are increased in astrocytes following treatment, 
the upregulation of vimentin, another hallmark o f astrocytosis (Dahl et al., 1981a), was 
examined (Figure 5.14). Nestin expression has also been reported in reactive astrocytes 
(Clarke et al., 1994; Frisen et al., 1995), as has PSA-NCAM (Alonso and Privat, 1993; 
Nomura et al., 2000), and therefore the expression of these markers was investigated on 
astrocytes in mono- and co-culture with Schwann cells and OECs, with or without SCM 
treatment (Figure 5.13; Figure 5.14). The number of cells expressing nestin was not 
significantly altered in any of the conditions, being approximately 50% in every case 
(Figure 5.13B). Both OECs and Schwann cells, as identified by their diffuse GFAP 
expression, were all nestin positive (white arrows). Astrocytes under these culture 
conditions all expressed vimentin (Figure 5.14A) but not PSA-NCAM (Figure 5.14B),
demonstrating that these markers were not significantly altered by any o f the culture 
conditions. As detected for nestin, both Schwann cells and OECs expressed vimentin 
(white arrows), although only a proportion of OECs expressed PSA-NCAM (reflecting a
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Figure 5.11. FGFR inhibitor treatm ent had no effect on SCM -induced CS-PG 
expression.
Astrocytes were treated with FCS, SCM and SCM with FGFR inhibitor for two 
days before immunocytochemistry (GFAP-TRITC; CS-56/neurocan-FFTC). White 
arrows indicate strong areas of CS-PG expression. Scale bar = 200 pm.
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Figure 5.12. N-cadherin expression is elevated in astrocytes treated  with
SCM.
(A) Astrocytes were treated in various culture conditions, such as FCS or 
SCM treatment, co-culturing with OECs or Schwann cells (SC), or wounding 
the astrocyte monolayer by scratching. Lysates were made 24 hours later, and 
immunoblotting performed with an N-cadherin antibody. (B) Densitometry of 
N-cadherin expression relative to vinculin.
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Figure 5.13. Nestin expression is unaltered by SCM treatm ent.
(A) Immunocytochemistry (GFAP-TRJTC and nestin-FITC) and (B) quantification of 
nestin-positive astrocytes. Astrocytes were cultured alone in FCS (i) or SCM (ii), and 
in co-culture with Schwann cells (iii) or OECs (iv) in FCS, and also co-culture with 
OECs with SCM treatment (vi). (A) Nestin-positive astrocytes are indicated with an 
open arrow, and OECs and Schwann cells are indicated with a solid arrow. Scale bar = 
200 pm. (B) The number of nestin-positive astrocytes did not vary significantly with 
treatment.
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Figure 5.14. Vimentin and PSA-NCAM expression is unaffected by SCM 
treatm ent.
(A) Vimentin and (B) PSA-NCAM immunocytochemistry (FITC), with GFAP 
(TRITC). Astrocytes in all conditions tested (in FCS (i) or SCM (ii), and in co-culture 
with Schwann cells (iii), OECs (iv) and OECs with SCM (v)) were 100% vimentin 
positive, but lacked PSA-NCAM expression. Vimentin-positive Schwann cells and 
OECs, and PSA-NCAM-positive OECs, are indicated with white arrows. Scale bar = 
200 pm.
subset o f OECs with astroyte-like morphology; Franceschini and Barnett, 1996). These 
data suggest that nestin, vimentin and PSA-NCAM are not suitable markers for monitoring 
the astrocytic response of astrocytes in these assays.
5.2.9 Active component of SCM is trypsin-sensitive
In order to assess if the active factor within SCM is a protein, SCM was digested by the 
protease trypsin bound to agarose beads, as described in the Materials and Methods 
(section 2.1.7). The extent of proteolysis was assessed by SDS-PAGE (Figure 5.15A). The 
major band that could be seen in the SCM lane was transferrin (confirmed by mass 
spectrometry), which was succesfully reduced following trypsin digestion, producing a 
fragment of a lower molecular weight. The digested SCM was then used in both the 
astrocyte proliferation assay (Figure 5.15B) and OEC:astrocyte confrontations (Figure 
5.15C) to assess function. In both assays, trypsin digestion of SCM reduced its activity. 
Astrocyte proliferation was reduced significantly from 24.9 +/- 3.1% after SCM 
stimulation, to 13.1 +/- 1.4% (p<0.05), although it was not decreased to levels seen with 
the control, DMEM-BS H/F, remaining significantly higher (p<0.05), presumably 
reflecting the incomplete digestion as seen in Figure 5.15A. Trypsinised SCM also failed to 
induce boundary formation in OEC:astrocyte confrontations. This confirms that a trypsin- 
sensitive component of SCM is responsible for the effect of SCM as seen in these assays. 
It cannot be excluded that residual trypsin, which could have come off the beads, may have 
influenced these results. However, due to the lack of effect of trypsin on cell adherence to 
the coverslips, this is probably unlikely.
5.2.10 Identification of protein components of SCM and OCM
In order to investigate the possible active components present in SCM, a proteomics 
approach was taken using both DMEM-BS H/F and OCM as controls. To achieve this, 
DMEM-BS H/F, SCM and OCM, collected from confluent Schwann cell and OEC cultures 
respectively, were concentrated by centrifugation using centricon filters to approximately
4X the initial concentration. Protein was precipitated from these media and cleaned using 
acetone prior to subjection to 2-dimensional gel electrophoresis (2D PAGE). The protein
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Figure 5.15. The active component of SCM is trypsin sensitive, suggesting it is 
a protein.
(A) SDS-PAGE gel stained with brilliant blue G-colloidal, showing breakdown of 
major protein bands following digestion with trypsin-agarose beads.
(B) Effect o f digested SCM (SCM tryp) on BrdU assay (percentage o f astrocytes 
taking up BrdU in 16 hours following treatment). Both SCM- and SCM tryp- 
treated sets have significantly greater proliferation compared to DMEM-BS H/H, 
but this is significantly different between SCM and SCM-tryp (*p<0.05, 
**p<0.001, n=6 ). (C) OEC/astrocyte confrontation assays treated with DMEM- 
10% (FCS, i), SCM-50% (SCM, ii) and digested SCM-50% (SCM tryp, iii; 
astrocyte (GFAP-TRITC), OEC (p75NTR-FITC)). Digested SCM no longer 
induces boundary formation (boundaries indicated by open arrows) Scale bar = 
2 0 0  pm.
content within the gel was assessed using a mass spectrometry-compatible fluoresent 
Supro orange dye (Figure 5.16). Several candidate proteins were present in SCM (all arrow 
heads, Figure 5.16B) but absent from both DMEM-BS H/F and OCM. These were excised 
from the gel, digested with trypsin, and identified by mass spectrometry (performed by 
Chris Ward). Problems arose from keratin contamination (black arrow heads), but possible 
candidates were identified as collagen alpha 1 , in several locations (white arrow heads). 
Despite removal of BSA from the DMEM-BS media, an overloading protein band was 
present in the middle of each gel. This was identified as transferrin, a component of the 
DMEM-BS media.
5.3 Discussion
It has previously been shown using in vitro assays similar to those employed here that 
OECs and Schwann cells induce different responses in astrocytes (Lakatos et al., 2000), for 
example, astrocytes co-cultured with Schwann cells, but not OECs, were greatly enlarged. 
It was also seen that the expression of CS-PGs by astrocytes was enhanced significantly in 
Schwann cell/astrocyte cultures, but not in OEC/astrocyte cultures. My data confirmed 
that astrocytes become hypertrophic in the presence of Schwann cells and not OECs. 
However, CS-PG expression was not dramatically increased by the presence of Schwann 
cells. This may reflect a level o f innate reactivity in the astrocytes used here, since CS-PG 
expression was already elevated in the control cultures compared to those documented in 
other studies (Lakatos et al., 2000). It has been remarked that astrocytes in culture tend to 
have a more reactive phenotype than their in vivo counterparts, as measured by expression 
of reactive markers such as vimentin (Bignami and Dahl, 1989). This was also confirmed by 
my data where all astrocytes were vimentin positive, irrespective o f cellular treatment. 
Despite this, in vitro assays remain useful for measuring degrees o f astrocytosis since 
many markers of reactivity, including CS-PG expression, were elevated significantly in the 
treated sets above those of control cultures. This has also been found in many other in vitro 
culture models of astrocytosis where expression patterns visibly alter following the 
induction of reactivity (Eddleston and Mucke, 1993; Wu et al., 1998).
Despite the relative clarity of in vitro studies, there is still some debate as to what degree 
these differences seen in OEC and Schwann cell interactions with astrocytes reflect the in

vivo environment following transplantation. Many studies have documented that following 
transplantation of Schwann cells, local astrocytes become reactive, upregulating both 
GFAP and CS-PGs (Plant et al., 2001, Takami et ah, 2002; Lakatos et ah, 2003a), and also 
that this response is greater than that induced by OECs (Verdu et ah, 2001; Takami et ah, 
2002; Lakatos et ah, 2003a). However, OECs induce more astrocytosis in vivo than in vitro 
(Lakatos et ah, 2003a). Explanations for this discrepancy include damage caused during the 
actual transplantation procedure such as that caused by the needle tract or a response to 
the presence of injected matter within the CNS. In addition, other cells which regulate 
astrocytosis, such as macrophages or microglia, are noticeably absent from in vitro assays. 
These assays therefore measure the response of astrocytes purely to a controlled stimulus, 
rather than modelling the complex cellular interactions which occur in vivo. Furthermore, 
the injured CNS may have a greater reactivity to stimuli, due to a ‘priming’ mechanism 
such that following an injury, astrocytes are more sensitive to any further insult. This is 
supported by observations that following stab wound injuries, astrocytes located in distant 
regions from the lesion site, do display an enhanced level of reactivity (Mathewson and 
Berry, 1985; Moumdjian et al., 1991). Thus these astrocytes may be become more 
sensitive to further stimulation, such as transplantation.
Despite these drawbacks, in vitro models of astrocytosis still have the benefit o f allowing 
us to dissect the various signalling events involved in this process using a well controlled 
and minimalist environment. In addition, the role astrocytosis plays in determining the 
ability o f cells to migrate within astrocyte-rich areas can be directly addressed.
5.3.1 CS-PG expression
Despite the high expression of CS-56-immunoreactive CS-PGs in control astrocyte cultures 
(as mentioned above), a clear increase in CS-PG expression was still detectable following 
the addition o f SCM. This media, obtained from confluent cultures of Schwann cells, might 
be more concentrated than that produced by the Schwann cells in co-culture, and therefore 
may reflect a concentration dependency upon the factors secreted by Schwann cells. In 
addition, this assay demonstrates that the reported increase in CS-PG expression in 
Schwann cell/astrocyte co-cultures (Lakatos et al., 2000), is not mediated by contact- 
dependent signals, but that secreted factors are sufficient.
In order to quantify the changes in CS-PG expression in these cultures, immunoblotting 
was used. However, limitations arose when using the CS-56 antibody since it binds to 
many different CS-PGs, resulting in a complex immunoblot profile which was difficult to 
interpret. It is for this reason, that the CS-56 antibody is generally considered poorly 
compatible with immunoblotting (Fidler et al., 1999; Moon et al., 2003), which lead me to 
use the neurocan antibody instead. This was more successful and gave a profile which 
correlated with the immunocytochemistry results, demonstrating that neurocan expression 
was elevated following treatment with both SCM and OCM.
In vivo studies have shown that CS-56 immunoreactive CS-PG expression is regulated 
differently in response to transplantation of either OECs or Schwann cells, being lower 
around OEC grafts than around Schwann cell grafts (Lakatos et al., 2003a). In contrast, the 
same study demonstrated that neurocan is upregulated to a similar level in response to both 
Schwann cells and OECs. This data is in agreement with my results presented in this 
chapter suggesting that Schwann cell-secreted and OEC-secreted factors are equally potent 
at stimulating neurocan expression. However, other studies reported no change in neurocan 
expression in response to Schwann cell grafting, despite noticeable changes in CS-56 (Plant 
et al., 2001). It remains to be addressed whether CS-56 immunoreactivity is increased in 
response to both OCM and SCM equally, as suggested by the immunocytochemical 
analysis here, or differently, as suggested by other Schwann cell and OEC co-culture 
experiments (Lakatos et al., 2000). This could be achieved using a clearer method than 
immunoblotting for quantification, such as pixel quantification of immunoreactivity images.
Previous experiments have shown that astrocytes express neurocan (Oohira et al., 1994: 
McKeon et al., 1999; Asher et al., 2000), and that the level o f neurocan expression is 
regulated by soluble cytokines. They demonstrated that EGF and TGFfJ caused an 
increase, whereas PDGF and IFNy reduced neurocan expression (Asher et al., 2000). Using 
receptor tyrosine kinase inhibitors, I have shown that EGFR and PDGFR do not regulate 
neurocan expression in these assays. It remains to be seen whether other cytokines, such as 
TGFp, are responsible for the stimulation caused by SCM and OCM. In support of this 
hypothesis, TGFJ3 expression was shown to be increased following a stab wound of the rat
spinal cord, with expression peaks correlating closely with expression o f various CS-PGs, 
including neurocan (Tang et al., 2003).
5.3.2 Hypertrophic markers
Both the upregulation of GFAP and an increase in astrocytic area were seen in Schwann 
cell/astrocyte co-cultures and OEC/astrocyte co-cultures treated with SCM, thus these two 
markers of hypertrophy correlate. Support that these markers are dependent upon both the 
addition of SCM and OEC contact, as demonstrated in the co-cultures, comes from 
analysis o f the astrocyte-OEC boundary in confrontation assays. Upon adding SCM to 
these cultures, GFAP expression was increased, and enlarged astrocytes were present, 
along the boundary where OECs contact the astrocytes. Likewise, evidence that Schwann 
cell/astrocyte confrontations may be providing both SCM and a necessary contact- 
mediated signal is provided by the fact that reactive astrocytes were mainly seen along the 
contact-boundary between Schwann cells and astrocytes (Figure 3.2). However, it can not 
be ruled out that Schwann cell contact alone may be sufficient to induce astrocytosis and 
therefore may be biochemically different to OEC contact which requires the addition of 
SCM.
The markers nestin and vimentin were also investigated since they have been shown to be 
additional markers of hypertrophy. Vimentin is developmentally regulated, being 
predominately expressed in immature astrocytes and progressively replaced by GFAP 
during differentiation (Dahl et al., 1981b). It remains, however, along with GFAP, as a 
hallmark o f reactive gliosis (Dahl et al, 1981a). In addition, nestin, another intermediate 
filament protein which is mainly expressed by CNS progenitor cells (Lendahl et al., 1990; 
Dahlstrand et al., 1995), is also re-expressed in reactive astrocytes (Clarke et al., 1994; 
Frisen et al., 1995). However, these markers were not altered in the treated sets of 
astrocytes. One explanation for why vimentin was still expressed in all astrocytes is that 
the GFAP-vimentin transition has been reported to be incomplete in primary cultures 
(Bignami and Dahl, 1989). Additionally, it might reflect the purity of cultures where low 
levels of contaminating microglia, which produce many types of cytokines, could alter the 
astrocytic status, or may even be due to the presence of blood-derived factors present in
serum, from which astrocytes are usually shielded by the blood brain barrier (Eddleston 
and Mucke, 1993).
PSA-NCAM expression was investigated since it has been reported to be upregulated in 
some reactive astrocytes in vivo (Alonso and Privat, 1993; Nomura et al., 2000). However, 
in these cases, expression was localised to a subset of astrocytes from specific regions 
(Nomura et al., 2000) or following different types of injury (Alonso and Privat, 1993), and 
therefore it is not a generic marker for astrocytosis. Hence, its lack of expression in the 
cultures used here is not necessarily surprising, but instead may reflect the cortical source 
of these astrocytes, or the type of stimulation.
5.3.3 Induction of reactivity
It can be concluded from the data presented here that different signals are required for 
different aspects o f the reactive response, i.e. they are independently regulated (see Table
5.1). Upregulation of CS-PG expression and an increase in astrocyte proliferation was 
dependent upon SCM alone, whereas hypertrophy and GFAP upregulation required OEC 
contact as well as SCM. Since Schwann cells alone can induce these responses in 
astrocytes, it can be speculated that Schwann cells not only provide the factors present in 
SCM, but also are the source of a contact-mediated signal which may or may not be 
fundamentally different from that provided by the OEC (see Figure 5.17A). This would 
help explain why previous SCM investigations reported no change in astrocyte 
morphology or GFAP expression following addition of SCM alone (Ghimiker and Eng 
,1994). In these experiments, contact-mediated signals were absent, whether from Schwann 
cells or OECs.
In addition, my results may shed some light on the observed heterogeneity of astrocyte 
reactivity seen in vivo following injury, where not all astrocytes in a given area undergo a 
reactive response (Fitch and Silver, 1997). Despite the possibility of secreted factors being 
evenly distributed throughout a locality within the CNS, there may be variations in 
additional signals through contact with particular cells, or even ECM components.
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Figure 5.17 Hypothesis
(A) Schwann cells produce SCM and may provide a contact signal (since SCM alone is not 
sufficient for increase in GFAP or astrocyte size); OECs provide contact signal (which may 
or may not be the same as the Schwann cell contact signal), but require additional SCM for 
astrocyte response.
(B) Role of FGFR. 1, FGFR may interact with Schwann cell/OEC contact signal. FGFR may 
also interact with N-cadherin, mediating inhibition of migration, as well as induction of 
hypertrophy. 2, FGFR is involved in mediation SCM signalling to astrocytes. 3, FGFR may 
be involved in signalling downstream from SCM signal, such as an FGF autocrine loop, 
resulting in hypertrophic response.
<=> Contact signal 
<=> FGFR
of SCM and FGFR function
5.3.4 Identity of SCM factor
The active factor present in SCM, whether absent from OECs or merely expressed at lower 
levels, may be an example of a further difference between OECs and Schwann cells, 
providing more evidence that they are distinct types of glia.
Mass spectrometry was employed in an attempt to determine the identity of this factor. 
Analysis of differential protein spots, as identified by 2D PAGE, highlighted the presence 
of collagen alpha 1 in various positions. Due to its occurance in protein spots of very 
different molecular weights, it remains to be seen whether these spots correlate to different 
breakdown products or alternative splicing. It may in fact be a contaminant, although this 
could be ascertained by immunoblotting. As it was a rat protein, rather than human like the 
common contaminant keratin, this is unlikely. In addition, collagen is not reported to be a 
usual contaminant of 2D PAGE gels. Type IV collagen, which contains collagen alpha 1 
fibrils, is produced by Schwann cells (Carey et al., 1983), however it is unclear whether 
OECs also produce it. Unlike Schwann cells, OECs have been reported to lack a basal 
lamina and collagen fibrils (Wozniak, 1993), although collagen IV is expressed along the 
olfactory nerve pathway (Doucette, 1996). Whether collagen alpha 1 would explain some 
of the observed effects of SCM remains to be tested. Collagen has been implicated in the 
regulation of cellular migration since type IV collagen inhibits migration of MCF-7 and in 
MDA-MB-231 breast cancer cell lines (Sisci et al., 2004). In addition, type I collagen has 
been shown to differentially regulate cell migration in neutrophils, where migration was 
promoted, and in macrophages, whose migration was inhibited (Kozlov et al., 1999). Thus 
collagen may pay a role in determining the ability of Schwann cells to migrate, particularly 
when in contact with astrocytes.
Other possible candidates for mediating the effects of SCM are the various cytokines 
which have been shown to induce astrocytes to become reactive (Eddleston and Mucke, 
1993). Many of these factors have been reported to be produced by Schwann cells under 
certain conditions, such as Wallerian degeneration, for example, IL-1 (Bergsteinsdottir et al., 
1991; Skundric et al., 1997; Rutkowski et al., 1999), IL - 6  (Murwani et al., 1996; 
Rutkowski et al., 1999) and TN Fa (Murwani et al., 1996; Wagner and Myers, 1996). 
Whether these factors are also produced by OECs is at present unknown, and may
highlight another similarity or difference between the two glia. Due to the high potency of 
these molecules, very low concentrations would be necessary to mediate these effects, and 
thus they might not be present at levels high enough for detection using 2D electrophoresis, 
as performed here.
5.3.5 Role of N-cadherin
The nature of the contact-mediated signal between OECs and astrocytes is also unknown. 
Based on previous investigation of the role of N-cadherin in glial cell interactions, it was 
postulated that the differential function of N-cadherin detected between Schwann cells and 
OECs make it a possible candidate. It is possible that the variability in N-cadherin function 
depends upon the presence of soluble factors in SCM, which may bind to N-cadherin- 
interacting receptors, or even regulate N-cadherin directly. It is therefore important to 
assess if the role of N-cadherin is involved in simple adhesion, or whether it also functions 
to induce astrocytosis. Based on the evidence provided here, it appears that N-cadherin is 
unlikely to be the contact-mediated signal necessary for induction of hypertrophy since 
removal of N-cadherin using siRNA did not reduce the average astrocyte area in Schwann 
cell co-cultures (Figure 4.13), nor did stimulation of astrocyte N-cadherin using stimulatory 
peptides in the presence of SCM compensate for OEC contact.
It remains to be seen if, and how, astrocytosis and adhesion are related. It can be seen that 
the disruption o f N-cadherin-mediated adhesion prevents boundary formation in 
confrontation assays (see Chapter 4), and that such boundary formation is promoted by 
inducing astrocytosis. Two possibilities could therefore exist. Firstly, astrocytic 
hypertrophy may prevent other cells from entering astrocyte areas due to the formation of 
a physical barrier through which these cells can not penetrate. That N-cadherin expression 
is upregulated in reactive astrocytes (Vazquez-Chona and Geisert, 1999; Figure 5.12), may 
suggest that such a barrier is N-cadherin rich and that cells may form strong adhesions to 
this barrier, preventing further migration. Secondly, evidence that the role of N-cadherin is 
more important than merely creating a physical barrier is provided by the observation that 
siRNA-treated Schwann cells are able to penetrate the astrocyte domains even when 
enlarged astrocytes are present. Therefore it appears that the presence of N-cadherin on 
Schwann cells is a more important determinant of boundary formation than the presence of
hypertrophic astrocytes. It may be that hypertrophy functions only to enhance the 
likelihood that cells will adhere strongly to astrocytes in an N-cadherin-dependent manner, 
through a greater binding site area (hypertrophy) and more binding substrate (N-cadherin 
upregulation) (see Discussion, Figure 6.1). However, since N-cadherin functionality is 
different between OECs and Schwann cells, it remains a possibility that SCM factors, 
normally present in Schwann cell cultures, could be modulating N-cadherin function. This 
was ruled out since addition o f SCM to OEC cultures, despite inducing boundary 
formation in confrontation assays, did not affect N-cadherin function as assessed by 
migration and adhesion assays. However, since confrontation assays test the ability of glial 
cells to migrate through an astrocytic territory, whereas migration assays test the ability of 
cells to migrate upon astrocytes (discussed in Section 3.3.4 and 3.3.5), these assays may be 
measuring different effects and therefore not be comparable.
Neurocan has been shown to regulate N-cadherin function through the neurocan receptor, 
GlcNAcPTase (Li et al., 2000). Thus, an upregulation of both neurocan and N-cadherin in 
SCM-treated astrocytes could promote neurocan-N-cadherin interactions when OECs 
contact astrocytes in the presence of SCM. However, neurocan stimulation of N-cadherin 
has been shown to promote rather than inhibit migration and thus is not likely to be the 
mechanism at work here (Li et al., 2000).
5.3.6 Role of FGFR
Inhibition of FGFR was shown to be involved in the induction of hypertrophy in 
OEC/astrocyte co-cultures, since inhibition significantly reduced the increase in astrocytic 
area in response to SCM. FGFR inhibition also prevented the formation of a distinct 
boundary in OEC/astrocyte confrontation assays when SCM was added. These two 
phenomena may be reflecting the same response, since the astrocytes in the confrontation 
assay would also have reduced hypertrophy following FGFR inhibition. Therefore, 
reduced hypertrophy could prevent the astrocytes from forming an impenetrable barrier to 
OEC invasion, allowing OECs to interdigitate with astrocytic processes. However, the 
reduced numbers of OECs able to penetrate the astrocyte domains compared to control 
(FCS-treated) cultures might reflect the effect of SCM on other aspects o f astrocytosis, 
such as CS-PG, or even N-cadherin, upregulation.
It appeared from the immunocytochemistry study, however, that CS-PG expression was 
not regulated by FGFR. Therefore, the CS-PG expression resulting from SCM treatment is 
unlikely to be changed in the inhibitory and permissive (FGFR-inhibited) confrontation 
assays. This demonstrates that CS-PG expression probably does not regulate the ability of 
OECs to enter astrocyte domains, or it is at least not a major determinant, with 
hypertrophy playing a more significant role. However, in contrast, a recent paper reported 
that CS-PGs do play a critical role in determining the ability of Schwann cells to enter 
astrocytic areas, using confrontation assays similar to those employed here (Grimpe et al.,
2002). Whether this highlights another difference between Schwann cells and OECs, in that 
Schwann cell migration may be more susceptible than OEC migration to CS-PG inhibition, 
or whether CS-PGs do play a significant role in OEC/astrocyte interactions, but less than 
that played by hypertrophy, remains to be determined.
The exact mechanism by which FGFR mediates SCM-induced effects in confrontation 
assays needs further investigation. FGFR can regulate the adhesive nature of adhesion 
molecules, such as NCAM and N-cadherin (Williams et al., 1995; Utton et al., 2001; 
Suyama et al., 2002), and thus may be influencing the adhesion of OECs to astrocytes. 
However, SCM treatment had no significant effect on OEC adhesion to astrocytes as 
assessed by the adhesion assay. In contrast, the evidence does suggests that FGFR is 
involved in the induction of astrocytic hypertrophy. Whether FGF-2 is responsible for the 
FGFR-dependent induction of astrocytosis remains to be seen. It is supported by the 
observation that injecting FGF-2 into cerebrospinal fluid induces astrocytosis (Goddard et 
al., 2002), and that Schwann cells have been reported to express FGF-2 in culture 
(Meisinger et al., 1996). However, preliminary studies suggested that addition of FGF-2 to 
OEC/astrocyte confrontations did not induce boundary formation, and therefore did not 
compensate for SCM, perhaps by requiring other factors (Figure 5.2Avii and viii). Whether 
FGFR function is involved in mediating direct SCM-stimulation itself, or whether SCM 
stimulates astrocytes, which as a result require downstream FGFR-dependent autocrine 
mechanisms, remains to be determined (see Figure 5.17B).
5.3.7 Summary
In conclusion, Schwann cells secrete factors which determine the astrocyte response, and in 
turn may inhibit the migration of Schwann cells into astrocytic areas. This is demonstrated 
by the ability of Schwann cell-secreted factors, present in SCM, to regulate the entry of 
OECs into astrocytic areas, and thus suggesting that they may be responsible for the lack 
o f migration seen in Schwann cell/astrocyte confrontation assays. Since SCM affected 
astroctic hypertrophy, but did not significantly modulate OEC adhesion or migration upon 
astrocytes, this supports a role for astrocytic reactivity in determining the ability of glial 
cells to penetrate astrocyte-rich areas. It cannot be ruled out, however, that hypertrophy 
may be providing more than just a physical barrier to OEC migration, and that astrocytes 
may also be producing factors in response to SCM which regulate cellular migration. In 
addition, GFAP has been shown to regulate the ability of neurons to migrate upon 
astrocytes, despite it being an intracellular component, suggesting that astrocyte inhibition 
may function by a mechanism other than just adhesion (Menet et al., 2000).
The influence o f SCM upon astrocytosis obviously has implications upon the use of 
Schwann cells in transplantation, where astrocyte responses may influence the ability of 
Schwann cells to coexist alongside them. Once the nature of these factors is determined, 
they may prove to be potential targets to improve Schwann cell/astrocyte interactions 
following transplantation. In addition, the presence o f Schwann cells which can invade the 
injured CNS, known as Schwannosis (Franklin and Bakemore, 1993; Bruce et al., 2000; 
King et al., 2003; Ramer et al., 2004a), may add to the reactive environment of the CNS. 
Understanding the processes involved in inducing and maintaining astrocytosis in more 
detail may allow us to manage Schwannosis more effectively, and prevent an inhibitory 
environment to regeneration from developing.
CHAPTER 6 
General Discussion
Central nervous system (CNS) pathologies are often very debilitating due to the inability of 
the CNS to undergo repair following damage. One such pathology is spinal cord injury 
(SCI) which affects almost a thousand new sufferers in the UK every year (data from the 
International Campaign for Cures of Spinal Cord Paralysis). The severity of SCI is very 
variable, depending on the type and location of the injury. Spinal cord injuries are classified 
as paraplegic and tetraplegic, paraplegia typically resulting from thoracic injuries, and 
tetraplegia from cervical injuries. Furthermore, SCI can be further classified as either 
complete or incomplete, which may affect the degree of recovery. CNS function can also be 
affected by demyelination, classically seen in diseases such as multiple sclerosis.
Many different potential therapies are being investigated at present to promote repair of 
the damaged CNS, ranging from growth factor delivery to improve survival rates of neurons 
and promote axonal outgrowth, to antibodies and pharmacological agents against inhibitory 
factors. However, one approach which has attracted a lot of attention over recent years is 
the use of cellular transplantation to mediate repair.
Although a range of cells have been studied for cellular transplantation, including 
oligodendrocyte progenitor cells (OPCs) and neural stem cells, this thesis has been 
concerned with two possible candidates, Schwann cells and olfactory ensheathing cells 
(OECs). Both Schwann cells and OECs have been put forward as potential candidates for 
transplant-mediated repair o f both demyelinating diseases and SCI (Franklin and Barnett, 
1997; Raisman, 2001; Wewetzer et al., 2002). Schwann cells and OECs share many 
properties in common, but there is still an open debate as to which is the superior cell type 
for transplantation therapies. One of the major differences between Schwann cells and 
OECs, which may be the critical test o f which is the better cell, is the difference in their 
abilities to interact with astrocytes. This has been seen in both in vitro and in vivo injury 
models, where Schwann cells have been shown to exhibit two major properties which affect 
their candidature: (1) poor survival and migration within astrocytic environments (Ramon- 
Cueto et al., 1998; Iwashita et al., 2000); and (2) the ability to induce reactive astrocytosis 
(Ghimiker and Eng, 1994; Lakatos et al., 2000; Plant et al., 2001; Takami et al., 2002). This 
lack of migration and survival would seriously diminish the potential of Schwann cells to 
reach an appropriate site for repair, and remain there long enough to mediate either axonal 
regeneration or to remyelinate demyelinated axons. In addition, astrocytic reactivity
induced by Schwann cells could limit the ability o f the host environment to support 
regeneration, since astrocytosis and the subsequent formation of a glial scar is inhibitory to 
repair (Clemente, 1964; Fawcett and Asher, 1999). Thus, a balance must be maintained 
after cellular transplantation between the repair-promoting properties of the transplant and 
the inhibitory environment o f the host response.
In contrast to Schwann cells, OECs have been demonstrated to co-exist with astrocytes 
following transplantation in a more favourable manner, being able to migrate within 
astrocyte-rich areas (Ramon-Cueto et al., 1998; Li et al., 1998; Gudino-Cabrera et al., 2000; 
Lakatos et al., 2000), whilst inducing a less reactive astrocytic response (Lakatos et al., 
2000, 2003a; Verdu et al., 2001). However, in some studies, OECs were not able to migrate 
extensively but were instead confined to the site of injection (Smale et al., 1996; Lakatos et 
al., 2003a). In the same way, Schwann cells can sometimes migrate within the CNS, but 
only following injury (Franklin and Blakemore, 1993; Bruce et al., 2000; Rainer et al., 
2004a). Reasons for these discrepancies may be due to the integrity of the host tissue, 
whereby both OECs and Schwann cells can migrate only if  there are appropriate pathways 
for migration such as along blood vessels, or through perivascular space (Franklin and 
Blakemore, 1993). However, OECs do appear to be a better candidate than Schwann cells 
as assessed by their inherent migratory capacities through astrocytes when compared side- 
by-side (Franklin and Barnett, 1997; Ramon-Cueto et al., 1998; Lakatos et al., 2000).
In order to maximise the use of cells for transplantation therapies, it would therefore be 
beneficial to promote their migration. This is important since the site of injection is not 
necessarily the best place for the cells to exert their capacity for repair, but if they can 
migrate away they may be able to provide continuous support for a regrowing axon across 
the injury site to its potential target In addition, demyelination in MS occurs at multiple 
plaques, which could be treated with a single transplant if these cells could successfully 
migrate. A need for efficient migration was demonstrated from a study using Schwann cell- 
seeded grafts transplanted into a transected spinal cord, where the Schwann cells were 
unable to leave the graft. Although they promoted the regeneration of axons into the graft, 
these axons could not subsequently leave the graft to re-enter the host tissue (Ramon- 
Cueto et al., 1998). This lack of axonal outgrowth may have resulted from the level of 
growth factors being higher and more favourable within the graft, and also due to the
occurrence of glial scarring at the graft edges. For these reasons, if the Schwann cells could 
be encouraged to migrate away from the graft, perhaps even forming a trajectory from the 
graft to the axon target, then they may be able to promote repair and regeneration through 
either the secretion of growth factors beyond the graft, or by providing a permissive 
substrate or environment. Interestingly, the limitation of axons to exit the graft was 
overcome by the transplantation of OECs at the graft-host interface which allowed axons 
to re-enter the host, perhaps by the mechanisms mentioned above. It would therefore be 
advantageous to improve the migratory capacity o f transplanted cells in order to enhance 
their regenerative properties.
For optimal repair, another consideration would be to keep the reactivity of the host in 
response to the transplant to a minimum, in order to maintain a permissive astrocytic 
environment for regeneration. For this reason, it is crucial to have an understanding of 
factors which trigger the reactive response, and how this may differ between Schwann cells 
and OECs. Furthermore, an increased knowledge of these processes may allow us to 
manage the reactive environment effectively, and therefore promote the migration of 
transplanted cells within the host (in the absence of a scar), in addition to enhancing the 
supportiveness of the host environment to repair.
From many studies in the literature, OECs appear to be the stronger candidate for 
transplantation based on the above criteria of migration and astrocyte reactivity (Franklin 
and Barnett, 1997; Lakatos et al., 2000; Wewetzer et al., 2002). This support for OECs, 
however, has not proved to be grounds on which to abandon the idea of using Schwann 
cells for transplantation.
In order that transplantation therapies can be translated to the clinic, it would be helpful to 
have an autologous supply of cells. This would avoid complications arising from 
xenotransplantation, including both the need to immunosuppress the patient in order to 
avoid rejection of the graft, and also the potential for zoonoses. Schwann cells are more 
easily accessible from peripheral nerve sources than OECs, which would require a highly 
invasive procedure to gain access to the olfactory bulb. This picture is beginning to change, 
however, due to the newly emerging peripheral sources of OECs from the olfactory mucosa 
(Au and Roskams, 2003). In addition, culture conditions at present may limit the number
of autologous OECs which can be cultured from the patient before transplantation of 
sufficient numbers (Barnett et al., 2000), although it may be possible to overcome this by 
finding appropriate growth factors. This is not so much of a problem for Schwann cells, 
where high numbers can easily be grown (Rutkowski et al., 1995).
In addition, Schwann cells have proved to be superior to OECs in some models of repair 
such as remyelination of dorsal root ganglion neurons under certain culture conditions 
(Plant et al., 2002) and in promoting locomotor recovery following a contusion injury 
(Takami et al., 2002). OECs and Schwann cells may also be able to compliment each other 
as a therapy, as in the study using both Schwann cells and OECs to promote axonal 
outgrowth discussed above (Ramon-Cueto et al., 1998). For these reasons, it may be 
beneficial to modify Schwann cell behaviour to function more like OECs in terms of 
migration and induction of reactivity. This would also allow us to make full use of the more 
accessible source of cells for transplantation (Franklin and Barnett, 2000).
In order (1) to assess the differences between Schwann cells and OECs in more detail 
regarding their potential as transplantation candidates, and (2 ) to identify mechanistic 
differences between them which may be a basis for improving Schwann cell transplantation 
therapies, I have investigated some of the molecular mechanisms which determine why 
OECs and Schwann cells interact differently with astrocytes.
My study has demonstrated that N-cadherin function is significant in determining the 
abilities o f Schwann cells and OECs to migrate and adhere in the presence of astrocytes 
(Chapter 4). In particular, removal of N-cadherin allowed Schwann cells, which are 
normally inhibited, to successfully penetrate astrocyte areas in confrontation assays. 
Interestingly, despite N-cadherin being similarly expressed and associated with cell-cell 
contacts in both OECs and Schwann cells, it functions differently in these cells. It remains 
to be definitively determined whether N-cadherin function is regulated differently within 
the two cell types or whether extracellular factors, such as the status of the astrocyte to 
which they are binding, or the presence of extracellular modulators, may determine this 
outcome. However, it is likely to be a functional inherent difference between the cell types 
since homotypic adhesion varied in terms o f both adhesion strength and N-cadherin 
dependency.
Furthermore, an investigation of factors involved in determining the astrocytic response to 
OECs and Schwann cells highlighted the role of Schwann cell-secreted factors (Chapter 5). 
It was also seen that the various aspects of astrocytosis, such as an increase in astrocytic 
area, and glial fibrillary acidic protein (GFAP) and chondroitin sulphate proteoglycan (CS- 
PG) upregulation, are regulated by different signals, whether by Schwann cell-conditioned 
media (SCM) alone, or also requiring contact-mediated signals. Thus, astrocytic reactivity 
is not an all or nothing response, but can be broken down into several measurable events 
that are regulated differently (see Table 5.1). It was also concluded that this astrocytic 
response was, in addition to N-cadherin function, another determining factor of the ability 
o f co-cultured cells to migrate within astrocyte territories (see Figure 6.1). This was 
demonstrated in two ways: (1) by induction of hypertrophy in OEC/astrocyte 
confrontation assays which prevented OEC infiltration, and (2) by reducing this 
hypertrophy using an FGFR inhibitor, allowing more OECs to migrate through astrocytic 
areas.
A connection between N-cadherin function and the astrocytic response, if there is one, has 
not yet been determined. N-cadherin did not appear to be necessary for the initiation of 
astrocytosis itself. However, the ability of glial cells to successfully penetrate astrocytic 
areas was dependent upon both N-cadherin adhesion and the astrocytic response. In 
addition, astrocyte levels of N-cadherin were upregulated in response to SCM treatment, in 
agreement with studies that showed its upregulation in hypertrophic astrocytes following 
injury (Vazques-Chona and Geisert, 1999). This may facilitate the astrocytes ability to 
reform a syncitium between tightly bound astrocytes, which can effectively seal off the 
injury site and become impermeable to cellular invasion (Fawcett and Asher, 1999; Shearer 
and Fawcett, 2001). In this way, it remains possible that SCM treatment of confrontation 
assays results in increasing the effect of reactive astrocytes acting as a physical barrier to 
penetration. Thus, both their increased size and their expression of N-cadherin synergise in 
preventing Schwann cells from entering astrocyte territories. Alternatively, it is a 
possibility that SCM factors could regulate N-cadherin function, either directly, or 
indirectly via other upregulated molecules (possibly CS-PGs). In conclusion, both N- 
cadherin, or its various signalling components, and the putative factors secreted by
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Schwann cells, now offer themselves as potential targets for intervention in order to 
improve the efficacy of transplant-mediated repair.
An understanding of how Schwann cells can induce astrocytosis would not only benefit 
success of repair following transplantation, but may also allow management of the reactive 
injury site by reducing the effects of endogenous Schwann cells which can infiltrate the 
injured spinal cord. It has been well documented that following disruption of the glia 
limitans, Schwann cells from the dorsal root are able to invade the CNS environment of the 
spinal cord (Schwannosis). This has been shown in both patients (Bruce et al., 2000), and 
in experimental models of CNS injury (Franklin and Blakemore et al., 1993; Ramer et al., 
2004a). In addition, following transplantation of fibronectin mats into a spinal cord lesion, 
they were also shown to be subsequently infiltrated by endogenous Schwann cells (King et 
al., 2002). Not only does the presence of these Schwann cells potentially add to the 
induction o f astrocytosis within the injured CNS, but also complicates the interpretation of 
experimental models. Resultant regeneration following transplantation experiments might 
not be attributable to just the transplant itself, but may result from the presence of these 
often unidentifiable invading cells. These cells may also be recruited in greater numbers as a 
response to the presence of the transplant, as has been demonstrated in a crush injury of 
the spinal cord, where the transplantation of OECs enhanced the number o f Schwann cells 
invading the lesion site (Takami et al., 2002; Ramer et al., 2004a). This presence o f both 
Schwann cells and OECs within the CNS may increase the likelihood that both the OEC- 
contact signal and Schwann cell-secreted factors, as has been shown in this thesis to induce 
astrocytosis, will be present together.
Due to the presence of recruited endogenous cells, and to determine the precise mechanisms 
by which transplants promote regeneration, there is, therefore, a need for better labelling 
techniques o f transplanted cells. It is important that this label persists within subsequent 
cellular generations in order to successfully monitor the fate of transplant-derived cells. 
Previous studies identified transplanted OECs by p75NTR immunolabelling, sometimes with 
GFAP and S I00 (Li et al., 1997, 1998; Takami et al., 2002; Plant et al., 2003), but this did 
not allow for reliable assessments to be made about OEC survival. For example there is the 
possibility of losing these markers due to differentiation, as occurs to p75NTR which is 
downregulated upon myelination. It was also not possible to distinguish the transplant
from endogenous Schwann cells present in the spinal cord (Plant et al., 2003). Similar 
results were also found following Schwann cell transplantation studies (Li and Raisman, 
1997; Takami et al., 2002). Recently, many groups have tried to overcome these limitations 
by labelling cells with cell tracer agents such as cell tracker green (Nash et al., 2002), CFDA 
(Imaizumi et al., 2000), or Hoechst (Ramon-Cueto et al., 1998, 2000). These labels are 
good for short term studies, but with cell divisions they are diluted to undetectable levels, 
and there is also a possibility that they can leak and be actively taken up by phagocytotic 
cells, or absorbed passively by other surrounding cells. In order to allow long term 
detection of the fate of transplanted cells, viruses have been successfully used to label cells 
before transplantation, allowing detection for over 4 weeks following transplantation. 
Methods used include adenovirus transfection of cells with green fluorescent protein (Li et 
al., 2003) and retrovirus transfection of cells with P-galactosidase (Lakatos et al., 2003a; 
Riddell et al., 2004). In addition, it has recently been demonstrated that labelling of OECs 
with superparamagnetic iron oxide (SPIO) permits tracing with magnetic resonance imaging 
for at least 2 months following transplantation into spinal cord (Lee et al., 2004).
The potential use of OECs for repair has been supported by successful transplantation 
experiments demonstrating their benefit for promoting both axonal regeneration (Ramon- 
Cueto et al., 1994, 2000; Smale et al., 1996; Li et al., 1997, 1998, 2003; Lu et al., 2002; 
McDonald et al., 1999; Navarro et al., 1999) and subsequent functional recovery (Navarro 
et al., 1999; Ramon-Cueto et al., 2000; Taylor et al., 2001; Lu et al., 2002; Li et al., 2003). 
However, despite the case for OECs being superior to Schwann cells due to their better 
compatibility with astrocytes, there may still be limitations to the use o f OECs. Not all 
studies confirmed the successful benefits of OEC transplantation for promoting 
regeneration (Ramer et al., 2004b; Riddell et al., 2004), with several studies suggesting that 
OECs were actually inferior to Schwann cells (Plant et al., 2002; Takami et al., 2002). It is 
likely that the high variability in results may reflect the equally variable OEC preparations 
and injury models being used to test this principle. As a result, there is a need for clarity in 
defining which injury model OEC transplantation better suits, and what kind o f OEC 
preparation is most successful.
For example, the tissue source from which OECs are derived often varies. Most studies 
have used OECs obtained from adult animals and purified by immunopanning with p75NTR
(Ramon-Cueto and Nieto-Sampedro, 1994; Navarro et al., 1999); whereas others have used 
postnatal animals which were purified by fluorescent-activated cell sorting (FACS) using 
the 0 4  antibody (Lakatos et al., 2003a; Riddell et al 2004), or have even used OECs from 
embryonic tissue (Smale et al., 1996). Furthermore, the tissue source of OECs can vary. 
Most studies have used OECs obtained from the olfactory bulb (Smale et al., 1996; 
Ramon-Cueto et al., 1998; Navarro et al., 1999; Plant et al., 2002, 2003; Li et al., 2003; 
Riddell et al., 2004). In recent years, however, a more peripheral source has been found in 
the lamina propria (Au and Roskams, 2003), which has been used successfully to promote 
regeneration (Ramer et al., 2004a).
Another variation which could arise between studies is the phenotypic heterogeneity of the 
OEC population transplanted. The OEC population is not homogenous, but instead has 
been shown to consist of several different phenotypes both in vivo and in vitro, which 
have been defined both morphologically and antigenically (Barnett et al., 1993; Franchescini 
and Barnett, 1996). Whether OECs obtained from different parts of the peripheral 
olfactory system possess characteristics of different OEC phenotypes remains to be seen. 
Studies have reported that OECs from the lamina propria consisted of two phenotypes 
similar to the two phenotypes found for olfactory bulb OECs, although they also 
expressed a novel combination of cellular markers (Au and Roskams, 2003). In addition, 
purification techniques may select for more o f one phenotype than the other, for example 
FACS purification using 0 4  antibody led to a population consisting of both p75NTR- 
positive and PSA-NCAM-positive OECs (Franceschini and Barnett, 1996), whereas 
immunopanning with p75NTR might result in a purely p75NTR-positive population. 
However, due to the great plasticity of OECs (Franceschini and Barnett, 1996; van den Pol 
and Santarelli; 2003; Vincent et al., 2003), it may be that the final OEC population would 
more likely reflect the culture conditions in which they were grown rather than their 
position in situ or even the method of purification. This is supported by the observation of 
both spindle-shaped and flat-shaped OECs following p75NTR immunopanning (Smale et al., 
1996; Lakatos etal., 2003b). However, the question remains as to which OEC phenotype 
best supports axonal repair.
There is also debate over the best cellular composition which facilitates regeneration 
following transplantation. Pure OEC populations have been used in most studies (Ramon-
Cueto and Nieto Sampedro, 1994; Li et al., 1998; Navarro et al. 1999; Ramon-Cueto et al.,
1998), but unpurified olfactory tissue has also been used successfully to promote axonal 
regeneration (Lu et al., 2001). In addition, it has also been shown that supplementing a pure 
OEC population with meningeal cells significantly enhances their potential for myelination 
(Lakatos et al., 2003b). It has been suggested that meningeal cells may be a common 
contaminant of OECs purified from the olfactory bulb. In fact, the ‘fibroblast-like’ OEC 
reported by Raisman and colleagues to form a perineural layer around the more ‘Schwann 
cell-like’ OEC may actually be a meningeal contaminant of the preparation (Li et al., 1998; 
Lakatos et al., 2003b). However, a recent study proposes that this ‘fibroblast-like’ OEC 
may actually be an olfactory nerve fibroblast (Li et al., 2003).
The effect the different preparations and purities of OECs have on their eventual success is 
not yet fully resolved. It could be concluded that unpurified OEC populations have 
resulted in an improvement in functional recovery over purified preparations (Li et al., 
1997, 1998; Imaizumi 2002a; Lu et al., 2002). In contrast, contaminating fibroblasts 
reduced the efficiency of Schwann cell remyelination of demyelinated axons (Brierley et al., 
2001), and may have similar effects in OEC preparations. Unpurified lamina propria has 
been used successfully to promote regeneration in paraplegic rats, with similar results to 
purified OECs (Lu et al., 2001). However, it is not clear what additional cells were present 
within this lamina propria, but it is likely to be mainly fibroblasts and endothelial cells. 
Despite showing the lack of neurons, a possibility remains that the preparation contained 
neuronal progenitors. Using tissue may also have benefits beyond just providing a source 
of cells, since they might prevent cavitation, and also provide a structure rich in ECM for 
axonal outgrowth. However, it has been suggested that modulation of OEC preparations 
might just help to optimise the effectiveness of the OEC transplant rather than being 
critical to its success (Riddell et al., 2004).
Another remaining question is which type of lesion or injury model would be best suited to 
study transplantation therapies. OECs have been used in a variety of injury models, 
including dorsal root rhizotomy (Ramon-Cueto & Nieto-Sampedro, 1994; Navarro et al.
1999) where functional recovery was reported in some studies (Navarro et al. 1999, Taylor 
et al., 2001), but not in others (Ramer et al., 2004b; Riddell et al., 2004). It has also been 
suggested that Schwann cells were of more benefit in some types o f injuries such as
following contusion of the spinal cord (Takami et al., 2002), whereas OECs were of more 
benefit following a hemitransection than Schwann cells (Ramon-Cueto et al., 1998). Both 
OECs and Schwann cells have been used successfully to remyelinate demyelination models 
(Blakemore and Crang, 1985; Honmouu et al., 1996; Imaizumi et al., 1998; Barnett et al.,
2000), however, it has been reported that Schwann cells were able to remyelinate under 
conditions where OECs failed (Plant et al., 2002). Taken together, these studies 
demonstrate that there may be a different potential for OECs and Schwann cells to repair 
the CNS depending upon the injury type and severity. It may be that different cells are 
suited to different injuries and further research is required to determine which therapy 
would best suit certain clinical conditions.
In addition, despite the observation of functional recovery in several transplantation 
models, as demonstrated by behavioural testing (Li et al., 1997, 2003; Ramon-Cueto et al., 
2000; Lu et al., 2002; Nash et al., 2002), little anatomical evidence exists that transected 
fibres are actually able to regrow across the injury site and form functional synapses 
(Barnett and Riddell, 2004; Riddell et al., 2004). In contrast, behavioural recovery may 
instead be resulting from intraspinal sprouting of intact fibres which were spared during 
injury. Thus, transplants may be functioning by mechanisms other than promoting long 
distance regeneration following injury. For example, transplantation o f OECs has been 
shown to promote sparing o f the intact tissue, and prevent cavitation from occurring (Plant 
et al., 2003; Ramer et al., 2004a). In order to definitively measure which fibres are 
responsible for the behavioural recovery recorded, electophysical methods may need to be 
more routinely employed. Knowledge of which mechanism is the most beneficial may 
allow therapies to be optimised towards this.
Despite the possibility that the promotion of plasticity and sparing of intact fibres are 
more achievable targets than long distance regeneration, it may also lead to complications. It 
has been reported that the distressing condition o f autonomic dysreflexia may result from 
sprouting and uncontrolled synapse formation (Wong et al., 2000). For this reason, only 
precise and correct synapses would be desirable, otherwise inappropriate firing of neurons 
may result. To achieve this end, more research into how the correct connections are made 
during embryogenesis may be useful.
An alternative strategy to promote regeneration following SCI, is to combine several 
different therapies. This is particularly important due to the various complex aspects of 
SCI. Since these treatments often target different aspects o f the injury, combining these 
would allow us to take advantages of several improvement strategies at the same time. For 
example, OECs have been successfully modified using viral vectors to express exogenous 
genes, such as those encoding neurotrophins (Ruitenberg et al., 2001). Secretion of glial- 
derived neurotrophic factor (GDNF) by transplanted OECs significantly improved 
recovery after SCI (Cao et al., 2004), as did transplantation of OECs expressing 
neurotrophin-3 (NT-3) or brain-derived neurotrophic factor (BDNF; Ruitenberg et al.,
2003). Schwann cells have been used in combination with matrix grafts composed of, for 
example, matrigel (Rodriguez et al., 2000), and collagen IV (Plant et al., 1998). Both were 
capable of promoting axonal outgrowth, and were suggested to improve the survival of the 
Schwann cells as well as providing a scaffold for regenerating fibres. In addition, an 
increased level of sparing, axonal regeneration and also functional recovery, were seen when 
Schwann cell transplantation was used in conjunction with methods to raise cAMP 
signalling in axons (Pearse et al., 2004). This allowed the axons to overcome inhibition 
caused by myelin debris in the lesion.
In conclusion, transplantation therapies are beginning to offer hope that successful repair of 
the CNS may not be too far in the future, although further research is still needed in order 
to determine the best strategy or combined approach. Both Schwann cells and OECs, 
despite their various differences, lend themselves to being a part o f this potential treatment, 
and further understanding of how they interact with the host following transplantation will 
allow us to maximise their potential and limit the level of reactivity induced. In this thesis, I 
have demonstrated a role for both N-cadherin and Schwann cell-secreted factors in 
determining some of these responses. It remains to be seen whether modulation of these 
factors can result in a better integration between graft and host, and how this can be applied 
to the clinical setting.
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APPENDIX
1 Equipment
Axioplan 2 fluorescent microscope 
Axioshop fluorescent microscope 
Axiovert S I00 time-lapse microscope 
Beckman DU 650 Spectrophotometer 
Biorad power pack 3000 
Camera controller (time-lapse)
Clifton unstirred water bath 
Dry blotter -  AE-6675 
Electronic heat sealer
Ettan IPGphor isoelectric focussing system
FACS Vantage SE sorter 
Fine Pix SI pro digital camera 
Halogen hot plate/stirrer 
Heraeus 6000 incubator 
Kodak 480 RA X-ray processor 
Leica SP2 confocal microscope
Zeiss, Herts, UK
Zeiss, Herts, UK
Zeiss, Herts, UK
Beckman, Bucks, UK
Biorad, Hemel Hempstead, UK
Hamamatsu Photonics Ltd, Middlesex, 
UK
Bennett Scientific, Devnon, UK
ATTO, Tokyo, Japan
Hulme Martin, Woking, UK
Amersham Pharmacia Biotech ltd., 
Bucks, UK
Becton Dickinson, Oxford, UK 
Photo Film, London, UK 
Bibby Sterilin, Stone, UK 
Kendro, Hertfordshire, UK 
Kodak, Hemel Hempstead, UK 
Leica, Milton Keynes, UK
Fuji
Microcentaur desk top centrifuge 
Microplate reader
Olympus CK2 phase microscope (in T/C)
R100/TW rotator shaker
Sigma 4K15 centrifuge (tissue culture)
Soniprep 150 sonicator
Sorvall RC3C centrifuge
Tissue culture hoods
Typhoon 9400 transilluminator
X-Cell II mini cell gel tank
2 General plastic ware
Bijous -  5 ml 
Centricon Plus-20 
Cell scrapers 
Cell strainer -  70 |il 
Coverslips
Eppendorfs -  0.5 ml, 1.5 ml
MSE Ltd, Kent, UK
Dynatech Laboratories, UK
Olympus, London, UK
Luckham Ltd, Sussex, UK
Sigma, Osterode am Harz, Germany
MSE, Ltd, Kent, UK
Du Pont, Hertfordshire, UK
Medical Air Technology, Oldham, UK
Amersham Pharmacia Biotech ltd., 
Bucks, UK
No vex, Frankfurt, Germany
Bibby-Sterilin, Stone, UK 
Millipore, Watford, UK 
Coming Inc, NY, UK 
Becton Dickinson, Oxford, UK 
BDH, Poole, UK 
Eppendorf, Cambridge, UK
Falcon tubes -  15 ml, 30 ml 
Filters with receiver -  250 ml 
F la sk s-T 2 5 , T75, T125 
Haemocytometer
Microscope slides 
Microcentrifuge tubes 
N eedles-21G , 23G 
Pastettes 
Petri dishes 
Pippette tips
Plates -  96-well, 24-well, 6-well 
Polystyrene round bottom tubes 
Scalpels
Syringes -  5 ml, 10 ml 
Syringe filters -  0.2 p.m 
Universals -  30 ml
Becton Dickinson, Oxford, UK
Nalge Nunc Int., Rochester, NY, USA
Bibby-Sterilin, Stone, UK
Weber Scientific Int. ltd., Middlesex, 
UK
BDH, Poole, UK
Elkay Lab products, Basingstoke, UK 
Becton Dickenson, Oxford, UK 
Elkay Lab products, Basingstoke, UK 
Bibby-Sterilin, Stone, UK 
Elkay Lab products, Basingstoke, UK 
Bibby-Sterilin, Stone, UK 
5 ml (for FACS) Becton Dickinson, Oxford, UK
Swann-Morton Ltd, Sheffield, UK 
Benton Dickenson, Oxford UK 
PALL Life Sciences, NY, USA 
Bibby-Sterilin, Stone, UK
3 Immunoblotting and autoradiography equipment
3MM filter paper
0.45mm pore size nitrocellulose membrane 
ECL kit
X-ray film
4-12% Bis-Tris Gels -  IPG well, 10-well, 15-well
4 Chemicals and reagents
Absolute Alcohol 
Amphotericin-B 
Antioxidant 
Aprotinin
Apo-transferrin (human)
Bovine Pituitary Extract 
Bromophenol Blue 
BSA -  fraction A 
BSA -  for standard curves 
BSA path-o-cyte 4
Whatman Int., Maidestone, UK
Millipore, Watford, UK
Amersham Pharmacia Biotech Ltd., 
Bucks, UK
Fuji Photo Film, London, UK 
Invitrogen, Paisley, UK
James Burrough Ltd., Essex, UK 
Gibco Life Sciences, Paisley, Scotland 
Invitrogen, Paisley, UK 
Sigma Aldrich, Dorset, UK 
Sigma Aldrich, Dorset, UK 
Gibco Life Sciences, Paisley, Scotland 
Fisher Scientific, Leicestershire, UK 
Sigma Aldrich, Dorset, UK 
Sigma Aldrich, Dorset, UK 
Sigma Aldrich, Dorset, UK
Bicinchironic acid
Bovine pancreas DNAse
CHAPS
Collagenase
CuS04
Cytosine Arabinoside 
DAPI
DMEM -  1885, 1966
DCS
DTT
EDTA
EGF
EGTA
FBS
Fibronectin
FGF
Formaldehyde
Forskolin
Sigma Aldrich, Dorset, UK 
Sigma Aldrich, Dorset, UK 
BDH Chemicals, Dagenham, UK 
Sigma Aldrich, Dorset, UK 
Sigma Aldrich, Dorset, UK 
Sigma Aldrich, Dorset, UK 
Sigma Aldrich, Dorset, UK
Invitrogen, Paisley, UK 
Sigma Aldrich, Dorset, UK 
Sigma Aldrich, Dorset, UK 
Fisher Scientific, Leicestershire, UK 
Peprotech, London, UK 
Sigma Aldrich, Dorset, UK 
Autogen Bioclear, Caine, UK 
Sigma Aldrich, Dorset, UK 
Peprotech, London, UK 
Fisher Scientific, Leicestershire, UK 
Sigma Aldrich, Dorset, UK
FuGENE Roche Diagnostics, West Sussex, UK
|3-glycerophosphate Sigma Aldrich, Dorset, UK
Glycerol Fisher Scientific, Leicestershire, UK
Gentamycin Sigma Aldrich, Dorset, UK
L-glutamine Sigma Aldrich, Dorset, UK
Hanks balanced salts (without sodium bicarbonate) Imperial Labs, Andover, UK
Heregulin
HEPES buffer
Hydrochloric acid
Hydrocortisone
Insulin (bovine pancreas)
Iodoacetamide
IPG buffer pH 3-10
L15
Laminin
Leupeptin
Modified MCDB 153 medium
Milk powder
R&D Systems, Abingdon, UK
Gibco Life Sciences, Paisley, Scotland
Fisher Scientific, Leicestershire, UK
Sigma Aldrich, Dorset, UK
Sigma Aldrich, Dorset, UK
Sigma Aldrich, Dorset, UK
Amersham Pharmacia Biotech ltd., 
Bucks, UK
Gibco Life Sciences, Paisley, Scotland 
Sigma Aldrich, Dorset, UK 
Sigma Aldrich, Dorset, UK 
Clonetics, San Diego, CA, USA 
Marvel, Premier Brands, Lines, UK
Methanol
(3-mercaptoethanol
MOPS running buffer
NaOH
NaCl
Na3V 0 4
Oligofectamine
Optimem
Paraformaldehyde
Penicillin/streptomycin
PLL
PMSF
Progesterone 
Putrescine 
Rabbit complement 
Re-blot plus strong 
4x Sample buffer 
SDS
Fisher Scientific, Leicestershire, UK 
Sigma Aldrich, Dorset, UK 
Invitrogen, Paisley, UK 
Fisher Scientific, Leicestershire, UK 
Fisher Scientific, Leicestershire, UK 
Sigma Aldrich, Dorset, UK 
Invitrogen, Paisley, UK 
Invitrogen, Paisley, UK 
BDH, Poole, UK 
Invitrogen, Paisley, UK 
Sigma Aldrich, Dorset, UK 
Sigma Aldrich, Dorset, UK 
Sigma Aldrich, Dorset, UK 
Sigma Aldrich, Dorset, UK 
Harlan Olac Ltd 
Chemicon International 
Invitrogen, Paisley, UK 
Fisher Scientific, Leicestershire, UK
SeeBlue Plus2 pre-stained standards
Selenium
siRNA
Sodium azide
Sodium deoxycholate
Sodium fluoride
Sodium pyrophosphate
Soybean trypsin inhibitor
SYPRO Orange protein gel stain
Thyroxine
Tris
Tween 20 
Tri-iodo-thyonine 
Triton X-100 
Trypsin
Trypsin -  bound to beads 
Ultra high purity water 
Urea
Invitrogen, Paisley, UK
Sigma Aldrich, Dorset, UK
Dharmacon Research
BDH/Merck Biosciences, Nottingham, 
UK
Sigma Aldrich, Dorset, UK
Sigma Aldrich, Dorset, UK
Sigma Aldrich, Dorset, UK
Sigma Aldrich, Dorset, UK
Molecular Probes, Leiden, Netherlands
Sigma Aldrich, Dorset, UK
Melford Labs, Suffolk, UK
Sigma Aldrich, Dorset, UK
Sigma Aldrich, Dorset, UK
Sigma Aldrich, Dorset, UK
Invitrogen, Paisley, UK
Sigma Aldrich, Dorset, UK
Braun, Sheffield, UK
Sigma Aldrich, Dorset, UK
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Vectashield mounting medium Vector Laboratories, Burlingame, USA
Vybrant cell tracer kit Molecular Probes, Leiden, Netherlands
IgG beads (sepharose and agarose) Amersham Pharmacia Biotech ltd,
Bucks, UK
5 Inhibitors
See Table 2.1 (Materials and Methods) fo r  list o f  inhibitors used
N-cadherin inhibitory peptide (10 mg/ml) Prof. P. Doherty, King’s College,
London
N-cadherin agonist peptide (20 mg/ml) Prof. P. Doherty, King’s College,
London
6 Buffers, solutions and media
all solutions made in dfyO unless otherwise noted
6.1 General reagents
Phosphate Buffered Saline (PBS), pH 7.4
140 mM NaCl
2.7 mM KC1
10 mM Na2H P 0 4
1.8 mM KH2P 0 4
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6.2 Tissue culture reagents
i) Bottenstein-Sato’s serum free media (DMEM-BS)
25 |i-g/ml Gentamycin
5 ng/ml Insulin
50 ng/ml Transferrin
0.011% SATO mix (see below)
100 mM Glutamine 
in DMEM -  1885
ii) Bottenstein-Sato’s serum free media in DMEM-1966 (DMEM-BS-1966)
25 pig/ml Gentamycin
5 ng/ml Insulin
50 ng/ml Transferrin
0.011% SATO mix (see below)
100 mM Glutamine 
in DMEM -  1966
iii) Collagenase
1.33% Collagenase (155 U/mg or 6.6 mg/ml) 
in L15
Dubco’s Modified Eagle Medium with 10% FBS (DMEM-10%)
10% FBS
25 fig/ml Gentamycin 
100 mM Glutamine 
in DMEM 1885
Dubco’s Modified Eagle Medium with 1% FBS (DMEM-1%)
1% FBS
25 |a,g/ml Gentamycin 
100 mM Glutamine 
in DMEM 1885
Dubco’s Modified Eagle Medium with 10% FBS from DMEM-1966 
(DMEM-10%-1966)
10% FBS
25 |ig/ml Gentamycin 
100 mM Glutamine 
in DMEM 1966 
OEC mitogen media (OMM)
75% SATO
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500 ng/ml FGF2 
50 ng/ml Heregulin 
5x10'7M Forskolin
20% ACM (astrocyte conditioned medium)
viii) SATO mix
0.01288% BSA path-o-cyte 4
72.5 ng/ml Putrescine 
180.2 ng/ml Thyroxine
151.8 ng/ml Tri-iodo-thyonine 
28.1 ng/ml Progesterone 
17.4 ng/ml Selenium
ix) Soybean trypsin inhibitor-DNase (SD) 
0.52 mg/ml Soybean trypsin inhibitor 
0.04 mg/ml Bovine pancrease DNAse
3.0 mg/ml Bovine serum albumin, fraction A 
inL15
x) Keratinocyte Growth Medium
0.4% Bovine pituitary extract
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10 ng/ml EGF
0.5 ng/ml Hydrocortisone
5 mg/ml Insulin
50 ng/ml Amphotericin-B
50 ng/ml Gentamycin
in modified MCDB 153 medium
6.3 Immunocytochemistry reagents
i) Hanks staining solution
10% Hanks balanced salt solution (HBSS) lOx 
5% DCS
0.1 M HEPES buffer 
0.25% Sodium azide
ii) Solution A
1 mM MgCl2 
0.1 mM CaC12 
in PBS
6.4 Immuno-blotting reagents
i) Blocking solution
256
5% Marvel 
in PBS-Tween
ii) Chondroitinase activating buffer, pH 8.0 
50 mM Tris
60 mM Sodium acetate 
0.02% BSA
iii) Coomassie blue 
0.5% Coomassie blue 
30% MeOH
10% Acetic acid
iv) Destain
7% Acetic acid 
5% MeOH
v) Dry blot buffer
10% lOx Dry blot buffer stock 
20% MEOH
vi) Dry blot buffer stock (lOx)
50 mM Tris
40 mM Glycine 
1.3 mM SDS 
20% MeOH 
Lysis buffer, pH 7.5 
500 mM HEPES 
150 mM NaCl 
1 mM EDTA
2.5 mM EGTA 
1 mM DTT 
0.1% Tween 20 
10% Glycerol
1 mM Sodium fluoride 
10 pg/ml Leupeptin
2 pg/ml Aprotinin
10 mM Glycerophosphate 
100 pM Na3V 0 4 
100 pM PMSF 
PBS-Tween
258
0.2% Tween 20 
in PBS, pH 7.4
ix) RIPA
50 mM Tris 
150 mM NaCl 
1% Triton X-100 
0.5% Sodium deoxycholate 
0.1% SDS 
2 mM EDTA
10 mM Sodium pyrophosphate 
2 (ig/ml Apoprotin 
100 [iM PMSF 
100 \iM  Na3V 0 4
6.5 Two-Dimensional electrophoresis reagents
i) 2D gel sample buffer 1
2 M Thiourea 
6 M Urea 
4% CHAPS
bromophenol blue 
0.5% IPG buffer (3-10)
0.5-1% DTT
ii) 2D gel sample buffer 2
200 pi sample buffer (4X Nupage)
300 pi glycerol 
500 ^1 urea 
0.5% DTT
iii) 2D gel sample buffer 3
200 pi sample buffer (4X Nupage)
300 pi glycerol 
500 pi urea 
0.5% DTT 
1% iodacetamide
7 Antibodies
The class and source o f  antibodies used are shown in Table 2.2 (Materials and Methods)
8 Hybridoma cells
0 4  (Somner and Schachner 1981 -  IgM)
(Ranscht et al 1982 -  lgG3) 
(Yan and Johnson, 1987) 
ECACC, Wiltshire,UK
